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Abstract 
 
A Role for Bik in B Lymphocyte Apoptosis and its Regulation by Epstein-Barr Virus 
Roya Hakimjavadi 
 
Inhibition of host cell apoptosis is central to the strategy of the B-lymphotrophic 
Epstein-Barr virus (EBV) and also plays an important role in the development of EBV-
related malignant disease and immune disorders. EBV promotes the survival of its host 
B cell during transit through the Germinal Centre (GC) of lymphoid follicles. The 
cellular Bcl-2 family (BH3-only protein) Nbk/Bik is a potent inducer of apoptosis and 
loss of Bik has been implicated in the development of cancers and the resistance of 
tumour cells to various therapeutic agents. 
Here, evidence is presented to show that the EBV growth programme down-
regulates bik and that this host-virus interaction contributes to the survival of the 
infected B cell. Bik was transcriptionally repressed in the presence of the EBV nuclear 
antigen-2 (EBNA-2) when the latter was expressed as sole viral protein. Furthermore, 
ectopic EBNA-2 led to increased cell survival when B cell apoptosis was induced by B 
cell receptor (BCR) cross-linking with anti-IgM antibody and TGFβ1–induced 
signalling, both of which are key pathways of relevance to B cell survival. 
Transient bik knockdown by anti-bik siRNA was seen to inhibit apoptosis induced by 
TGFβ1 whereas this was not sufficient to protect cells from apoptosis triggered through 
the BCR. 
An increased rate of apoptosis due to TGFβ1 was observed to coincide with elevated 
Smad3/4 recruitment to the bik promoter in EBV-negative cell lines and this effect was 
reversed in cells proliferating due to the EBV growth programme or in EBV-negative 
cells expressing ectopic EBNA-2. The latter coincided with a decreased level of total 
Smad3 present in cells proliferating due to EBV or expressing ectopic EBNA-2. 
Furthermore for the first time bik trans-activation was observed to coincide with 
apoptosis induced by 1α,25-(OH)2D3, the active metabolite of vitamin D. Bik is 
therefore potentially a key common target for the major intrinsic apoptotic signalling 
pathways in the GC reaction and is a negative target of EBV. In summary, the EBV-
bik interaction is likely to make an important contribution to the survival of EBV-
infected B cells during EBV infection and in some EBV-associated malignant diseases. 
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1.1 Epstein-Barr virus Discovery 
 
The Epstein - Barr virus (EBV) is a ubiquitous human gamma herpes virus that infects 
approximately 95% of the world’s adult population. EBV was discovered in 1958, in 
Uganda by an Irish surgeon, Denis Burkitt, who observed what he described as a 
lymphosarcoma primarily affecting children in equatorial Africa. This malignancy 
would later be re-designated and named Burkitt’s lymphoma (BL) (Harford 2012). Due 
to the onset of BL at a young age and the climatic and geographical distribution of the 
patients affected, Burkitt began to suspect that an external pathogen, such as a virus, 
may play a role in the development of this form of cancer. In order to further investigate 
and better understand of the cause of this endemic cancer, he sent tumour biopsies from 
Kampala to London in 1961. A few years later in 1964 Anthony Epstein, Bert Achong, 
and Yvonne Barr observed and described a virus particle in electron microscopic images 
of cultured Burkitt lymphoma cell lines that they named Epstein-Barr Virus (EBV) 
(Harford 2012).  
 
High titers of anti-EBV antibody were found in BL patients compared to control 
patients (Henle, et al. 1969). In south China high antibody titers were also observed in a 
lymphoepithelial malignancy with a high incidence (Henle, et al. 1970). These 
observations together with further subsequent investigations led to the implication of 
EBV as the first candidate for a human oncogenic virus, not only in Burkitt’s lymphoma 
but also in a number of other malignancies including undifferentiated nasopharyngeal 
carcinoma (NPC; Reviewed in (Bornkamm 2009)). Interestingly however, it soon 
became evident that EBV infection was widespread, indicating that EBV alone was not 
a causative agent for malignancy, and that other genetic and environmental factors were 
required for tumour development (Bornkamm 2009). EBV is now well known as the 
causative agent of infectious mononucleosis (IM; also known as glandular fever) and 
for its capacity to potently growth-transform its principal target cell, the B lymphocyte. 
In culture, these ‘immortalised’ cells are referred to as lymphoblastoid cell lines (LCLs). 
In later life Burkitt noted that his ‘lymphoma belt’ study carried out on BL was also a 
map of malaria-infested regions in Africa. The link between endemic BL occurrence 
and malarial transmission areas had been established, but to date no defined functional 
role for malaria in EBV-led BL has been elucidated (Reviewed in Moormann, Snider 
and Chelimo 2011 and Griffin,B., Rochford, R. 2005). 
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1.2 EBV Epidemiology  
 
Infection with EBV is worldwide, affecting more than 95% of human population during 
the first two decades of their lives (Ng and Khoury 2009). In developing countries, 
primary infections occur mainly in young children and are usually asymptomatic. In 
developed countries, primary EBV infection can occur in 25% to 50% of children 
younger than five years of age. A second peak of primary infection occurs in 
adolescence, and 30% to 50% of cases will go on to develop the self-limiting condition 
known as glandular fever/infectious mononucleosis (IM) (Ng and Khoury 2009, 
Papesch and Watkins 2001). While the virus is normally a harmless passenger 
throughout one’s life, EBV has been associated with several malignancies, as will be 
described below (see section 1.11). Co-factors that contribute to the development of 
clinical disease include immune status, genetic and dietary factors, age of the individual 
at the time of exposure and various physiological variables (reviewed in (Crowcroft, et 
al. 1998, Hocker, et al. 2013, Taylor and Blackbourn 2011, Dojcinov, et al. 2011)). 
 
 
1.3 EBV Classification 
 
The herpesviridae is a family of herpes viruses that infects birds, reptiles and mammals 
(Lacoste, et al. 2010). The herpes family of viruses can be separated into three sub-types 
according to their genome organisation, growth characteristics and cell tropism, namely 
α-herpes viruses, β-herpes viruses and γ-herpes viruses (Hardie 2010). The γ-herpes 
viruses are further divided into lymphocryptoviruses (LCV; also known as gamma1-
herpes virus) and rhadinoviruses (RV; also known as gamma2-herpes virus) (Lacoste, et 
al. 2010). It is generally accepted that the LCV evolved from the RV due to the more 
divergent genomes that are found in RVs. EBV [also known as human herpes virus 4 
(HHV4)], is a γ-herpes viruses of the genus lymphocryptovirus that targets B 
lymphocytes (Lacoste, et al. 2010, Hardie 2010, Barozzi, et al. 2007). EBV was the first 
herpes viral genome to be completely sequenced (Baer, et al. 1984). Typical γ-herpes 
viruses replicate in epithelial cells and then establish a lifelong latent infection in host 
lymphocytes (Hardie 2010, Kieff, E., Rickinson, A, B. 2007).  
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The EBV genome, like that of all herpes viruses, has a signature structure of conserved 
genes divided by defined regions of genetic variation (Lacoste, et al. 2010). EBV, has 
extensively co-evolved with its host, adapting its genetic code and incorporating genes 
of host origin to enable the latent virus to go undetected by the immune system (Hardie 
2010).  
 
 
1.4 Structure of EBV 
 
Herpes viruses possess a toroid shaped DNA/protein associated core enclosed in a 162 
capsomer nucleocapsid. This icosahedral nucleocapsid is surrounded by a protein 
tegument that is itself confined by an outer envelope. This outer envelope is coated by 
glycoprotein spikes (Kieff, E., Rickinson, A, B. 2007, Thompson and Kurzrock 2004) 
see (Figure 1-1). 
  
 
 
 
 
Figure 1-1: Schematic representation of herpes virus structure. 
The EBV associated toroid protein core is illustrated within the icosahedral nucleocapsid. This 
capsid is itself covered by a protein tegument and enclosed in a glycoprotein covered envelope. 
Adapted from (van Kooten and Banchereau 1997)  
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The EBV genome is 170-184 kilobase pairs (kb) in length with a guanine/cytosine 
content of approximately 60%, encoding around 85 genes. The viral genome is wrapped 
around a toroid-shaped protein. This structure is covered with a nucleocapsid with 162 
capsomers. The space between the nucleocapsid and the viral envelope is filled by a 
protein tegument and a range of glycoprotein spikes are seen on the outer envelope of 
the virus, consisting of the viral glycoproteins gp350, gp85, gp25, gp110, and gp84/11 
(Thompson and Kurzrock 2004, Knipe, D.M, Howley, P.M. 2001). Due to the splicing 
potential of EBV RNA transcripts, it is likely that the number of possible proteins 
exceeds the number of genes present on the viral episome. The ends of the EBV genome 
contain a 500 base pair (bp) motif of variable number terminal repeats, this genome 
variation is further compounded by the presence of four internal tandem repeats that 
divide the genome into unique long and short fragments (Lacoste, et al. 2010). The 
internal repeats include one 3 kb tandem internal direct repeat (IR1) that defines the 
unique short region (US) from the unique long region (UL) which contains another three 
short tandem internal direct repeats (IR2-4)(Lacoste, et al. 2010, Kieff, E., Rickinson, 
A, B. 2007) (see Figure 1-2). Upon entry into the host cell, the linear genome becomes 
circularised by the fusion of the two termini (Lindahl, et al. 1976). In latently infected 
cells the change in viral genome structure from linear to episomal occurs around 12-24 
h after infection of B cells, therefore each latently infected cell contains about 10-20 
circular viral episomes in its nucleus. Viral episomes divide as independent replicons 
once per cell cycle in early S phase using cellular DNA polymerase II and III (Knipe, 
D.M, Howley, P.M. 2001). 
 
 
Figure 1-2: The EBV Genome. 
A schematic drawing of the 172 kb EBV genome, including the terminal repeats (TR), internal 
repeats (IR) 1-4, the unique long arm (UL) and the unique short arm (US) as indicated. Figure 
adapted from Lacoste et al 2010. 
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1.5 Primary Infection and Lytic Replication  
 
Upon initial infection following exposure to saliva carrying EBV, the virus infects the 
oropharyngeal epithelial cells where it replicates, and then infects naïve IgD+ B cells in 
the oropharynx ((Kieff, E., Rickinson, A, B. 2007, Bollard, Rooney and Heslop 2012) B 
cells have the most important role in the EBV infection process, as patients with X-
Linked agammaglobulinemia disorder, who do not have mature B cells, do not show 
any evidence of infection with EBV during their life (Faulkner, et al. 1999). 
EBV infection of B cells is instigated with the attachment of the gp 350/220 viral 
membrane glycoprotein to the CD21 (complement C3d component (CR2)) molecule on 
lymphocytes. It has recently been shown that CD21 is not the only cellular receptor for 
EBV glycoprotein, but also CD35, the human complement receptor type I, which serves 
as another attachment receptor for gp350/220 glycoprotein (Ogembo, et al. 2013). Other 
viral envelope proteins including gp42 (part of the trimolecular viral envelope 
glycoprotein complex gp42/gp85/gp25 (also known as gH/gL complex)), which binds to 
HLA class II molecules and gp110 which also initiates the interaction of virus and its 
target cells are also involved in mediating viral entry into B cells (Ogembo, et al. 2013). 
It has been shown that the infection rate of epithelial cells increases when they are in 
close contact with virus-producing B cells (Shannon-Lowe, et al. 2006). EBV binds via 
its envelope glycoprotein gH/gL complex to gHgL receptor (gHgLR) on epithelial cells. 
In addition to this interaction, higher infection efficiency is obtained when the EBV 
multi-spanning envelope glycoprotein BMRF2, binds to α5β1 integrin on the surface of 
epithelial cells (Klein, Klein and Kashuba 2010, Odumade, Hogquist and Balfour 2011). 
EB virions secreted from reactivating B cells (or plasmablasts) are low in gp42 and thus 
show a greater tropism for epithelial cells which are HLA-class II-negative cells. On the 
other hand viruses derived from epithelial cells possess higher levels of gp42 envelope 
glycoprotein, which increases viral affinity for B cells (HLA-class II positive cells) 
(Hutt-Fletcher 2005, Borza and Hutt-Fletcher 2002). This finding suggested that 
epithelial cell infection facilitates viral access to B cells and that this process is critical 
for virus cycle maintenance (Hutt-Fletcher 2005). Studies have shown that most of the 
EBV genome and gp350 remains at the surface of the B cells for several days following 
virus/cell contact (Shannon-Lowe, et al. 2006). In addition that study showed that a 
gp350 knockout-EBV cell free virus preparation was able to infect epithelial cells with 
high efficiency, but unable to bind and infect B cells, thus it was suggested that the 
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gp350 envelope glycoprotein was an inhibitor for direct infection of epithelial cells by 
EBV, and that interaction of gp350 with CD21 is required to remove this inhibition and 
facilitate the unmasking of other virus envelope components required for epithelial cell 
infection. In this proposed model of primary infection, EBV binds to the surface of 
resting B cells and uses them as a vehicle to infect epithelial cells rather than there being 
an initial round of virus replication in B cells prior to epithelial cell infection (Shannon-
Lowe, et al. 2006). After antigen binding, EBV is endocytosed by CD21-derived 
cytoplasmic vesicles and viral capsids are released into the cytoplasm (Bollard, Rooney 
and Heslop 2012, Nemerow and Cooper 1984, Carel, et al. 1990). This initiates mRNA 
synthesis, B cell blast formation, homotypic cell adhesion, surface CD23 expression and 
interleukin (IL)-6 production (Thompson and Kurzrock 2004). The linear viral genome 
moves into the nucleus within 12 hours whereupon it becomes a circular episome 
(Reviewed in (Kieff, E., Rickinson, A, B. 2007)) with a variable number of terminal 
repeats (TR) (Figure 1-2) which gives rise to a DNA fingerprint for the original infected 
cell and any arising daughter cells. This is a valuable feature that can be exploited to 
determine the clonality of EBV-associated tumours (Kutok and Wang 2006, Raab-
Traub and Flynn 1986). EBV does not encode its own RNA polymerase for 
transcription, it utilises the cellular RNA polymerase II (Kieff 1996). The first 
detectable EBV proteins are EBNA-LP and EBNA-2 (Thompson and Kurzrock 2004, 
Thompson and Kurzrock 2004, Karlberg, et al. 2010). 
Viral DNA polymerase accomplishes linear viral replication, which occurs during the 
lytic phase of the viral life cycle.  There are three classes of viral lytic gene products, 
immediate-early (IE), early (E), and late (L). BZLF1 and BRLF1 are some of the IE 
products that act as transactivators of the viral lytic programme (El-Guindy, et al. 2013). 
Activation of lytic replication or reactivation from latency is crucial for transmission. 
The early products for example, BNLF2a have an inclusive range of roles, including 
replication, metabolism, and blockade of antigen processing, while late products tend to 
code for structural proteins such as the viral capsid antigens (VCA) and gene products 
used for immune evasion (e.g., BCRF1). The significant importance of EBV infection 
in B cells is that they are induced to activate their growth program and trigger 
differentiation into memory B cells via the germinal centre reaction. Infected memory B 
cells are released into the peripheral circulation (Figure 1-4). The number of infected B 
cells declines over time after the beginning of symptoms of primary infection 
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(Hadinoto, et al. 2008), but these cells are never eliminated fully (El-Guindy, et al. 
2013, Zhao, et al. 2011).  
 
 
1.6 EBV Latency Programmes and gene expression patterns 
 
Latency is the state of persistent viral infection without active viral production. EBV 
persists mostly in the memory B-cell compartment and possibly also in epithelial cells 
(Thorley-Lawson, Duca and Shapiro 2008). Due to differing combinations of EBV 
latency gene expression in various EBV associated malignancies and EBV derived cell 
lines, a set of distinct EBV latency programmes have been defined (Shah and Young 
2009). These have been characterised as latency Type 0, I, II and III (Table 1-1). By 
using different transcription programs, latent EBV genomes can multiply in dividing 
memory cells (type I), induce B-cell differentiation (type II), activate naïve B cells (type 
III), or completely restrict all gene expression in a context-specific manner (Figure 1-3) 
(Thorley-Lawson, Duca and Shapiro 2008).  
 
 
Figure 1-3: The infection life cycle and latency states of EBV 
EBV infection is transmitted from host to host via saliva, and infects epithelial cells where it 
replicates in the oropharynx before infecting naïve B cells. Following infection of naive B cells 
in the lymph node, all latent genes are expressed (Latency III) and the viral latent proteins drive 
the B cell through subsequent proliferation and the germinal centre (GC) reaction in the absence 
of a cognate antigen. To establish a persistent latent infection, EBV must access the memory B 
cell compartment and reside within long-lived peripheral B cells where the expression of highly 
immunogenic viral latency antigens EBNA1, EBNA-2, and EBNA-3, are down-regulated and 
only few viral gene products (Latency II, Latency 0 and Latency I) as indicated in (Table 1-1) 
are expressed in order to escape immune detection. Terminal differentiation to plasma cells 
results in reactivation of the virus to the lytic cycle, expression of lytic proteins and production 
of infectious virus.  The virus can infect B cells within the lymphoid tissue or be shed into the 
saliva. Adapted from (Bollard, Rooney and Heslop 2012). 
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Table 1-1: EBV latency types and associated gene expression pattern. 
(Bollard, Rooney and Heslop 2012, Shah and Young 2009, Young and Rickinson 2004a, Klein, 
Kis and Klein 2007) 
 
Type of Latency Viral Genes Expressed 
Type 0 None Detectable 
Type I EBNA-1,  EBERs, 
BARTs 
Type II EBNA-1, EBERs, 
BARTs, BARF0 
LMP1,LMP2A, 
LMP2B 
 
Type III All EBV Latent Genes 
 
 
After infection of naive B-cells, EBV activates a growth programme (also termed 
latency III) that drives B-cell proliferation, and is characterised by expression of its 
entire latency gene complex (Figure 1-3) which consists of eleven characterised EBV 
latently expressed genes, including six EBV Nuclear Antigens EBNA1, EBNA-2, 
EBNA-3A, EBNA-3B, EBNA-3C and EBNA-LP, three integral latent membrane 
proteins LMP1, LMP2A and LMP2B and two small non-polyadenylated EBV encoded 
RNAs known as EBER1 and EBER2. There is also a further set of poorly understood 
transcripts known as BARTs (Murray and Young 2002) and recently discovered 
microRNAs (Riley, et al. 2012). Type III latency gene products, which drive B cell 
transformation and proliferation, are highly immunogenic. In order to escape detection 
by CD8+ cytotoxic T lymphocytes, the virus survives in B cells by downregulating the 
expression of its immunogenic proteins including the viral transcription factor EBNA-2 
(Okur and Brenner 2010). Primarily B cells enter lymphoid follicles where they 
proliferate and express only three viral proteins (type II latency) (Thorley-Lawson, 
Duca and Shapiro 2008). This facilitates minor proliferation of the cells in the GC 
where the cell is hidden from immunosurveillance. Once leaving the GC the infected 
cells switch to either latency type I or type 0 to maintain infection without activating an 
immune response (Bollard, Rooney and Heslop 2012, Allday 2009). Terminal 
differentiation to plasma cells results in reactivation of the virus to the lytic cycle, 
expression of lytic proteins and the production of infectious virus.  The virus can infect 
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B cells within the lymphoid tissue or be shed into the saliva (Laichalk and Thorley-
Lawson 2005).  
 
 
 
 
 
Figure 1-4: EBV Latent Genes. 
Diagram of the double-stranded EBV episome showing EBV latent genes transcription. The 
episomal origin of replication (OriP) is shown in orange, EBNA1 binds to the OriP in a 
sequence specific manner to activate replication of the EBV genome. The large green arrows 
depict the coding regions for the six nuclear antigens (EBNA1, 2, 3A, 3B, 3C and EBNA-LP) 
and the three latent membrane proteins (LMP1, 2A and 2B). The highly transcribed non-coding 
RNAs EBER1 and EBER2 are represented at the top of the genome by the blue arrows. The 
BamHIA region contains the BARF0 and BARF1 transcript codes. The thin green arrow 
indicates the direction and transcript region utilised from the EBNA Cp/Wp promoter during 
type III latency. The EBNA latency III primary transcript is alternatively spliced to give rise to 
the EBV nuclear antigen-coding mRNAs. The EBNA Qp promoter is active during latency I and 
II and gives rise to EBNA1 mRNA, as highlighted by the red arrow. (Figure adapted from 
(Young and Rickinson 2004a) . 
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1.7 The EBV-encoded nuclear antigens 
1.7.1 EBNA1 
 
EBV nuclear antigen 1 (EBNA1), a 641 amino acid protein, is the only viral protein 
consistently expressed in all EBV-associated malignancies and EBV-proliferating cells 
in healthy carriers (reviewed by (Frappier 2012)) EBNA1 is essential for lifelong viral 
persistence and is required for maintenance and replication of the EBV genome, through 
specific binding of EBNA1 to the EBV-origin of replication (oriP) (reviewed by(Young 
and Murray 2003a)). EBNA1 can also activate expression of critical cellular genes 
affecting cellular growth control and is known to possess oncogenic properties (Young 
and Murray 2003a, Tsimbouri, et al. 2002, Wilson and Levine 1992). This 73 kDa 
protein consists of a short amino-terminal region a 20-40 kDa, glycine-alanine (Gly-
Ala) repetitive sequence flanked by arginine-rich sequences and a highly charged acidic 
carboxyl-terminal sequence (Young and Murray 2003a, Young and Rickinson 2004b). 
The presence of the Gly-Ala repeat domain in EBNA1 prevents processing by the 
proteasome, and has also been found to inhibit EBNA1 mRNA translation. In this 
manner EBNA1 greatly reduces its own recognition by cytotoxic T cells, enabling 
infected cells to evade the immune response (Blake 2010).  
 
 
1.7.2 EBNA-2 
 
EBNA-2 is an 83 kDa transcription factor that plays a critical role in B cell 
immortalisation. It is a transcriptional co-activator that modulates the expression of viral 
and cellular genes, driving cell cycle progression from G0 to G1. Together with EBNA-
LP, EBNA-2 is the first EBV latent gene expressed upon infection of a B cell 
(Reviewed in (Middeldorp, et al. 2003)). EBNA-2 can be nucleoplasm-, chromatin- and 
nuclear-matrix associated and localises to large nuclear granules (Petti, Sample and 
Kieff 1990, Hennessy and Kieff 1985). A crucial role for EBNA-2 in B cell 
immortalisation was discovered when a mutant strain of EBV, called P3HR1 was 
isolated and found to lack the ability to transform B cells in vitro. Further investigation 
showed that P3HR1 possessed a deletion encompassing the EBNA-2 open reading 
frame (ORF) and also partially that of EBNA-LP. It was soon discovered that the ability 
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of P3HR1 to transform B cells could be restored by the re-introduction of EBNA-2 to 
the genome. This implicated EBNA-2 as a vital EBV latent protein in the process of 
EBV-driven B cell immortalisation (Reviewed in (Thompson and Kurzrock 2004, 
Young, Dawson and Eliopoulos 2000)).  Further studies have shown that EBNA-2 is 
also essential for maintaining immortalisation (Kempkes, et al. 1995a, Cancian, et al. 
2011). 
 
Structure of EBNA-2 
 
EBNA-2A is 483 amino acids (aa) long whilst EBNA-2B is composed of 455 aa. Both 
contain a negatively charged highly homologous amino terminal region that facilitates 
homo-dimerisation (Figure 1.6). This is followed by a proline-rich domain which can 
contain from 10-40 successive prolines. The homology between the two types of 
EBNA-2 is least in the “diversity” region which then leads into the domain responsible 
for binding cellular CBF1/RBP-Jκ DNA-binding protein. This region is followed by an 
arginine-glycine rich domain that spans approximately 18 aa, and is followed by a 
negatively charged trans-activation domain that has been found to interact with a 
number of general transcription factors and co-activators in the cell. Finally the 
carboxyl terminus is responsible for nuclear localisation (Zimber-Strobl and Strobl 
2001). Three regions of importance for B cell immortalisation by EBNA-2 have been 
identified through extensive mutational analysis: residues 94-110, encompassing the 
proline rich region; 280-337, containing the region required for interaction with CBF1; 
and 425-462, a region that harbours the acidic trans-activation domain(Zimber-Strobl 
and Strobl 2001, Ling, Rawlins and Hayward 1993, Cohen and Kieff 1991). While the 
transactivation domain, the nuclear localisation motif and the region which mediates 
promoter contact are located in the C-terminal half of EBNA-2, most of the N-terminal 
half of EBNA-2 does not have a critical role in transforming B cells and 
immortalisation, except for seven proline motif (Yalamanchili, Harada and Kieff 1996). 
The C-Terminal region of EBNA-2 determines the greater transforming ability of EBV 
type A through enhanced regulation of LMP-1 and CXCR7 expression (Cancian, et al. 
2011). 
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N-terminal  C-terminal 
 
Figure 1-5: The structural domains of EBNA-2.   
EBNA-2 consists of a negatively charged region at the amino-terminus, which is likely to play a 
role in homo-dimerisation (Dim), a polyproline region (Pro) consisting of 10-40 consecutive 
prolines depending on the virus strain, a diversity region with low homology between EBNA-
2A and EBNA-2B, a domain responsible for interaction with RBP-Jk/CBF1 (RBP-Jκ), an 
arginine-glycine rich stretch (ArgGly) and a negatively charged region carboxyl terminus, 
which harbours a trans-activation domain (TAD), conserved regions (CR1-9), which have been 
defined by comparison of EBV strain type A and B, baboon and rhesus macaque 
lymphocryptoviruses  and a nuclear localisation signal (NLS) (Figure adapted from(Zimber-
Strobl and Strobl 2001)). 
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Table 1-2: The CR1-CR9 and their putative functions in EBNA-2 mediated 
transformation and immortalisation (Zetterberg,H., Rymo, L. 2005).  
Conserved 
Region 
Respective Fonction 
CR1 Increases the LMP1 promoter activity. 
CR2- CR3 PPR is located between these two Conserved regions. The number of proline 
repeats differs between the two: types 1 (43 out of 45 amino acids are proline)& 
type 2 (14 out of 16 amino acids are proline).[25] 
Interacts with RNA helicase DP103 and SW1/SNF, chromatin-remodelling 
complex. 
CR5-CR6 CR5, CR6, and the sequence between these, associates with RBP-JK or PU.1 in 
order to mediate promoter targeting. 
CR4-CR5 Divergent region is located at CR4/CR5, which mediates self-association in 
addition to the two other regions at Amino terminal with the same function. 
CR5 Interaction with SKIP. 
CR6-CR7 
 
Poly-RG motif is in between CR6 and CR7. It cooperates with CR9 at the C-
terminal end of EBNA-2, for nuclear localisation signal. 
CR8 This consists of an acidic activation domain, which associates with TFIIH, 
TAF40, TFIIB, p100, and P300, CBF, and PCAF histone acetyltransferases. 
Amino acids 453-466 (the core fragment) of acidic activation domain of EBNA-
2 can be replaced by the herpes simplex viral protein VP16 activation domain, 
which indicates functional similarities. 
CR9 Nuclear localisation signal and conserved Arginine-Glycine rich region. 
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Transcriptional regulation by EBNA-2 
 
EBNA-2 does not directly bind DNA, rather it utilises a number of cellular transcription 
factors to achieve specific promoter targeting including (i) CBF1/RBP-Jκ, (ii) the ETS 
family protein Spi-1/Pu.1, (iii) the ATF/CRE complex, (iv) the CREB-binding protein 
CBP and (v) the chromatin remodelling complex SWI/SNF (Wu, Krumm and Schubach 
2000, Wang, Grossman and Kieff 2000, Pegman, et al. 2006b, Ling, et al. 1994, Laux, 
et al. 1994, Johannsen, et al. 1995a, Henkel, et al. 1994). EBNA-2 has two principal 
mechanisms by which it activates EBNA-2-responsive genes: (i) it associates with its 
target genes to alleviate the repressive effect elicited by bound CBF1 (Figure 1-6) and 
followed by (ii) strong transcriptional promotion of the target gene (Figure 1-6) 
(Palermo, et al. 2008). EBNA-2 can also interact with members of the basal 
transcription machinery (BTM), including TFIIH, TFIIE, TFIIB, TAF40 and RPA70 
through its acidic trans-activation domain (Palermo, et al. 2008, Tong, et al. 1995a, 
Tong, et al. 1995b, Tong, et al. 1995c). Further to these interactions, EBNA-2 has been 
shown to associate with the DEAD-box protein DP103 (Grundhoff, et al. 1999) which 
has an established role in transcriptional repression (Yan, et al. 2003). Of the BTM 
utilised by EBNA-2 for specific promoter regulation is the cellular DNA binding 
protein, Cp binding factor 1 (CBF1) which binds to the cognate DNA sequence 5’CGT 
GGG AA 3’ (Nikrad, et al. 2005). CBF1 is also known as recombination signal-binding 
protein 1 for Jκ (RBP-Jκ). CBF1 is a ubiquitously expressed transcription factor that has 
been highly conserved during evolution (Zimber-Strobl, et al. 1993). CBF1 directs 
EBNA-2 to its target genes allowing regulation of the genes by EBNA-2. EBNA-2 
drives one of its own gene promoters, the EBNA Cp promoter, via an upstream EBNA-2 
responsive element (called the EBNA-2-responsive enhancer (E2RE) by alleviating 
CBF1 mediated repression (Jin and Speck 1992, Sung, et al. 1991). In the absence of 
EBNA-2, CBF1 acts as a co-repressor in the cell bound by a large multi-protein 
complex of cellular proteins which includes SMRT/NcoR, Sin3-associated protein 30 
(SAP30), SIN3A, the CBF1-interacting co-repressor (CIR), histone deacetylase 
(HDAC) 1 and HDAC2. Another protein that can bind to this complex is Ski-interacting 
protein, SKIP. EBNA-2 mediates trans-activation of genes by competing with the 
SMRT-HDAC co-repressor complex thus relieving the target promoters of this 
repressor complex (Figure 1-6).  
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(A) EBNA-2 acts as a transcriptional activator by interacting with the DNA-binding Jκ-
recombination-binding protein (RBP-Jκ/CBF1) and relieving transcriptional repression that is 
mediated by a large cellular multi-protein complex consisting of SMRT/NcoR, SAP30, SIN3A, 
CIR, SKIP, HDAC1 and HDAC2.  The binding of SKIP to SMRT facilitates nuclear entry of 
CBF1. (B) EBNA-2 abolishes CBF1-mediated repression by competing with the SMRT-HDAC 
co-repressor for binding to both CBF1 and SKIP. The EBNA-2 acidic domain recruits the BTM, 
TFIIB, TFIIH and p300 to drive transcriptional activation. (Figure adapted from (Young and 
Rickinson 2004a)). 
 
Once repression is relieved, EBNA-2 brings strong transcriptional activation to the 
promoter (Hsieh and Hayward 1995). To activate this, EBNA-2 binds histone 
acetyltransferases (HATs) and SW1/SNF, the chromatin-remodelling factors to alter 
chromatin structure rendering the gene accessible for transcription. EBV utilises cellular 
RNA polymerase II (RNA pol II) for transcribing viral target genes (Figure 1-7).  
 
EBNA-2 interacts with general transcription factors such as TFIIH and TFIIE along 
with the cyclin dependant kinase (CDK) 9 to initiate and maintain phosphorylation of 
RNA pol II. The main phosphorylation sites of the CTD are Ser-2 and Ser-5. Bark-
Jones et al, have shown by CDK9 inhibition studies, that EBNA-2 requires CDK9 
recruitment for efficient transcriptional activation (Bark-Jones, Webb and West 2006). 
A
B
Figure 1-6: EBNA-2-mediated promoter activation (I) 
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The CTD Ser-5 phosphorylation has also been shown to fluctuate relative to EBNA-2 
expression levels, demonstrating that Ser-5 phosphorylation may be an EBNA-2-
dependant process (Reviewed in (Palermo, et al. 2008)). In peptide studies CDK9 has 
been shown to preferentially phosphorylate Ser-5 (Ramanathan, et al. 2001), implicating 
a transcriptional initiation model that involves recruitment of CDK9 by EBNA-2 for the 
phosphorylation of Ser-5 thus activating the CTD and RNA pol II activity(Palermo, et 
al. 2008, Ramanathan, et al. 2001). EBNA-2 interaction with TFIIH aids 
phosphorylation of the CTD leading to strong sustained transcriptional up-regulation of 
the target gene (Palermo, et al. 2008). 
 
 
 
Figure 1-7: Mechanism for EBNA-2-mediated promoter activation (II). 
Association with the target promoter leads to binding of EBNA-2 and the chromatin remodelers 
SWI/SNF along with HATs, to make the gene accessible for transcription. EBNA-2 then 
promotes assembly of the transcription complex by interacting with the general transcription 
factors TFIIH and TFIIE. Transcription initiation is activated by CDK9 stimulated 
phosphorylation of the Ser-5 and possibly the Ser-2 on the C-terminal domain (CTD). TFIIH 
also plays a role in Ser-5 phosphorylation through its bound subunit, CDK7. However, there is 
no evidence to suggest that EBNA-2 has a role in this process (Figure adapted from (Bark-
Jones, Webb and West 2006)). 
 
 
 
EBNA-2 functions in two ways; (i) reduce repression to allow up-regulation of its target 
genes, thus it binds to the repressor domain as described in (Figure 1-7) and abolishes 
the repression complex, (ii) EBNA-2 also brings a strong transcriptional activation 
domain to the promoter which plays an important role in the trans-activation of the 
target gene (Palermo, et al. 2008, Hsieh and Hayward 1995). EBNA-2 directly up-
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regulates the expression of a range of viral and cellular genes, some of the most 
significant among these targets are those encoding the activated B cell surface marker 
CD23, the cellular proto-oncogene c-myc, the B cell differentiation marker CD21, the 
anti-apoptotic Bcl-2 family member bfl-1, the B cell specific transcription factors 
Runx3 and BATF, the chemokine receptor CCR7 that navigates the B cell to lymphoid 
organs, along with the EBV LMP1, LMP2A and LMP2B and the EBNA Cp promoter 
(Pegman, et al. 2006b, Ling, et al. 1994, Johannsen, et al. 1995a, Burgstahler, et al. 
1995, Spender, et al. 2002) (Reviewed in(Kieff, E., Rickinson, A, B. 2007)). EBNA-2 
has also been shown to elicit negative transcriptional regulation. Evidence from LCL 
studies has exposed EBNA-2 as a repressive influence on Nurr77-mediated apoptosis. 
This inhibition mechanism involves the interaction of the EBNA-2 transcriptional 
complex with Nurr77 protein, sequestering Nurr77 within the nucleus and preventing 
signalling to the mitochondria that would otherwise lead to cytochrome c release and 
stimulation of apoptosis (Lee, et al. 2002, Li, et al. 2000). To date EBNA-2 is known to 
transcriptionally repress cellular genes the immunoglobulin heavy chain locus (IgM) 
(Jochner, et al. 1996), BCL6 and TCL1 (Boccellato, et al. 2007). DNA microarray 
studies have been used to catalogue EBNA-2 cellular target genes and proteins (Maier, 
et al. 2006, Spender, et al. 2006, Schlee, et al. 2004c). 
 
 
Latent promoter switching by EBNA-2  
 
It is accepted that transcription through the EBNA W promoter (Wp) is an inefficient 
process that leads only to the expression of the promoter proximal genes, EBNA-LP and 
EBNA-2 (Palermo, et al. 2008, Bell, et al. 1998), (see Figure 1-4: EBV Latent Genes. 
for Wp coordinates relative to the EBNAs). The Wp is located in the IR1 and thus there 
are multiple copies of the Wp present on the genome. This is thought to facilitate the 
production of abundant EBNA-2 transcripts which are required to switch transcription 
from the Wp. Initially the Wp drives EBNA expression, however as EBNA-LP and 
EBNA-2 expression increases transcription switches predominantly to the Cp promoter 
(Cp) (Palermo, et al. 2008). The Wp itself does not appear to competently maintain 
transcription to allow the remaining EBNAs to become fully transcribed. The Wp 
however produces sufficient EBNA-2 mRNA such that the EBNA-2 protein stimulates 
CDK9 dependant phosphorylation and recruits general transcription factors that activate 
and maintain the RNA pol II function from the Cp (Palermo, et al. 2008, Bark-Jones, 
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Webb and West 2006). The Cp contains an EBNA-2-responsive element (E2RE), 
allowing successful transcriptional initiation, promoter clearance, elongation and RNA 
processing of the product of interest. This yields a family of transcripts of up to 120 kb 
long that encodes the full range of EBNAs. Due to the inefficiency of the Wp activity, 
the switch to EBNA-2-led Cp transcription does not occur until approximately 48 hours 
after infection (Reviewed in (Palermo, et al. 2008)). EBNA-2 activation of Cp is 
required for transactivation of the remaining EBNAs (1, 3A, 3B and 3C) which are 
required for immortalisation. 
 
 
EBNA-2 subverts the cellular Notch Signalling pathway 
 
EBNA-2 subverts and manipulates B cell function, by usurping the mechanisms and 
diverse roles of Notch signalling in normal B cell physiology as well as B lymphocyte 
malignancy (Reviewed in (Kempkes,B., Strobl,L.J., Bornkamm,G.W., Zimber-Strobl, 
U. 2005, Johnson, et al. 2010)). In order to develop lymphocytes bearing functional 
receptors that are not harmful to the host, B cells are subjected to several checkpoints 
(apoptosis, proliferation or differentiation) at multiple stages of development (Cariappa, 
et al. 2001, Hase, et al. 2004, Rhee, et al. 2005, Mackay, et al. 2010). During B cell 
maturation, cell fate decisions are directed by signals derived from the 
microenvironment, and these interact with receptors expressed on developing B cells 
(Hardy and Hayakawa 2012, Wen, et al. 2005). These signals may be antigen-dependent 
through surface B cell receptor (BCR) on B cells (Kurosaki 2000, Kurosaki 2011) and 
modulated by co-stimulatory signals (Chung, et al. 2012). B cell maturation is also 
modulated by BCR independent signals, such as IL-4 (Sims, et al. 2005), IL-7 (Purohit, 
et al. 2003), IL-10 (Gary-Gouy, et al. 2002), BLyS/BAFF (Batten, et al. 2000) and 
Notch ligands (Cruickshank and Ulgiati 2010). Notch signalling regulates multiple 
aspects of lymphoid development and function and stimulates the development of 
marginal zone lymphocytes. It has been well documented that Notch is required for the 
later stages of B cell development, and Bertrand et al. showed Notch1 is expressed 
throughout human B cell development, while Notch2 is only detected in the late pre-B 
cell compartment (CD34−CD19+µlo) (Bertrand, et al. 2000). Several viral proteins 
appear to utilize Notch signalling in B cells to mediate their functions, including 
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Kaposi’s sarcoma-associated herpes virus (KSHV) and EBV (Cheng, Pekkonen and 
Ojala 2012).  
 
Functional overlap of EBNA-2 and Notch 
 
As stated previously, EBNA-2 function is elicited through the recruitment of cellular 
transcription factors such as CBF-1 which is a key component of the Notch signalling 
pathway. This CBF1-associated gene regulation usually relies upon activation of the 
Notch signalling cascade, however, EBNA-2 appears to act as a functional homologue 
of activated Notch, usurping the cellular Notch function and acting as a constitutively 
activated NIC (Hsieh, et al. 1996, Hayward 2004). The mechanism by which EBNA-2 
and NIC dismantle the CBF-1 repressor complex appears to be one and the same: each 
protein interacts with CBF-1 and SKIP, subsequently displacing SMRT/NcoR from the 
complex. Both EBNA-2 and NIC proceed to enlist chromatin modifying molecules, 
some of which overlap. EBNA-2 binds p300, PCAF and CBP (Wang, Grossman and 
Kieff 2000) and p100, a co-activator that stimulates TFIIE (Tong, et al. 1995b), while 
NIC recruits GCN4, PCAF and p300. Indeed, unsurprisingly EBNA-2 and NIC overlap in 
functional activities and target genes. Both EBNA-2 and NIC can inhibit Nur77-induced 
apoptosis by binding to and sequestering this pro-apoptotic transcription factor (Lee, et 
al. 2002, Jehn, et al. 1999). Both have also been implicated in modulating the activity of 
a number of overlapping genes in B cells such as Hes1, LMP2A (EBV), BATF, CD21 
and IgH. Contrastingly, Notch cannot regulate the EBNA-2 targets LMP1, CD23 and c-
myc (Reviewed in (Zimber-Strobl and Strobl 2001)). There is well documented 
evidence that EBNA-2 and Notch1-IC associate with different transcription factors 
other than CBF1, for instance PU.1 (Johannsen, et al. 1995b) and that this contributes to 
a different EBNA-2 versus Notch1 response. For example EBNA-LP cooperates with 
EBNA-2 in trans-activating the LMP1 promoter (Nitsche, Bell and Rickinson 1997). 
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1.7.3 The EBNA-3 family (EBNA-3A, EBNA-3B and EBNA-3C) 
 
The EBNA-3 family consists of 3 nuclear proteins, EBNA-3A, -3B and -3C (previously 
referred to as EBNA-3, EBNA-4, and EBNA-6 respectively). The nuclear proteins are 
encoded by alternatively spliced transcripts initiated at the Cp promoter (Kieff, 1996) 
and are composed of 944, 937 and 992 amino-acid residues, respectively (Petti et al, 
1990). While EBNA-3A and -3C are essential for the growth transformation of 
lymphocytes in vitro, EBNA-3B is not required for B cell immortalisation under these 
conditions (Young and Murray 2003a).  EBNA-3C can induce the up-regulation of both 
cellular and viral gene expression, and is also known to repress the Cp promoter (as 
reviewed in (Bark-Jones, Webb and West 2006, McClellan, et al. 2012)). EBNA-3C 
interacts with the retinoblastoma protein, pRb, to promote cell transformation (Skalska, 
et al. 2010). In addition, EBNA-3A and EBNA-3C co-operate as the main factors of 
drug resistance in BL cells and in the down-regulation of the pro-apoptotic Bcl-2-family 
member Bim (Skalska, et al. 2010). EBNA-3B has been shown to induce expression of 
vimentin and CD40 (Silins and Sculley 1994). All three EBNA-3 proteins can also bind 
CBF1, negatively regulating gene expression in the Notch pathway. This results in 
repression of EBNA-2 trans-activation, which in turn regulates the synthesis of the 
EBNA-3 proteins themselves (Skalska, et al. 2010). Thus the EBNA-3 proteins balance 
and fine-tune the action of EBNA-2 by precisely regulating CBF1 activity, thus 
regulating the expression of cellular and viral promoters containing CBF1 binding sites 
(Young and Rickinson 2004b, Skalska, et al. 2010).  
 
1.7.4 EBNA-LP 
 
The EBNA Leader Protein (EBNA-LP/EBNA-5) is one of the first viral proteins 
produced during EBV infection of B-lymphocytes (Portal, et al. 2011). EBNA-LP is 
encoded by the first ORF (leader sequence) of the extensively spliced primary 
transcript, originating from either the Wp or Cp promoter, and is composed a multi-
repeat domain (W1W2) and a unique carboxyl-terminal domain (Y1Y2). EBNA-LP 
encodes a protein of variable size (20-130 kDa) depending on the number of BamHI W 
repeats contained by a particular EBV isolate. During early infection in B cells and 
following expression of EBNA-LP in type I BL cell lines, EBNA-LP is distributed 
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throughout the nucleus, whereas in LCLs, EBNA-LP localises to promyelocytic 
leukemia nuclear bodies (PML NBs) (Ling, et al. 2005). Although not essential for 
transformation, EBNA-LP enhances the efficiency of the process (Portal, et al. 2011). 
EBNA-LP is known principally as a transcriptional co-activator of EBNA-2. It has 
previously been shown that EBNA-LP co-operates with EBNA-2 in the up-regulation of 
LMP1/LMP2 and Cp latency promoters in B cells and that EBNA-LP and EBNA-2 co-
operative to stimulate expression of cyclin D2 in resting B cells in addition to mediating 
G0 to G1 transition during immortalisation (Peng, et al. 2005a). EBNA-LP co-activates 
EBNA-2 through interacting with the promyelocytic leukemia nuclear body (PML NB)-
associated protein Sp100 and displacing Sp100 and heterochromatin protein 1 α (HP1α) 
from PML NBs (Ling et al, 2005). Numerous other co-factors that potentially associate 
with EBNA-LP have been identified including pRb, p53, hsp72/hsc73, hsp27, Hax-1, 
ERR1, p14ARF, DNA-Pkcs, α-tubulin, β-tubulin, prolyl-4-hydroxylase, and HA95 
(Ling, et al. 2005). However, to date, no correlation has been made between the 
association with these factors and EBNA-LPs ability to co-operate with EBNA-2.  
 
 
1.8 The EBV-encoded latent membrane proteins 
 
1.8.1 LMP1 
 
Latent Membrane Protein 1 (LMP1) is a major transforming protein of EBV. Several 
studies have shown that this protein functions as a classic oncogene and is essential for 
EBV-induced B-cell transformation in vitro (reviewed in (Young and Rickinson 2004b, 
Middeldorp and Pegtel 2008, Lo, et al. 2010)). LMP1 has pleiotropic effects when it is 
expressed in BL-derived cells, resulting in many of the phenotypic changes observed 
during EBV-infection, including induction of cell adhesion molecules and activation 
markers (Kieff, E., Rickinson, A, B. 2007), and the up-regulation of anti-apoptotic 
proteins Bcl-2, Mcl-1, Bfl-1, A20 and c-IAPs  (D'Souza, et al. 2004, Pratt, Zhang and 
Sugden 2012). LMP1 also induces cellular MicroRNA miR-146a, a modulator of 
lymphocyte signalling pathways (Cameron, et al. 2008). This 63 kDa integral 
membrane phosphoprotein functions as a constitutively activated receptor (Young and 
Murray 2003b) and is a member of the tumour necrosis factor receptor (TNFR) 
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superfamily, activating several signalling pathways in a ligand-independent manner (as 
reviewed in (Young and Rickinson 2004b)). Functionally, LMP1 mimics the cellular 
growth signal that normally results from the binding of CD40 ligand (another member 
of the TNFR superfamily) and can partially substitute for CD40 in vivo, providing both 
growth and differentiation signals to B cells (Graham, Arcipowski and Bishop 2010). 
The LMP1 protein can be divided into three domains (Figure 1-8).  Firstly, an amino-
terminal cytoplasmic tail (amino acids 1-23), which tethers LMP1 to the plasma 
membrane and orientates the protein.  Secondly, a trans-membrane region, consisting of 
six hydrophobic trans-membrane loops, which are involved in self-aggregation and 
oligomerisation (amino acids 24-186).  Third, a long carboxyl-terminal cytoplasmic 
region (amino acids 187-386), which possesses most of the signalling activity of the 
molecule (Young and Rickinson 2004a, Young and Murray 2003a). LMP1 signals 
mainly from the intracellular compartments. Both oligomerisation and localisation 
within glycosphingolipid-rich membrane rafts are essential for the initiation of 
signalling which results in the activation of several signalling pathways in a ligand-
independent manner that contributes to the many phenotypic consequences of LMP1 
expression (Lam and Sugden 2003). At least four signalling pathways have been 
implicated in the function of LMP1, namely nuclear factor κB (NF-κB), c-Jun NH2 
terminal kinase (JNK), p38/mitogen activated protein kinase (p38/MAPK) and janus 
kinase/signal transducers and activators of transcription (JAK/STAT) (Shair, et al. 
2007). It is the cytoplasmic C-terminus of LMP1 that is responsible for the transduction 
of signalling cascades that result in primary B cell transformation and phenotypic 
changes. Within the C-terminus of LMP1, there are at least two major activating 
domains (Figure 1-8), C-terminal activating region 1 (CTAR1) and CTAR2 (Young and 
Rickinson 2004b). CTAR1 (also known as transformation effector site 1, TES1) is 
located proximal to the membrane (amino acids 186-231), binds TNFR-associated 
factors (TRAFs), and is essential for EBV-mediated B-cell immortalisation.  
CTAR2/TES2, which is located near the C-terminus, supports the long-term growth of 
immortalised B cells and recruits the TNFR-associated death domain (TRADD) protein 
and receptor-interacting protein (RIP) (Eliopoulos, et al. 2003). The activities of 
CTAR1 and CTAR2 affect diverse signalling cascades and provide the basis for the 
transforming properties of LMP1. Figure 1-8 explaining the structure and function of 
LMP1. 
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Figure 1-8: Structure and Function of LMP1. 
The C-terminus of LMP1 contains at least two activating regions, referred to as C-terminus 
activation regions 1 and 2 (CTAR1 and CTAR2).  CTAR1, which is essential for EBV-
mediated B cell immortalisation, binds TRAF1, TRAF2, TRAF3 and TRAF5 and activates the 
NF-κB and p38 signalling pathways.  CTAR2 supports the long-term growth of immortalised B 
cells and recruits TRADD to activated downstream signals, such as NF-κB, JNK, and p38.  
Both LMP1 C-terminal domains also mediate the activation of the JAK/STAT pathway, 
although an intermediated region has also been shown to bind JAK3 and induce STAT binding 
activity independently of CTAR1 and CTAR2.  The trans-membrane domains of LMP1 are 
responsible for the activation of the small GTPase Cdc42 leading to cytoskeletal changes 
(adapted from Eliopoulos and Young, 2001). 
 
 
 
1.8.2  LMP2A and LMP2B 
 
Transcription of LMP2 is regulated by two separate promoters, located 3kb apart on the 
viral DNA (Speck, et al. 1999, Wasil, et al. 2013)(Speck, et al. 1999, Wasil, et al. 2013). 
Two mRNAs that have unique 5' exons followed by eight common exons encode two 
distinct proteins of 2.0 and 1.7kb in length, namely LMP2A and LMP2B, respectively 
(Speck, et al. 1999, Wasil, et al. 2013). Thus the structures of LMP2A and LMP2B are 
similar; LMP2A contains an N-terminal cytoplasmic domain of 119 amino acids with 
eight tyrosines that are phosphorylated in LCLs, 12 trans-membrane domains, and a C-
terminal domain of 12 amino acids. LMP2B, however, lacks the entire N-terminal 
cytoplasmic domain (Young and Rickinson 2004b).  
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The EBV LMP2A is a functional homologue of the cellular B Cell Receptor (BCR)  
(Schaadt, et al. 2005b), and constitutively associates with Src family kinases through its 
N-terminal cytoplasmic tail to activate Ras/PI3K/Akt (Moody, et al. 2005a) and 
mTOR (Moody, et al. 2005b) in order to signal to NF-κB (Guasparri, Bubman and 
Cesarman 2008). LMP2A is dispensable for LCL generation and B cell 
proliferation (Vrazo, et al. 2012), but seems to indorse survival through upregulation of 
Bcl-XL and Survivin (Portis, Dyck and Longnecker 2003). In certain cell models, 
LMP2A overcomes the necessity for BCR expression (Caldwell, Brown and 
Longnecker 2000, Caldwell, et al. 1998, Casola, et al. 2004), improves antibody 
production and plasma cells occurrence (Swanson-Mungerson, Bultema and 
Longnecker 2006), and alters tolerogenic signals prompted through the BCR on the 
transgenic BCRHEL background (Swanson-Mungerson, et al. 2005). 
LMP1 and LMP2A signalling mimics CD40 and BCR signalling, respectively, and has 
been suggested to modify B cell functions including the ability of latently-infected B 
cells to access and transit the germinal center. It has been shown recently in a transgenic 
mouse model that LMP1 and LMP2A coexpression changes B cell maturation and the 
response to antigen. In vitro, LMP1 upregulated activation markers and promoted B cell 
hyperproliferation, and co-expression of LMP2A restored a wild-type phenotype. It thus 
may be the case that LMP2A modulates LMP1 function (Vrazo, et al. 2012). LMP2A is 
known to block BCR signal transduction through specific phosphotyrosine motifs in its 
N-terminal domain, to prohibit induction of lytic EBV infection and to promote B-cell 
survival. Neither LMP2A nor LMP2B are essential for EBV-induced B-cell 
transformation in vitro (Mancao and Hammerschmidt 2007, Schaadt, et al. 2005a). 
While most of the research to date has focussed upon LMP2A, LMP2B has been shown 
to colocalise with LMP2A in the membrane where the C terminus of both splice variants 
can interact and regulate the activity of one another (Lynch et al, 2002). LMP2B was 
shown to negatively regulate LMP2A activity by interfering with its aggregation 
(Rovedo and Longnecker 2007). Furthermore, LMP2B has been found to regulate 
susceptibility to induction of lytic EBV infection (Rechsteiner, et al. 2008). 
Taken together, these data support a role for LMP2A in modifying the normal 
programme of B cell development to favour the maintenance of EBV latency and to 
prevent inappropriate activation of the EBV lytic cycle. It is also evident that LMP2B is 
involved in the regulation of switching from latent to lytic EBV in B cells harbouring 
functional EBV through impacting the activity of LMP2A (Rechsteiner et al, 2008).  
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1.9  Other EBV latent transcripts 
 
1.9.1  EBER1 and EBER2 
 
EBV encodes two small non-polyadenylated RNAs termed EBV-encoded RNAs 1 and 
2 (EBER 1 and EBER 2), the most abundant viral transcripts in latently EBV infected 
cells with the exception of oral hairy leukoplakia lesions from AIDS patients and some 
hepatocellular carcinomas. In addition to the latent proteins, EBER1 and EBER2 are 
expressed in all forms of latency (Wu, et al. 2007a). EBERs 1 and 2 are uncapped, non-
coding RNAs of 167 and 172 nucleotides respectively (Mahjoub, et al. 2008). The 
EBERs are not essential for the EBV-induced transformation of primary B 
lymphocytes, since recombinant EBV harbouring EBER gene deletions was able to 
infect but not able to transform lymphocytes (Yajima, Kanda and Takada 2005, Wu, et 
al. 2007b). Expression of the EBERs in BL cell lines has been found to increase 
tumourigenicity, promote cell survival and induce IL10 expression (Yajima, Kanda and 
Takada 2005, Sheikh and Qadri 2011, Iwakiri, et al. 2009) and it has been suggested 
that EBER-mediated inhibition of PKR (a latent, IFN-inducible Ser/Thr kinase) function 
might be important for viral persistence (Nanbo, et al. 2002). Furthermore, transfection 
of the EBER genes into the EBV-negative AKATA cell line restored the oncogenic 
potential that was originally present in the EBV-positive AKATA cells but was lost in 
the EBV-negative subclones (Nanbo, et al. 2002). 
 
1.9.2 BARTs/ CSTs 
 
The EBV Bam HI A rightward transcripts (BARTs) or complementary-strand 
transcripts (CSTs) are a group of abundantly expressed RNAs that are encoded by the 
Bam HI A region of the EBV genome and were originally identified in nasopharyngeal 
carcinoma (NPC) tumour tissues, but were subsequently found to be expressed in other 
EBV-associated malignancies, such as BL, HL and nasal T-cell lymphoma, as well as in 
the peripheral blood of healthy individuals (Reviewed in (Kieff, E., Rickinson, A, B. 
2007, Young and Rickinson 2004b, Yamamoto and Iwatsuki 2012)). The protein 
products –if any- of these highly spliced transcripts remain to be conclusively identified. 
Another transcript that is generated from the Bam HI A region is BARF1, which 
encodes a 31 kDa protein that was originally identified as an early antigen expressed 
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upon induction of the EBV lytic cycle. The BARTs are often expressed in 
circumstances in which the EBNA-2 and EBNA-3 proteins are not synthesised, such as 
epithelial cell infection and in EBV-associated malignancies in immunocompetent 
individuals (Yamamoto and Iwatsuki 2012).  
 
1.10 Serotypes of EBV 
 
Limited genetic variation has been found among the EBV isolates studied to date. 
Indeed, there are only two designated subtypes, known as type A and type B (also called 
as type 1 and type 2). EBV A and B were classified originally through the analysis of 
two EBV isolates that presented significant differences in their EBV nuclear antigen 2 
(EBNA-2)-coding regions (Chang, et al. 2009). EBV type A was characterised from an 
EBV genome isolated from an IM patient in North America, designated B95-8. AG987, 
a strain derived from an African BL case, was found to have a shorter EBNA-2 
sequence and was designated EBV type B. Remarkably, the EBNA-2s of the two strains 
show only 55% homology at the protein level (Knipe, D.M, Howley, P.M. 2001, 
Lucchesi, et al. 2008b). In the cell culture-based in vitro immortalisation assay, EBV 
Type A has been proven to be more competent at transforming human B cells into 
proliferating lymphoblastoid cell lines (LCLs) than EBV type B (Rickinson, Young and 
Rowe 1987). The two strains show differing geographical distributions. In Africa, both 
strains are present at approximately the same frequency, however the type A strain 
predominates in Europe and the United States (Reviewed in (Lucchesi, et al. 2008b)). 
The two serotypes show significant variation, including the presence of three additional 
open reading frames (ORFs) in type B (BFRF1A, BGLF3.5 and BDLF3.5) (Lacoste, et 
al. 2010, Dolan, et al. 2006) and type specific differences have been demonstrated to 
extend to EBNA-3A, EBNA-3B, EBNA-3C, EBNA-LP and the EBERs (Rickinson, 
Young and Rowe 1987, Sample, et al. 1990, Arrand, Young and Tugwood 1989). 
However the differences in the EBNA-2 region have been proven to be the key behind 
the altered transforming efficiency capabilities of the two strains. In 1989, Cohen et al 
proved that the distinction between the immortalising capabilities of the two strains was 
EBNA-2-dependant. A recombinant type B EBV strain was developed in which the type 
B EBNA-2 coding region was substituted by the coding sequence for type A EBNA-2. 
This resulted in an increased transforming efficiency in the type B strain on a par with 
the type A variant (Cohen and Kieff 1991, Lucchesi, et al. 2008a).  
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The diminished transformation proficiency of the type B EBNA-2 compared to the type 
A variant, has not yet been fully elucidated. However, a number of recent findings may 
clarify the differing effects of the two EBNA-2s on B cell immortalisation. The EBNA-
2 target LMP1 shows similar expression levels in LCLs proliferating due to either EBV 
type A or B. It has now been shown however, that there is a transient difference in 
LMP1 levels immediately following B cell infection by the two types of EBV 
(Lucchesi, et al. 2008b, Cohen, et al. 1989). The initial induction of LMP1 by EBNA-2 
type A is a significantly earlier and more intense response than the induction initiated 
by EBNA-2 type B. LMP1 is a key player in B cell immortalisation, and delayed 
expression caused by inefficient LMP1 induction by EBV type B may be one reason 
why the type B variant is less proficient at B cell immortalisation than type A EBV. A 
small number of cellular genes were also highlighted as differentially regulated by the 
two types of EBV (Lucchesi, et al. 2008b). 
 
 
1.11 EBV-Associated Diseases 
 
Primary infection of EBV in early childhood results in short-term proliferation of 
infected B cells. The infection is usually self-limited and controlled by the strongly 
elevated T cell immune response. If the infection occurs in adolescence or adulthood, up 
to 50% T cells in the host can be specific to the virus, which may develop the clinical 
symptom of infectious mononucleosis (IM). EBV then persists latently in the host 
within long-life memory B cells (Thorley-Lawson 2001a). After primary infection, a 
subset of EBV positive B cells survives and emerges into the memory compartment. 
These cells can go for limited expansion or extrafollicular proliferation and remain in 
the host for a long time. The virus can be reactivated periodically and infect new hosts 
through virus shedding in saliva. Although the virus is normally a harmless passenger in 
patients without obvious immune-deficiencies, EBV-associated lymphomas are well 
characterised, where the host’s cellular immune system fails to control EBV-induced B-
cell proliferation, thus the infected B cells can transform from their latent state into 
malignant cells. EBV infection has been linked to lymphoproliferative disorder of B, T 
and NK lymphocytes such as Burkitt’s lymphoma (Allday 2009), Hodgkin’s lymphoma 
(HD) (Ambinder 2007), peripheral T cell lymphoma and nasal T/NK lymphomas that 
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arise in both immunosuppressed and immunocompetent hosts (Dunleavy, Roschewski 
and Wilson 2012).  
Endemic Burkitt's lymphoma occurs frequently in young children in the equatorial 
regions of Africa and Papua New Guinea and has an incidence of 50-100 cases per 
1,000,000 individuals (Kutok and Wang 2006). In contrast, EBV-associated sporadic 
lymphomas occur in children and young adults and have no specific geographic 
distribution, with an incidence of 2-3 cases per 1,000,000 individuals (Kutok and Wang 
2006). EBV accounts for 40 - 50% of childhood non-Hodgkin's lymphomas (NHLs) and 
1-2% of adult lymphomas in Western Europe and the United States. Endemic Burkitt's 
lymphoma is almost 100% associated with EBV, whereas, association of sporadic 
Burkitt's lymphoma with EBV is low (15-30% of cases) (Kutok and Wang 2006). 
Nasopharyngeal carcinoma (NPC) (Gullo, Low and Teoh 2008) is most common in 
southern China, and accounts for approximately 20% of all adult cancers. It is extremely 
rare in Europe and North America, with an incidence rate of less than one per 100,000 
population (Shah and Young 2009, Magrath 2012). EBV has also been associated with a 
host of non-lymphoid malignancies including smooth muscle tumours in 
immunocompromised patients (Purgina, et al. 2011) and a selection of gastric 
carcinomas (Iizasa, et al. 2012, Paniz-Mondolfi, et al. 2013). There is evidence that 
EBV triggers autoimmune liver disease (Rigopoulou, et al. 2012), thyroid disease, 
multiple sclerosis (MS) (Tzartos, et al. 2012, Holmoy 2008b) systemic lupus 
erythematous (SLE), and rheumatoid arthritis (RA) (Lossius, et al. 2012). It has been 
observed from a diverse panel of cancers that high grade tumours are three times more 
likely to be EBV-positive than corresponding low grade tumours (Qin, et al. 2002, 
Hummel, et al. 1995)(Qin, et al. 2002). A list of EBV-associated diseases and their 
features are given in Table 1-3. 
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Table 1-3: EBV Associated Diseases 
Non-Malignant EBV Associated Diseases 
Disease Infection Site Latency 
Infectious mononucleosis (IM) B cell III 
Chronic active EBV B cell III 
Oral hairy leukoplakia (OHL) Epithelium N/A 
Malignant EBV Associated Diseases 
Burkitt's Lymphoma (BL) B cell I 
Hodgkin’s Disease (HD) B cell II 
Nasopharyngeal Carcinoma (NPC) Epithelium II 
T/NK Lymphoma T Cell II 
Peripheral T Cell Lymphoma T Cell II 
Gastric Carcinoma Epithelium II 
AIDS-Burkitt's Lymphoma B cell I/II 
AIDS-immunoblastic or large cell lymphoma B cell II/III 
X-linked lymphoproliferative disease B cell III 
Post-transplant lymphoproliferative disease 
(PTLD) 
B cell III 
AIDS-CNS lymphoma  III 
Lymphatoid granulomatosis B cell III 
Smooth muscle tumours (e.g. 
Leiomyosarcomas) 
 
Mesenchymal Various 
   
 
 
The loss of gene promoter methylation has been suggested to play a key part in early 
stages of haematological malignancies including B cell malignancies (Lee, et al. 2012). 
DNA methylation in gene promoters has a key role for repressing gene expression, and 
the hypomethylation of this region is associated with gene activation (Ooi, O'Donnell 
and Bestor 2009, Poetsch and Plass 2011). Recent comprehensive studies indicated that 
the B cell transcription program is associated with gene promoter hypomethylation and 
overexpression of key genes in Epstein-Barr virus-associated transformation of resting 
B lymphocytes (RBLs) to proliferating B lymphoblastoid cells. EBV-mediated 
transformation and B cell activation share common pathways (Thorley-Lawson 2001a), 
however methylation changes associated with EBV-mediated transformation to LCLs 
are independent of B cell activation and hypomethylation takes place only when 
proliferation has started (Hernando, et al. 2013). Hernando et al, showed that the 
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maintenance of DNA methylation is less efficient in transcriptionally active regions as 
cells start to proliferate. B cell transcription machinery was observed to associate with 
the subset of genes that undergo hypomethylation and further upregulation of genes 
relevant in EBV-mediated transformation of B lymphocytes (Hernando, et al. 2013). 
There are three main types of Burkitt's lymphoma; Endemic (mainly occurs in 
equatorial Africa, associates with chronic EBV and Malaria infection), Sporadic 
(occurring in scattered instances outside of Africa, also associates with EBV but to a 
lesser degree) and Immunodeficiency-associated, (usually associated with HIV 
infection or the use of immunosuppressive drugs, also associated with EBV infection). 
The B lymphocytes in BL have rearranged immunoglobulin genes and contain one of 
three translocations of the proto-oncogene c-myc, c-myc/Ig (8:14, 2:8, 8:22), and the 
most common translocation is from the long arm of chromosome 8 to chromosome 14, 
t(8:14). The complex interaction of EBV, Malaria, and HIV with B lymphocytes as 
cofactors in BL, enhances B cell activation and proliferation and therefore survival of B 
cells carrying the c-mys/Ig translocation (Reviews, (Thorley-Lawson, Duca and Shapiro 
2008, Brady, Macarthur and Farrell 2008)).  
Hodgkin lymphoma (HL) is derived from B cells and subdivided into classical HL 
(cHL) and nodular lymphocyte predominant HL (NLPHL) (Eberle, Mani and Jaffe 
2009). Classical HL is further divided by histological measures into mixed-cellularity, 
nodular-sclerosis, lymphocyte-rich, and lymphocyte-depleted subtypes. These so-called 
classical forms of the disease are different from lymphocyte-predominant HL in 
NLPHL, which is not associated with EBV (Reviewed in (Banerjee 2011)). HL is 
distinctive amongst human B cell lymphomas because of the infrequency of the 
malignant cells (the Hodgkin and Reed-Sternberg (H/RS) cells) in classical HL and the 
lymphocyte-predominant (LP) cells in NLPHL, which usually account for 0.1% to 10% 
of the cells in the affected tissues (Kuppers 2009). Furthermore, H/RS cells are unique 
in the extent to which they have lost their B cell typical gene expression pattern, for 
instance when H/RS cells acquire Ig mutations during affinity maturation that results in 
a non-functional Ig molecule (Brauninger, et al. 2006). Deregulation of transcription 
factor networks plays a key role in this reprogramming process. H/RS cells show strong 
constitutive activity of the transcription factor NF-κB (Younes, Garg and Aggarwal 
2003). Multiple mechanisms likely contribute to this deregulated activation, including 
signalling through particular receptors and genetic lesions. Inactivating mutations or 
deletion in the TNFAIP3 tumor suppressor gene, encoding a negative regulator of NF-
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κB activity, were recently identified in about 40% of patients with classical HL 
(Nomoto, et al. 2012). H/RS cells are latently (Type II latency) infected by EBV in 
about 40% of patients (Ambinder 2007), and an important role of this virus in HL 
pathogenesis, in particular for cases in which H/RS cells had lost the capacity to express 
a BCR due to destructive somatic mutation/ suggests that these B cells can be rescued 
by activation of this transcription factor and subsequent induction of anti-apoptotic cell 
genes.  Bfl-1 is an NF-κB target gene and plays a critical role in this cell context 
(Loughran, et al. 2011). Thus, EBV infection may provide alternative mechanisms for 
rescuing abnormal B cells from apoptosis and illustrates how EBV gene products can 
substitute for specific molecular alterations that are important for tumorigenesis. 
 
The association between EBV infection and NPC is complex and not yet completely 
defined. EBV infection alone is not enough to cause NPC, since more than 95% of 
human population are EBV seropositive and occurrences of this cancer is rare (Shah, et 
al. 2000, Lin 2009). Other factors, such as a person’s genes, diet, work place (exposure 
to formaldehyde or wood dust (Hildesheim, et al. 2001)) may contribute, along with 
EBV, to the development of NPC. For instance NPC is found about twice as often in 
males as it is in females (Xie, et al. 2013). People who live in parts of Asia, northern 
Africa, and the Arctic region (Devi, et al. 2004), where NPC is common, typically eat 
diets very high in salt-cured fish and meat. Indeed, the ratio of this cancer is falling in 
places where those traditional diets are now higher in fruits and vegetables (Hsu, et al. 
2012b, Yu, et al. 1986). 
 
 
1.12 Regulation of cell growth and survival by EBV 
 
Suppression of the cellular apoptotic program by EBV is central to both the 
establishment of latent infection and the development of EBV-associated malignancies. 
When EBV infects it primarily encounters resting B cells in the oropharyngeal mucosal 
lymphoid tissue (Kieff, E., Rickinson, A, B. 2007, Sarid and Gao 2010). It drives the 
infected cells into cell cycle and maintains cell division, increasing the population of 
infected cells and allowing them to progress, via the B-cell maturation pathways, to the 
site of latent persistence of the virus, in resting memory B cells. The complex 
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mechanisms by which EBV affects cell growth and can prevent cell death are a result of 
a combination of EBV-induced pathways that affect both cell growth and apoptosis, and 
the co-operative roles of the latent genes, especially EBNA-2, EBNA-3C and LMP1 in 
these processes has long been established (Richards, et al. 2008). 
 
1.12.1 EBV affects Cell Cycle Progression 
 
Cells typically progress through the cell cycle in an orderly fashion through a growth 
phase (G0/G1), to a synthetic phase in which the DNA is copied (S), to a second growth 
phase (G2), prior to cell division or mitosis (M) and back to a quiescent cell arrest phase 
(G0/G1) following cell division (Figure 1-9).  Entry of a B lymphocyte into the cell 
cycle is a well-co-ordinated procedure. Mitogenic signals may be derived from a range 
of sources: from protein or polysaccharide antigens (Ags) that stimulate the B cell 
receptor (BCR), to pathogenic products that signal via Toll like receptors (TLRs) 
(Allen, Okada and Cyster 2007, Gerondakis, Grumont and Banerjee 2007, Niiro and 
Clark 2002). Proliferation occurs only at precise points during a B cell's development or 
through an immune response, when the B cells increase in reaction to Ags and form 
germinal centres (GCs) with T cell help (Allen, Okada and Cyster 2007). Deregulated 
proliferation is a trademark of autoimmunity, where autoreactive B cells react to 
stimulation with activation rather than anergy, and in B cell cancers, where proliferation 
can be detached from external controls (Cambier, et al. 2007). 
Progression through the cell cycle is regulated by many different proteins, such as 
tumour suppressor gene products, p53 and pRb (retinoblastoma gene product), which 
act within the cell cycle facilitating the repair of damaged or mutated DNA within 
single cells, or alternatively, induce these injured cells to undergo apoptosis (Fajas 
2013, Matsumoto and Nakayama 2013). EBV exploits normal cellular pathways to 
regulate cell cycle progression. Indeed EBV genes can manipulate the proliferation 
machinery of the infected cell through the deregulation of the function of several 
oncogenes and tumour suppressor genes implicated in the cell cycle such as c-myc, p53 
and pRb, thus inhibiting the ability of these proteins to redirect cells with damaged or 
mutated DNA toward a DNA repair pathway or apoptosis. As a consequence, host cells 
with latent viral infection are allowed to proliferate without regulation. Although rare 
events, these virally-infected cells may then develop mutations induced by ‘DNA-
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damaging’ events, including tobacco, alcohol, carcinogens, toxins, ionizing radiation, 
prolonged ultraviolet light/sun exposure, chemical insult, or even other viral infections 
which may result in the development of a malignant tumour (Flaitz and Hicks 1998).  
 
 
Figure 1-9: Phases of lymphocyte cell cycle 
 
The cell cycle may be divided into four distinct phases; G1, S-phase, G2 and M-phase.  
The G1 phase of the cell cycle is the longest and occurs prior to DNA synthesis, which 
occurs during S-phase.  During M-phase, cell division takes place.  The progression 
through the cell cycle is regulated by many different proteins, some of which are 
illustrated.  The first biochemical event observed, in early G1 phase, is the induction of 
the D-type cyclins and their partners, cyclin dependent kinases (cdks), cdk4 and cdk6.  
One of either cd4 or cd6 partners a D- type cyclin, in the absence of cyclin dependent 
kinase inhibitors (CDKIs), to become catalytically active.  The induction of D-type 
cyclins is paralleled by a loss in CDKIs.  The most important substrate of the cyclin 
D/cd4/6 complex is the family of pocket proteins, typified by pRb, the retinoblastoma 
susceptibility gene product.  Other members of the pocket protein family include p130 
and p107.  These pocket proteins repress a family of transcription factors called E2F, 
and the E2F-pocket protein complexes also act as gene suppressors.  Phosphorylation of 
pRb by the cyclin D/cdc4/6 complex results in the release of E2F transcription factors 
and transcription of E2F-responsive genes.  E2F binding sites have been identified in 
the promoters of many genes important for cell cycle regulation and the promoters of 
proteins involved in DNA synthesis.  In many systems, the induction of E2F 
transcriptional activity results in entry into the cell cycle (Adapted from Brennan, 
2001). 
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Interactions of EBV proteins with the cell cycle 
 
EBV facilitates the establishment of a persistent viral infection in the host by 
influencing pathways that control cell cycle checkpoints (G1/S, G2/M and mitotic cell 
cycle checkpoints) and DNA repair (Seto, et al. 2010, O'Nions and Allday 2004). Cyclin 
D2 is probably the first cell cycle protein to be induced following EBV infection of B 
cells and it is accompanied by a loss of the CDKI p27kip1(Dolcetti and Carbone 2010).  
Phosphorylation of the pocket protein pRb is observed approximately 6 hours later.  All 
these events correspond to those seen during normal B cell proliferation, thus implying 
that EBV exploits normal cell pathways to regulate pRb phosphorylation during the cell 
cycle (Frost, et al. 2001a). 
 
 pRb 
 
Retinoblastoma protein (pRb) is a central regulator of cellular proliferation, controlling 
entry into G1/S in the cell cycle, mainly through its interaction with the cellular 
transcription factor E2F, which activates genes important in DNA synthesis (Fajas 
2013). EBV has been shown to regulate pRb-modulated pathways and to drive cells 
through the G1/S restriction point (Saha, et al. 2011) (Figure 1-9). Through the up-
regulation of cyclins involved in the inactivation of pRb, such as cyclin D2 and cyclin 
A, or by directly inactivating pRb itself, EBV liberates the E2F transcription factors to 
drive potentially infected cells through the cell cycle. In this regard, it has been shown 
that EBNA-2 and EBNA-LP are sufficient to activate the expression of cyclin D2 
during immortalisation of resting human B lymphocytes (Sinclair et al, 1994) and 
LMP1 is also thought to regulate cyclin D2 (Arvanitakis, Yaseen and Sharma 1995). 
Moreover, the c-myc oncogene, a direct target of EBNA-2 (Polack, et al. 1996, Schlee, 
et al. 2004a) has also been shown to trans-activate the cyclin D2 promoter (Bouchard, 
et al. 2001). EBV may also repress cyclin dependent kinase inhibitors in order to 
facilitate the inactivation of pRb. The induction of cyclin D2 is paralleled by the loss of 
the CDKI p27kip1 in response to EBV (Frost, et al. 2001b) and EBNA-3C has been 
shown to play a role in the regulation of p27kip1 (Knight and Robertson 2004).  Since 
cyclin D2 and p27kip1 together regulate the cyclin dependent kinases, cdk4 and cdk6 
activity, the link between EBNA-3C and p27kip1 suggests that EBNA-3C along with 
EBNA-2, EBNA-LP and LMP1 is implicated in the progression through the G1 phase of 
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the cell cycle. Recent studies conducted in LCLs showed that EBNA-3C stabilizes as 
well as enhances the functional activity of Cyclin D1 and subsequently enhances the 
kinase activity of Cyclin D1/CDK6 which enables ubiquitination and degradation of 
pRb. Thus this complex efficiently reverses the inhibitory effect of pRb on cell growth 
and enables the G1/S transition in EBV transformed LCLs (Saha, et al. 2011). 
Cyclin A, an activator of S phase progression, has been shown to interact with the 
carboxyl terminus of EBNA-3C in vitro. EBNA-3C has been shown to stimulate cyclin 
A-dependent kinase activity and rescue p27-mediated inhibition of cyclin A/Cdk2 
kinase activity by decreasing the molecular association between cyclin A and p27 in 
cells (Knight and Robertson 2004). In addition, EBNA-3C can target the SCFSkp2 
complex, thereby regulating the activity and stability of cyclin A/cdk2 and pRb 
complexes (Knight and Robertson 2004, Knight, Sharma and Robertson 2005a, Knight, 
Sharma and Robertson 2005b). 
 
p53  
 
The p53 pathway is targeted for inactivation in most human cancers either directly or 
indirectly, highlighting its critical function as a tumour suppressor. p53 is normally 
activated by cellular stress and mediates a growth-suppressive response that involves 
cell cycle arrest and apoptosis (Olsson, et al. 2012, Kuribayashi and El-Deiry 2008, 
Kuribayashi, Finnberg and El-Deiry 2008). Elevated incidences of p53 mutation have 
been identified in BL tumour biopsies and BL cell lines (Gaidano, et al. 1991). In 
addition BL cells with p53 mutations have been shown to be relatively resistant to 
DNA-damaging drugs such as cisplatin compared to those cell lines harboring wild-type 
p53 (Gaidano, et al. 1991, Simoes Magluta, et al. 2009). EBV LMP1 can protect against 
wild-type p53 mediated apoptosis (Fries, Miller and Raab-Traub 1996a). Moreover, 
LMP1 regulates p53 both at transcriptional and translational level (Li, et al. 2012). In 
addition, BZLF1 has been shown to interact with p53 and inhibit its trans-activating 
function in lymphoid cells (Mauser, et al. 2002) and EBNA-LP can also interact with 
p53 in vitro, although the functional significance of this interaction has not yet been 
determined (Szekely, et al. 1993). Moreover EBNA-3C has been shown to block p53-
mediated apoptosis through stabilizing Gemin3,  a member of DEAD RNA helicase 
family which exhibits diverse cellular functions including DNA transcription, 
recombination and repair, and RNA metabolism (Cai, et al. 2011). 
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c-Myc  
 
c-Myc, a helix-loop-helix leucine zipper transcription factor, is known to be involved in 
numerous cellular functions such as cell cycle progression, apoptosis, cellular 
transformation cell proliferation, adhesion, and differentiation in a variety of different 
cell types. Myc promotes proliferation and growth through both the induction of genes 
involved in cell cycle control (including CDK4, CDC25A, cyclin D1, D2, A, and E), and 
through the suppression of growth-arresting genes (such as GADD45, p15INK4b, 
p21CIP1, p27KIP1, GAS1) and induction of (p16INK4A and p14ARF) (Rui and 
Goodnow 2006, Maruo, et al. 2011). The C-terminal basic helix–loop–helix zipper 
domain facilitates binding to DNA sequences with the core consensus sequence 5’-
CACGTG’3’ known as an "E-box", and requires the association of its hetero-dimeric 
partner, Max (Brady, Macarthur and Farrell 2008). c-Myc also possesses an N-terminal 
trans-activation domain through which it drives the expression of a multitude of target 
genes (Brady, Macarthur and Farrell 2008). To date, there are approaching 1,700 genes 
which have been identified as Myc-responsive genes (www.myccancergene.org). 
However, only a minority of these have been implicated as direct target genes (Sionov 
2013, Zeller, et al. 2006). c-Myc expression is required to drive cells through the G1 into 
the S phase of the cell cycle (Figure 1-9). A model explaining the role of c-Myc in the 
apparently diverse roles of apoptosis and proliferation, predicts that c-Myc expression 
preferentially results in proliferation under favorable growth conditions with this 
activity being dependent on its apoptosis-promoting activity being blocked (Evan, et al. 
1994, Jamerson, Johnson and Dickson 2000). c-Myc also regulates gene expression by 
upregulating microRNAs (miR-17 and miR-20a) which regulate E2F1 and cyclin D1 
translation or by down regulation of a series of microRNAs (miR-30 cluster miR-15a, 
miR-16, tumour suppressor let-7 miRNA, miR-22, miR-23a/b, miR-26a/b, miR-29a/b/c, 
miR-34a, miR-146a, miR-150, and miR-195) (reviewed in (Sionov 2013)). 
c-Myc over-expression has been observed in tumour cells from 91% of BL cases. 
Indeed, chromosomal translocations of c-myc into the Ig loci is observed in practically 
all BLs, and the most frequent translocation, the c-myc/IgH t(8; 14), accounts for 
approximately 80% of these. The remaining 20% of cases are split between the 
translocations with the IgK and IgL (t(2;8) and t(8;22) respectively). The c-myc gene 
becomes transcriptionally activated as a consequence of the chromosomal translocation 
and is sustained by up-stream c-myc regulators such as NF-κB or BCL-6 (Rui and 
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Goodnow, 2006). Thus c-Myc deregulation is regarded as priming normal proliferating 
cells for apoptosis (Sionov 2013). It is clear that c-Myc expression is deregulated in 
EBV-immortalised (non-tumour-derived) B cells (Cherney, Bhatia and Tosato 1994). 
Studies using an LCL in which the function of EBNA-2 is dependent on the presence of 
oestrogen have revealed that EBNA-2 is the EBV protein predominantly responsible for 
driving c-Myc in LCLs (Kempkes, et al. 1995b) and that c-myc is a direct target gene of 
EBNA-2 in this context (Kaiser et al, 1999; Moore et al, 2001). c-Myc is also induced to 
moderate levels by LMP1 (Schlee, et al. 2004b). In addition EBNA-3C has been shown 
to stabilise c-myc expression, and this recruitment of both c-Myc together with its 
cofactor Skp2 to c-myc-dependent promoters can enhance c-Myc-dependent 
transcription (Bajaj, et al. 2008). 
 
 
1.13 Cytokines activated during EBV-mediated immortalisation 
 
Following B lymphocyte activation, EBV also induces the synthesis of several 
cytokines including TNF, IL-1, IL-6 and IL-10. Both IL-6 and IL-10 play a significant 
role in the growth of EBV-transformed cells (Wroblewski, et al. 2002, Spender, et al. 
2001a, Incrocci, McCormack and Swanson-Mungerson 2013b, Waldman, et al. 2008, 
Eliopoulos, et al. 1997). LMP1 has been implicated in the regulation of both of these 
cytokines via NF-κB and the p38 stress-activated protein kinase (Eliopoulos, et al. 1997, 
Wakisaka and Pagano 2003).  Further studies indicate that IL-10 may also be regulated 
by the EBERs (Sheikh and Qadri 2011) and by the EBV transcription factor EB1/Zta 
(Mahot, et al. 2003) and LMP2A (Incrocci, McCormack and Swanson-Mungerson 
2013a). The receptor molecules that IL-6 and IL-10 use to mediate their activities both 
activate the JAK family of tyrosine kinases, and downstream signalling cascades 
including STAT proteins and the PI3K pathway (Brennan 2001). Significantly, IL-10 
has been shown to act as a co-factor for B cell growth (Moore, et al. 2001), and it has 
been demonstrated that PI3K is important for IL-10-mediated cell growth of both 
primary monocytes and a murine mast cell line (Antoniv and Ivashkiv 2011). 
Interestingly, EBV vIL-10 enhances the growth transformation of a B cell infected with 
EBV (Jochum, et al. 2012) and both human and EBV-encoded IL-10 can induce LMP1 
in the absence of EBNA-2 (in the Daudi, P3HR1, and other BL cell lines) (Kis, et al. 
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2006). Furthermore, exposure of the KMH2-EBV cells to CD40-ligand and IL-4 
induced LMP1 expression, in the absence of EBNA-2 and IL-10 could induce the 
expression of LMP1 in tonsillar B cells infected with the non-transforming, EBNA-2-
deficient EBV strain P3HR1 and enhance LMP1 expression in two EBV-positive NK 
lymphoma lines suggesting that IL-10 might contribute to the establishment of type II 
EBV latency (Kis, et al. 2006). 
 
1.14 Signalling Molecules involved in EBV-mediated immortalisation 
 
Constitutively active signalling pathways are a common feature of many malignant 
cells.  Thus, it is important to characterise the potential role of signalling molecules that 
are activated by EBV-induced cytokines and by EBV gene products themselves. The 
pathways activated by IL-6 and IL-10 (JAK family of tyrosine kinases, PI3K and 
STATs) have previously been implicated in lymphocyte growth and transformation 
(Rane and Reddy 2000). The STAT family of transcription factors are one substrate of 
the JAK family of tyrosine kinases. STATs have been shown to be active in EBV-
immortalised cells (Weber-Nordt, et al. 1996) and are thought to play a role in 
oncogenesis (O'Shea, Holland and Staudt 2013). It has also been reported that LMP1 
can activate JAK3 and STAT1 (Gires, et al. 1999) and a STAT reporter that is known to 
bind STAT1, STAT3 and STAT5 (Brennan 2001, O'Shea, Holland and Staudt 2013).   
PI3K, a lipid kinase that is involved in lymphocyte survival and proliferation (Novak, et 
al. 2010, Beckwith, et al. 1996, Brennan, et al. 2002), can be activated by oncogenic 
Ras (Yang, et al. 2012). Reports indicate that pathways downstream of the small G 
protein Ras are active in EBV-immortalised cells and significantly, inhibition of PI3K 
using a chemical inhibitor, inhibits the proliferation of EBV-immortalised cells (Yang, 
et al. 2012, Castellano and Downward 2011). Interestingly, LMP2 was found to activate 
a PI3K-mediated pathway, Akt (Portis and Longnecker 2004).  Furthermore, PI3K has 
also been shown to affect D-type cyclin expression in EBV-immortalised B cells 
(Brennan 2001), suggesting a mechanism for its role in EBV-induced lymphocyte 
growth.   
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1.15 Apoptosis 
 
The induction of early cell death in response to viral infection would limit virus 
production and consequently diminish or eliminate spread of virus progeny in a 
population. Thus, in order to maximise their replicative capacity many viruses 
deregulate the normal cell cycle and secure selective advantage and biological success 
by developing mechanisms which either suppresses or triggers apoptosis. By preventing 
infected lymphocytes from undergoing apoptosis, EBV ensures survival/persistence in 
the host system (Spender and Inman 2011, Fu, He and Mao 2013). Apoptosis is a 
genetically controlled pre-programmed cellular suicide, in which individual cells are 
destroyed while the integrity of the surrounding tissue is preserved.  While this targeted 
cell destruction is essential in many physiological contexts including embryogenesis, 
immune cell maturation and response, tissue homeostasis and in the cellular response to 
injury, it also functions as an emergency response to aberrant growth induced by the 
activation of oncogenes and viral infection and its deregulation is implicated in many 
pathological states(Taylor, Cullen and Martin 2008b). The process involves dramatic 
morphological changes including cell shrinkage, nuclear re-organisation, plasma 
membrane blebbing and eventual fragmentation of the cell into membrane bound 
apoptotic bodies (Giansanti, Torriglia and Scovassi 2011, Saraste and Pulkki 2000).  
Apoptosis is orchestrated by a family of cysteine proteases known as the caspases. 
These molecules are activated upon receipt of divergent pro-apoptotic stimuli and play 
an essential role in the implementation of apoptosis coordinating the efficient 
dismantling and engulfment of targeted cells. Caspases are synthesised as relatively 
inactive precursors that require proteolytic processing in order to achieve activation 
(MacKenzie and Clark 2012).  To date, fourteen caspases have been identified, with 
eleven caspases known to be expressed in humans. Depending on their involvement in 
the life and death of a cell, caspases are broadly divided into apoptotic or inflammatory 
caspases (Figure 1-10). The inflammatory caspases are involved in cytokine activation 
(Caspase 1, 4, 5). The apoptotic caspases are generally divided into two distinct groups; 
initiator caspases (Caspase 2, 8, 9, 10) at the top of the cascade, which are activated first 
by the action of caspase adaptor molecules, such as Fas-associated protein with death 
domain (FADD) or apoptotic protease-activating factor-1 (Apaf-1). These molecules 
instigate a caspase cascade, activating the effector caspases (Caspase 3, 6, 7) further 
downstream, whose function is principally to dismantle cellular structures. There are 
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three main apoptotic cascades activated by specific initiator caspases: the death receptor 
pathway, the mitochondrial pathway and the ER pathway. These are activated by 
caspase-8, caspase-9, and caspase-12, respectively (MacKenzie and Clark 2012, Bratton 
and Salvesen 2010, Gupta, Reutelingsperger and Narula 2005).  
 
 
Figure 1-10: The caspase family 
The major groups of caspases, apoptotic (with two main subgroups of effectors and initiators 
caspases) and inflammatory caspases are illustrated in figure. Caspases contain three main 
domains: a prodomain and large and small catalytic subunits. Activation of caspases involves 
the proteolytic cleavage of zymogens, the removal of the prodomain and separation of the large 
and small subunits. The prodomains of activator and inflammatory caspases contain protein–
protein-interaction domains (such as the caspase-recruitment domain (CARD) and the death 
effector domain (DED)) that link them to apoptosis signalling molecules. Figure adapted from 
(MacKenzie and Clark 2012). 
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Two separate pathways of apoptotic cell death can be distinguished by the involvement 
of the Bcl-2 family proteins and by which caspases are required for their execution 
(Figure 1-11) (Giansanti, Torriglia and Scovassi 2011, Youle and Strasser 2008). The 
intrinsic pathway, (also called the Bcl-2-regulated or mitochondrial pathway), is 
activated by various developmental triggers or cytotoxic insults, such as viral infection, 
DNA damage and growth-factor deprivation, and is regulated by the Bcl-2 family of 
proteins. This pathway predominantly leads to the activation of caspase-9 but in certain 
cell types is known to take place in the absence of caspase-9 or Apaf-1(Youle and 
Strasser 2008, Hardwick and Soane 2013). The extrinsic (or death-receptor pathway) is 
triggered by ligation of the death receptor molecules such as Fas or tumour necrosis 
factor (TNF) receptor-1 (TNFR1) (members of the TNF receptor family) which harbour 
an intracellular death domain with the ability to recruit and activate caspase-8 through 
FADD at the cell surface (Youle and Strasser 2008, Schultz and Harrington 2003, 
Cancro 2009). This recruitment causes subsequent activation of downstream effector 
caspases, such as caspase-3, -6 or -7, independently of any involvement of the Bcl-2 
family (described in Figure 1-11). Interestingly, it has been suggested that the two 
pathways may also be interconnected and that the molecules in one pathway have the 
ability to influence those of the other. In this regard it has been established that the 
extrinsic pathway can intersect the intrinsic pathway through caspase-8 cleavage-
mediated activation of the pro-apoptotic BH3-only protein Bid in which the C-terminal 
truncated form of Bid (tBid) translocates to mitochondria from where it promotes 
further caspase activation through the intrinsic pathway (Caspase 9) (Tait and Green 
2010).  
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Figure 1-11: A schematic drawing depicting intrinsic and extrinsic pathways of 
apoptosis 
Apoptosis can be triggered by cell surface receptors, (such as Fas and TNFR1) (extrinsic 
pathway, right), or by genotoxic agents, metabolic insults or transcriptional cues (intrinsic 
pathway, left). The intrinsic pathway begins with BH3-only protein induction or post-
translational activation, resulting in the inactivation of some Bcl-2 family members. This 
relieves inhibition of Bax and Bak activation, which in turn promotes apoptosis. Some BH3-
only proteins, such as Bim and Puma, may also be able to activate Bax and/or Bak (as shown by 
the dotted line). When activated, Bax and Bak promote cytochrome c release and mitochondrial 
fission, leading to activation of Apaf-1 into an apoptosome and activation of caspase-9. 
Caspases in turn cleave a series of substrates, activate DNases and orchestrate the destruction of 
the cell. Mitochondrial release of second mitochondrial derived activator of caspase (SMAC) 
and OMI neutralizes the caspase inhibitory function of X-linked inhibitor of apoptosis protein 
(XIAP). The extrinsic pathway can bypass the mitochondrial step and activate caspase-8 
directly, ultimately leading to cell demolition. The Bcl-2 family regulates the intrinsic pathway 
and can modulate the extrinsic pathway when cleavage of Bid communicates between the two 
pathways. A detailed discussion of the Bcl-2 family can be found in Section 1.15.1 (Adopted 
from (Hardwick and Soane 2013)). 
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The extrinsic and intrinsic pathways both come together upon the execution phase, 
which is considered the final chapter of apoptosis, beginning with the activation of the 
effector caspases. Caspase-3, caspase-6, and caspase-7 function as effector caspases 
activating cytoplasmic endonucleases and proteases, which degrade nuclear material 
and cytoskeletal proteins (MacKenzie and Clark 2012, Bratton and Salvesen 2010). 
These effector caspases cleave various substrates including cytokeratins, PARP, the 
plasma membrane cytoskeletal protein alpha fodrin, the nuclear protein NuMA and 
others, ultimately causing the morphological and biochemical alterations seen in 
apoptotic cells. Caspase-3 is thought to be the most important of the effector caspases, 
and is activated in response to any of the initiator caspases. Caspase-3 specifically 
activates the endonuclease caspase-activated DNase (CAD). In healthy proliferating 
cells CAD is complexed with its inhibitor, ICAD (inhibitor of caspase-activated 
DNase). In apoptotic cells, activated caspase-3 cleaves ICAD to release CAD (Taylor, 
Cullen and Martin 2008a)(MacKenzie and Clark 2012, Taylor, Cullen and Martin 
2008c)(MacKenzie and Clark 2012, Taylor, Cullen and Martin 2008c). CAD then 
degrades chromosomal DNA within the nuclei and causes chromatin condensation. 
Caspase-3 also induces cytoskeletal reorganisation and disintegration of the cell into 
apoptotic bodies and facilitates disruption of the cytoskeleton, intracellular transport, 
cell division, and signal transduction (MacKenzie and Clark 2012, Taylor, Cullen and 
Martin 2008a). 
Phagocytic absorption of apoptotic cells is the final phase of apoptosis. Phospholipid 
asymmetry and externalisation of phosphatidylserine (PS) on the surface of apoptotic 
cells and their fragments is a key characteristic of this stage. Although the mechanism 
of PS translocation to the outer leaflet of the cell during apoptosis is not well 
understood, research indicates that Fas, caspase-8, and caspase-3 are involved in the 
regulation of PS externalisation on oxidatively stressed erythrocytes (Schultz and 
Harrington 2003, Krysko, et al. 2008). However, it should be noted that caspase-
independent PS exposure occurs during apoptosis of primary T lymphocytes. The 
appearance of PS on the outer leaflet of apoptotic cells then assists non-inflammatory 
phagocytic recognition, facilitating their early uptake and subsequent disposal 
(Schutters and Reutelingsperger 2010, Peng, et al. 2005b). 
 
 
45 
 
1.15.1 Bcl-2 Family proteins 
 
Key players in the determination of cell survival and death are the members of the Bcl-2 
family of proteins. The Bcl-2 family, both pro- and anti-apoptotic, are responsible for 
controlling the intrinsic pathway of apoptosis in mammals (Hardwick and Soane 2013). 
The founder member of this family the B-cell lymphoma-2 (bcl-2) gene was discovered 
at the t(14;18) chromosome translocation breakpoint in B-cell follicular lymphomas, 
where its transcription becomes excessively driven by the immuno-globulin heavy chain 
gene promoter and enhancer on chromosome 14 (Tsujimoto, et al. 1985, Bakhshi, et al. 
1985, Arif, et al. 2009). One key early discovery that introduced a new paradigm for 
carcinogenesis was that over-expression of bcl-2 does not promote cell proliferation as 
most previously discovered oncogenes do; rather, over-expression of bcl-2 inhibits cell 
death (Vaux, Cory and Adams 1988). The Bcl-2 family of regulators function upstream 
of the caspase cascade and display a range of bioactivities, from inhibition to promotion 
of apoptosis (Hardwick and Soane 2013).  
In mammals, there are at least 23 Bcl-2 family members, including Bcl-2 itself and 
proteins that have either three-dimensional (3D) structural similarity or a predicted 
secondary structure that is similar to Bcl-2 (Figure 1-12) (Young and Rickinson 2004a, 
Fu, He and Mao 2013, Hardwick and Soane 2013). Bcl-2 family members possess up to 
four conserved Bcl-2 homology (BH) domains designated BH1, BH2, BH3 and BH4 
which correspond to α-helical segments (Youle and Strasser 2008, Hardwick and Soane 
2013). A characteristic of the Bcl-2 family proteins is their ability to form homo- and 
hetero-dimers, as well as their ability to become integral membrane proteins (Youle and 
Strasser 2008, Hardwick and Soane 2013). The anti-apoptotic members of this family 
(Bcl-2, Bcl-XL, Bcl-w, Mcl-1, A1, Boo/Diva, Bcl-B, and C. elegans CED-9) are known 
to contain at least three of the four Bcl-2 homology domains. The pro-apoptotic 
members can be further characterised into to sub-categories being either “Bax-like” in 
their structure (Bax, Bak, Bcl-XS, Bok/Mtd and Bcl-GL) i.e. containing two or three BH 
domains, or alternatively, the so-called “BH3-only” proteins which share homology 
with each other and the remainder of the Bcl-2 protein family only through the short 
BH3 motif (Figure 1-12) (Bad, Bik, Blk, Bid, Hrk, Bim/Bod, Bmf, Noxa, Puma and C. 
elegans Egl-1) (Hardwick and Soane 2013, Tait and Green 2010).  Some of the Bcl-2 
family members do not fit into these classical subgroups. One of them, the Bcl-G, has a 
BH2 and a BH3 region, and was proposed to trigger apoptosis (Guo, Godzik and Reed 
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2001) initially. However recently it has been shown Bcl-G possibly does not function in 
the canonical stress-induced apoptosis pathway, but rather has a role in protein 
trafficking inside the cell (Giam, et al. 2012).  
Overall the structures of the BH3-only proteins seem to be unrelated and appear to lack 
a close evolutionary relationship to the core members of the Bcl-2 family (Aouacheria, 
Brunet and Gouy 2005). However, all BH3-only proteins interact with and regulate the 
core Bcl-2 family proteins to promote apoptosis. The BH3 domains of the Bcl-2 family 
members are crucial to their function indeed; just the 51 amino acids that code the 
domain in bak are enough to have a pro-apoptotic effect, while mutations of the BH3 
regions in bax, bak and bik were found to render the proteins ineffective (Elangovan and 
Chinnadurai 1997a, Tong, et al. 2001). However recent in vitro studies demonstrated 
that mutations to Bax outside the BH3 domain interrupted interactions with prosurvival 
proteins and promoted apoptosis, so they concluded that Bax is directly controlled by 
prosurvival proteins leading to blockage of apoptosis (Czabotar, et al. 2011).    
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Figure 1-12: The pro-apoptotic and anti-apoptotic Bcl-2 family members. 
Bcl-2 family members possess up to four conserved Bcl-2 homology (BH) domains designated 
BH1, BH2, BH3 and BH4 which correspond to α-helical segments. Each of the BH domains is 
indicated above. (Adapted from (Taylor, Cullen and Martin 2008a)).  
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The pro-apoptotic family members Bax and Bak are critical in the permeabilisation of 
the outer mitochondrial membrane (OMM) and the subsequent release of apoptogenic 
molecules such as cytochrome c and SMAC/DIABLO into the cytosol, which ultimately 
leads to caspase activation. The anti-apoptotic family members, such as Bcl-2 and Bcl-
XL, are known to inhibit the activity of Bax and Bak. A growing body of evidence 
indicates that BH3-only proteins de-repress Bax and Bak by directly binding and 
inhibiting Bcl-2 and other anti-apoptotic family members or alternatively that they may 
directly activate Bax and Bak (Czabotar, et al. 2011, Westphal, et al. 2011) (Figure 
1-11). It has been established that both Bax and Bak promote caspase activation by their 
effects on mitochondria. These two pro-apoptotic proteins induce the release of proteins 
from the space between the inner and outer mitochondrial membranes (Westphal, et al. 
2011). This process of mitochondrial outer membrane permeabilisation (MOMP) leads 
to the release of cytochrome c and other soluble proteins. While it is generally believed 
that Bax and Bak form integral membrane pores, the biochemical nature of such pores 
and how anti-apoptotic Bcl-2 family proteins might regulate them remains to be seen 
(Tait and Green 2010). During cytochrome c release into the cytosol, Bax and Bak 
induce mitochondria to fragment into more numerous and smaller units (Tait and Green 
2010, Chipuk, Bouchier-Hayes and Green 2006, Martinou and Youle 2006). 
Once the OMM has been permeabilised, soluble proteins diffuse from the 
intermembrane space into the cytosol, where they promote caspase activation. The best 
studied of these proteins is cytochrome c, which binds to Apaf-1 and leads to the 
assembly of the apoptosome, which can bind pro-caspase-9 or and thereby induce its 
activation through a conformational change in the molecule. Cytochrome c–Apaf-1-
dependent activation of caspase-9 is absolutely required for neuronal and fibroblast cell-
death processes (Tait and Green 2010, Chipuk, Bouchier-Hayes and Green 2006). 
However, lymphocytes may use alternatives to Apaf-1-, caspase-9- and cytochrome c-
independent pathways, such as pro-apoptotic Bcl-2-family-member-dependent 
pathways for caspase activation (Hao, et al. 2005, Marsden, et al. 2002). One such 
pathway which is Apaf-1-independent, involves the relief of caspase inhibition by 
inhibitor of apoptosis proteins (IAPs), such as XIAP, which bind and neutralise certain 
caspases (such as caspase-9 and caspase-3). This inhibitory action of IAPs can be 
antagonised by the binding of SMAC/DIABLO, which is released from mitochondria 
after the activation of Bax and/or Bak (Youle and Strasser 2008, Fulda and Debatin 
2006, Degterev and Yuan 2008).  
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1.15.2  BH3-only proteins 
BH3-only proteins are essential for cell death initiation (Happo, Strasser and Cory 
2012b). A growing body of evidence indicates that different apoptotic stimuli can 
activate distinct but sometimes overlapping sets of BH3-only proteins. The pro-
apoptotic activity of BH3-only proteins is tightly controlled by diverse transcriptional 
and post-translational mechanisms to prevent inappropriate cell death (Lomonosova and 
Chinnadurai 2008a, Bouillet and Strasser 2002, Happo, Strasser and Cory 2012a). Puma 
and Noxa are transcriptionally induced in response to DNA damage by p53 for 
example, whereas other BH3-only proteins, such as Bid or Bad, are thought to be 
mainly regulated at the post-translational level (Youle and Strasser 2008, Happo, 
Strasser and Cory 2012a). 
While the molecular basis of BH3-only protein activity is still under investigation, it is 
clear that BH3-only proteins have the ability to bind to a hydrophobic groove on the 
surface of Bcl-2-like molecules, formed by their BH1, BH2 and BH3 domains thereby 
antagonising their pro-survival function (Willis and Adams 2005a). This physical 
interaction is dependent on a functional BH3-domain within the BH3-only protein. It 
has been suggested that BH3 only proteins can function via at least three separate 
modes of action (Letai et al, 2002; Kuwana et al, 2005; Strasser, 2005) and since the 
signalling pathways that mediate apoptosis seem to proceed through a succession of 
interconnected amplification loops, it is conceivable that more than one of these 
processes takes place (Happo, Strasser and Cory 2012a, Strasser 2005).  
In one model of BH3-only protein function, this interaction is thought to block the 
ability of Bcl-2-like pro-survival proteins to regulate the pro-apoptotic Bax/Bak, 
preventing them from undergoing oligomerisation and causing loss of mitochondrial 
outer membrane integrity and cell death (Happo, Strasser and Cory 2012a, Strasser 
2005) (Figure 1-13 a). It has also been suggested that the BH3-only proteins and 
Bax/Bak-like proteins function in parallel in a mutually dependent manner (Strasser 
2005, Lomonosova and Chinnadurai 2008b)(Figure 1-13 b). In an alternative model, the 
BH3-only proteins activate Bax/Bak directly. In support of this model tBid and Bim 
have this ability. Bid and Bim directly activate Bax (Du, et al. 2011), causing its 
insertion into the mitochondrial membrane where it becomes active. However, Bim and 
tBid can be bound and neutralised by Bcl-2-like proteins and the role of other BH3-only 
proteins in this model is to occupy Bcl-2-like proteins and stop them from sequestering 
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Bim/tBid. Accordingly, these BH3-only proteins (e.g., Bad and Bik) are called 
sensitisers (Happo, Strasser and Cory 2012b, Lomonosova and Chinnadurai 2008b) 
(Figure 1-13 c). It has been shown recently that in the absence of potent direct 
activators, like Bim and Bid, other BH3-only proteins, Bmf and Noxa, can directly 
activate Bax/Bak (Du, et al. 2011). Additionally a further possibility is that, to keep 
cells from dying, Bcl-2 (and/or its pro-survival homologues) might bind and inhibit a 
protein, perhaps a caspase activator (such as Apaf-1), and that apoptotic stimuli might 
trigger both BH3-only proteins and Bax/Bak-like proteins, which together would disrupt 
this binding (Happo, Strasser and Cory 2012a, Strasser 2005, Lomonosova and 
Chinnadurai 2008b) (as illustrated in Figure 1-16).  
 
 
Figure 1-13: Models for interaction between BH3-only proteins, Bax/Bak-like 
proteins and pro-survival Bcl-2-family members in signalling in apoptosis. 
Three possible models are illustrated above. (A) BH3-only proteins might inactivate Bcl-2-like 
pro-survival proteins, which keep cells alive by inactivating Bax/Bak-like proteins. (B) Death 
stimuli might simultaneously activate BH3-only proteins and Bax/Bak -like proteins, which 
both block the pro-survival function of Bcl-2 and its homologues. (C) BH3-only proteins might 
activate the pro-apoptotic activity of Bax/Bak-like proteins directly, and pro-survival Bcl-2-
family members might function by binding and inactivating BH3-only proteins and/or Bax/Bak-
like proteins. (Adapted from(Strasser 2005)). 
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BH3-only proteins have distinct (only partially overlapping) binding preferences for 
their pro-survival Bcl-2-like relatives (Happo, Strasser and Cory 2012a, Zhang, et al. 
2011), indicating that certain BH3-only proteins can only antagonise a very distinct 
subset of Bcl-2-like molecules in vivo. For example Noxa can only block Mcl-1 and A1 
while others, such as Bim and Puma, are able to bind with similar affinities to all known 
Bcl-2 pro-survival proteins and therefore, may have broader physiological functions 
than other BH3-only proteins (Happo, Strasser and Cory 2012a). Since these proteins 
are essential initiators of cell death pathways, understanding their regulation may 
provide novel therapeutic targets to prevent pathological cell death. Inhibitors of BH3-
only proteins may alleviate degenerative disorders, whereas small molecule mimetics, 
for example ABT-737 may be used to kill cancer cells or self-antigen-specific 
lymphocytes in autoimmune disease (Karlberg, et al. 2010, Bodet, et al. 2011, Touzeau, 
et al. 2011, Reed and Pellecchia 2005). 
 
 Bik  
 
The regulation of bcl-2 family members by EBV is a significant research interest in the 
laboratory. Bik, in particular, was a major interest in the present study and will now 
therefore be discussed in detail. Bik was originally identified as a binding partner and 
antagonist of anti-apoptotic Bcl-2 and its adenovirus homologue, E1B 19K. Bik also 
displayed affinity for Bcl-XL, Bcl-XS and the EBV BHRF1 suggesting that Bik might be 
a mutual target for cellular and viral anti-apoptotic proteins (Chinnadurai, Vijayalingam 
and Rashmi 2008b). Bik shares only the short BH3 signature domain with other 
members of the Bcl-2 family and has no homology for the other Bcl-2 signature 
domains BH1, BH2 and BH4 (Figure 1-12). 
 
 Bik Expression 
 
The bik transcript has a tissue-specific expression profile (Verma, et al. 2000)(Verma, et 
al. 2000) with strong expression in the kidney and pancreas in comparison to other 
organs (Daniel, et al. 1999). The gene is also expressed in many tumour lines (Kim, et 
al. 2010) and in B cells. In humans, Bik seems to play a key role in B cell homeostasis. 
In a gene expression profiling study of B cell germinal center reaction, bik transcript 
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was detected during naive B cell to centroblast transition and remained up-regulated in 
memory B cells. Increased expression of Bik was also identified in cells that had been 
induced to apoptosis followed by antigen receptor stimulation (by ligation of surface 
IgM) and TGFβ signalling induction (Verma, et al. 2000, Jiang and Clark 2001a, 
Spender, et al. 2009).  
 
Bik Structure 
 
Bik is localised on chromosome 22q13 and consists of five exons and four introns, 
spanning a region of 19kb. Bik gene encodes the 160 amino acid pro-apoptotic Bik 
protein that shares the distinct sequence motif with the Bcl-2 family and a characteristic 
C-terminal trans-membrane segment (Boyd, et al. 1995b, Han, Sabbatini and White 
1996b) which determines its sub-cellular localisation  (Elangovan and Chinnadurai 
1997c) (Figure 1-14). Bik is predominantly localised to the endoplasmic reticulum (ER) 
and to lower extent to mitochondrial outer membrane (MOM) (Chinnadurai, 
Vijayalingam and Rashmi 2008b) from where it elicits its pro-apoptotic signals by 
regulating BAX/BAK-dependent release of Ca2+ from the endoplasmic reticulum stores 
and cooperates with other BH3-only proteins such as Noxa to cause rapid release of 
cytochrome c from mitochondria. Bik is also known to selectively inhibits BCL-XL, 
BFL-1, or BCL-w through complex formation (Chen, et al. 2005), and given sufficient 
time, these signals lead to cell death (Zhao, et al. 2008b, Germain, et al. 2005, 
Chinnadurai, Vijayalingam and Rashmi 2008a, Kvansakul, et al. 2010b).  
The translational start site and BH3 domain are located in exon 2 and 3, respectively 
(Figure 1-14). The alpha-helical BH3 region is required for both death promoting 
activities and dimerisation with anti-apoptotic proteins. In addition to the BH3 domain, 
the C-terminal domain adjacent to the TM also has been shown to be essential for 
optimal cell death activity. Human Bik protein has been shown to be phosphorylated on 
Thr(33) and Ser(35) by a casein kinase II-like kinase and mutations that prevented 
phosphorylation reduced the cell death activity (Verma, Zhao and Chinnadurai 2001) 
whereas enhanced apoptosis was the result of mutations that increased the 
phosphorylation (Tong, et al. 2001, Boyd, et al. 1995a, Li, et al. 2003). The C-terminal 
trans-membrane hydrophobic domain and the stop codon are contained within exon 5. 
The transcriptional initiation site was identified as a G residue marked as +1(Figure 
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1-14), located approximately 13kb from the translational start site. The gene has a long 
un-translated sequence in exon 1. No canonical TATA or CCAAT boxes were identified 
near the transcriptional initiation site (Verma, et al. 2000).   
 
 
Figure 1-14: Arrangement and sizes of exons and introns in the bik gene (Top). Bik 
protein structure (Bottom). Adapted from, (Chinnadurai, Vijayalingam and Rashmi 2008b, 
Verma, Zhao and Chinnadurai 2001). 
 
 
A role for Bik in B cell biology  
 
Several lines of evidence suggest that the balance between pro-apoptotic Bik and the 
anti-apoptotic Bcl-XL protein plays a key role in determining B cell fate and that 
apoptosis activation signals the up-regulation of Bik protein in order to antagonize the 
function of Bcl-XL. Consistent with this hypothesis, cell surface IgM ligation 
(equivalent to signalling from the BCR) in human B104 B cell lymphoma cells induces 
Bik accumulation and increases the amount of Bik associated with Bcl-XL ultimately 
leading to apoptosis through the activation of caspases (Jiang and Clark 2001a). 
Furthermore, the cytokine transforming growth factor-β (TGFβ)-mediated apoptosis in 
the Ramos B-lymphoma cell line involves the activation of caspases and is 
accompanied by Bik up-regulation and a simultaneous loss of Bcl-XL expression 
(Spender, et al. 2009). The involvement of Bcl-XL in regulating immature B cell 
apoptosis is well established (Motoyama, et al. 1995, Fang, et al. 1998) and indeed the 
ability of Bcl-XL to rescue Bik induced apoptosis is also recognised (Boyd, et al. 1995c, 
Spender and Inman 2009a). Bik binds to and can antagonise anti-apoptotic Bcl-XL 
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under physiological conditions (Jiang and Clark 2001a, Shimazu, et al. 2007). Thus it 
may be the relative proportion of Bcl-XL not associated with Bik that determines 
whether B cells survive.  
Bik is also weakly down-regulated following CD27 ligation, whereas CD40 ligation 
(both belong to the TNF/TNFR family) resulted in a similarly weak increase in Bik 
levels in B cell receptor (BCR)-mediated apoptosis of Ramos cells. Thus, it is possible 
that CD27 signals regulate BCR-mediated apoptosis at the mitochondrial level in a 
manner different from CD40 signals through the alteration of the balance among Bcl-2 
family members to regulate mitochondrial permeability. In addition, since CD27 and 
CD40 inhibit p53 activation it is conceivable that Bik might be involved in the p53-
dependent apoptosis pathway in B cells (Hase, et al. 2002). The possible involvement of 
other pro-apoptotic Bcl-2 members such as Bax or Bak in B cell apoptosis can also not 
be ruled out (Chinnadurai, Vijayalingam and Rashmi 2008a). Interestingly Bik has been 
shown to be necessary for IFNγ-induced cell death in human airway epithelial cells 
(Mebratu, et al. 2008). Hence it is possible, that blocking Bik function may have a 
significant role in the evasion of host immune responses. 
 
Mechanism of bik-induced apoptosis 
 
It has been well established that Bcl-2 family proteins function at the mitochondria to 
prevent or promote the release of apoptogenic factors such as cytochrome c, AIF and 
SMAC/Diablo. In addition to their mitochondrial localisation, some anti-apoptotic 
members of the Bcl-2 family are also present at the endoplasmic reticulum (ER) and 
perinuclear membrane regions, suggesting a role of the Bcl-2 family proteins at sites 
other than mitochondria (Zhao, et al. 2007, Zong, et al. 2003). The evidence suggests 
that Bik may act from the ER, coupling upstream death signals to events at the surface 
of the mitochondria via activation of the death effectors Bax and Bak, resulting in cell 
death (Wei, et al. 2001, Zong, et al. 2001b). 
The ER is well characterised as a calcium (Ca2+) store that sequesters excess cytosolic 
Ca2+ and serves as a reservoir for Ca2+ signalling to maintain intracellular calcium 
homeostasis (Giorgi, et al. 2012). A growing body of evidence suggests that changes in 
intracellular Ca2+ homeostasis plays a significant role in the modulation of apoptosis 
55 
 
(Giorgi, et al. 2012, Hetz 2007). Bcl-2 family proteins regulate apoptosis by a 
mechanism that affects the Ca2+ stores within the ER, or alternatively via a mechanism 
that controls the apoptotic cross talk between the ER and the mitochondria. Members of 
the Bcl-2 family appear to differentially regulate intracellular Ca2+ level. Translocation 
of Bax, an apoptotic signalling protein, from the cytosol to the mitochondrial membrane 
is another step in this apoptosis signalling pathway (Reviewed in (Giorgi, et al. 2012, 
Hetz 2007)). 
Bik is exclusively localised to the ER rather than mitochondria through its trans-
membrane domain (Germain, Mathai and Shore 2002, Zhao, et al. 2008a). Bik can 
induce changes in the content of cytosolic as well as ER Ca2+ stores (Zhao, et al. 2008a, 
Mathai, Germain and Shore 2005) and this process is thought to be mediated through a 
Bax/Bak regulated mechanism (Giorgi, et al. 2012, Mathai, Germain and Shore 2005). 
The depletion of ER Ca2+ stores rather than the elevation of intracellular Ca2+ or the 
extra-cellular Ca2+ influx play an important role in Bik-induced apoptosis (Zhao, et al. 
2008b). Furthermore, it has previously been demonstrated that ER Bik initiates 
dynamin-related protein-1 (DRP1)-regulated remodelling of mitochondrial cristae 
during apoptosis in a manner dependent on the transmission of Ca2+ to the mitochondria 
(Germain, et al. 2005) further supporting a role for Bik in the regulation of the ER Ca2+ 
stores.  Exactly how the over-expression of Bik affects the intracellular Ca2+ 
homeostasis remains unknown. Bik may oligomerise with the other Bcl-2 member 
proteins and create a non-selective or selective ion pore across the ER membrane 
causing leakage of Ca2+ from the ER Ca2+ stores. Alternatively, Bik protein may interact 
directly or indirectly with the ER Ca2+ pump, or other Ca2+ channels (Giorgi, et al. 
2012, Zhao, et al. 2008a).  
Upon induction of apoptosis Bax translocates from the cytosol to mitochondrial 
membranes where it is thought to oligomerise into an active trans-membrane pore (Hsu, 
Hsu, Wolter and Youle 1997, Desagher, et al. 1999, Wolter, et al. 1997). Bik is thought 
to function through the initiation of cell death signalling, whereas Bax/Bak-like 
proteins, function further downstream (Zong, et al. 2001a, Lindsten and Thompson 
2006). Further reiterating this point is the finding that Bik induces exposure of an N-
terminal Bax epitope mediating its insertion into the outer mitochondrial membrane, 
release of cytochrome c, and cell death in H1299 cells (Gillissen, et al. 2003). Since the 
interaction of Bik with Bax is associated with a change in conformation of Bax leading 
to cytochrome c release (Gillissen, et al. 2003) it would suggest that Bik functions as a 
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positive death effector, engaging downstream components of the cell death pathway. 
Furthermore, Bik can co-operate with Noxa, to release cytochrome c from the 
mitochondria and this pathway involves conformational changes in Bax leading to its 
activation and ultimately caspase activation (Germain, et al. 2005). 
Thus it appears that Bik initiates a pathway from its location at the ER that stimulates 
the release of Ca2+ from the ER via activation of the death effectors Bax and Bak, which 
leads to cytochrome c release and signalling of apoptosis from mitochondria (Germain, 
et al. 2005, Germain, Mathai and Shore 2002). The collapse of membrane potential 
along with the release of cytochrome c from mitochondria is followed by the activation 
of caspases (Smaili, et al. 2003). Accordingly Bik, is known to elicit pro-apoptotic 
signals which lead to cell death by pathways which involve the activation of caspases 
(Zhao, et al. 2007, Germain, Mathai and Shore 2002, Mathai, Germain and Shore 2005, 
Gillissen, et al. 2003) which can  be inhibited by the broad range caspase inhibitor N-
benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethyl ketone (zVAD-fmk) (Mathai, et 
al. 2002, Naumann, et al. 2003, Hur, et al. 2004). In one study Bik induced the 
depolarisation of mitochondrial membrane potential (MMP) through a caspase-12-
dependent pathway, leading to the activation of initiator caspase-9 and ultimate cell 
death in 293 and Hep3B cells suggesting that caspase-12 may directly or indirectly 
influence the intrinsic apoptosis signal transduction pathways triggered by Bik at the ER 
(Zhao, et al. 2007). Bik has also been shown to induce the catalytic activation of 
caspase-9, caspase-7 and caspase-3 processing in chemoresistant human tumour prostate 
and colon cell lines (Tong, et al. 2001). A model for caspase-dependent Bik-induced 
apoptosis can be seen in Figure 1-15. 
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Figure 1-15: The caspase-dependent bik-induced apoptotic pathway.  
Upon various stimuli that transcriptionally activate the expression of endogenous bik, Bik 
protein activates BAX through interaction of Bik with BCL-XL and BCL-2, induces the 
depletion of ER Ca2+ stores, exposure of an N-terminal Bax epitope mediating its insertion into 
the outer mitochondrial membrane, release of cytochrome c, and activation of a caspase-12-
dependent pathway, leading to the activation of initiator caspase-9 and ultimately cell death. 
Adapted from, (Chinnadurai, Vijayalingam and Rashmi 2008a). 
 
 
Interestingly it has also been reported that Bik can induce cell death in a caspase-
independent fashion in human melanoma cells (Oppermann, et al. 2005) and that 
inhibition of caspases by treatment with zVAD-fmk in the absence of Bcl-2 actually 
enhances Bik-induced cell death in mouse embryonic fibroblasts (MEFs) (Rashmi, et al. 
2008). Interestingly a pathway in which Bik-mediated cell death induces the release of 
cytochrome c but not mitochondrial membrane potential loss and without modulating 
voltage-dependent anion channel activity (VDAC), (an important component of the 
PTP), has also been reported, suggesting that Bik may target molecules other than the 
PTP or act alone to induce cytochrome c release (Shimizu and Tsujimoto 2000). 
Furthermore, findings have suggested that Bik can induce cytochrome c release from 
mitochondria independently of Bax in H1299 cells. This report favoured a direct 
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induction of the mitochondrial apoptotic signalling cascade by bik and subsequent 
activation of caspases (Germain, Mathai and Shore 2002). It is conceivable that bik 
could be acting on separate distinct pathways, in response to different stimuli.  
A mechanism of Bik-induced apoptosis regulated by Bcl-2 family members, such as 
Bax or Bcl-2/Bcl-XL cannot be excluded. The pro-apoptotic activity of BH3-only 
proteins is proposed to be governed by their propensity to interfere with at least a dual 
layer of protection of cells from the pro-apoptotic activity of Bak (Willis and Adams 
2005b). It has previously been shown that binding of Bik inactivates Bcl-XL and 
releases both Bax and Bak. While the interaction between Bik and Bcl-XL seems to be 
stronger, Bik is also known to bind to Bcl-2 (Verma, Zhao and Chinnadurai 2001, 
Gillissen, et al. 2003, Elangovan and Chinnadurai 1997b), indicating that Bcl-2 is at 
least in part inhibited by Bik. Once the capacity of Bcl-2 to bind Bax has been 
surpassed, the liberated Bax protein becomes activated. Notably, the Bax inhibitors Bcl-
2 and Bcl-XL are not stabilised by Bik. In contrast, Bak released from Bcl-XL upon Bik 
expression is still kept in check by Mcl-1 and this is enforced by the up-regulation of the 
Bak inhibitor Mcl-1 by Bik. Mcl-1-mediated repression of Bak thereby provides a 
molecular rationale for the strict Bax dependency of Bik-induced cell death. Thus it 
appears that Mcl-1 determines the Bax dependency of Bik-induced apoptosis (Gillissen, 
et al. 2007). In this instance Bik appears to act as de-repressor molecule binding to 
distinct anti-apoptotic proteins. The consequent de-repressed pro-apoptotic multi-
domain proteins can then be counteracted by a second set of anti-apoptotic proteins. 
This adds a higher degree of specificity and the outcome of triggering this tightly 
balanced interaction network would be determined by both the specific BH3-only 
proteins induced by a given death stimulus and the abundance of their anti-apoptotic 
counterparts forming this second obstacle to apoptosis (Gillissen, et al. 2007). A model 
for the regulation of Bik-induced apoptosis by Bcl-2 family members can be seen in 
(Figure 1-16). 
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Figure 1-16: Model for the regulation of Bik -induced apoptosis by Bcl-2 family 
members. 
(A) In healthy cells, Bax is inactivated by Bcl-2 and Bcl-XL, whereas Bak is sequestered by Bcl-
XL and Mcl-1. (B) Bik/Nbk activates the pro-apoptotic Bax through neutralisation of the anti-
apoptotic Bcl-XL. In contrast, increased levels of the anti-apoptotic Mcl-1 keep in check Bak that 
was released from Bcl-XL upon competition with Nbk. Adapted from (Gillissen et al, 2007). 
 
 
Regulation of Bik 
 
Regulation of bik on several different levels has been reported. Evidence of roles for 
transcriptional regulation, methylation, phosphorylation and protein degradation by the 
proteasome have all been indicated. Additionally, the specificity of the interplay 
between hetero-dimerising partners is also thought to be associated with bik control. 
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Indeed stringent regulation of bik expression at various steps is probably essential, given 
the fact that Bik is predicted to possess an already exposed BH3 domain and is thus 
considered constitutively active (McDonnell, et al. 1999). It is clear that external and 
internal stimuli lead to bik regulation at several different levels, including tissue-specific 
expression (Daniel, et al. 1999), transcriptional and translational control and 
intracellular localisation (Germain, Mathai and Shore 2002, Zhao, et al. 2008a, Mathai, 
et al. 2002). Evidence that bik is transcriptionally regulated by a number of transcription 
factors including p75NTR , SFRP1, IgM, E4orf6, E1A, GRP78/BiP, the E2F transcription 
factors and TGFβ has been demonstrated (Jiang and Clark 2001a, Mathai, et al. 2002, 
Saltzman, et al. 1998, Tabassum, Khwaja and Djakiew 2003, Han and Amar 2004). 
Furthermore, apoptosis triggered by Bik can be either p53-dependent or independent 
depending on the induction stimulus (Mathai, et al. 2002, Han, Sabbatini and White 
1996a, Bartke, et al. 2001). 
The regulation of Bik function by phosphorylation has also been verified (Verma, Zhao 
and Chinnadurai 2001). Bik is phosphorylated on consensus CKII phosphorylation sites 
(Thr-33 and/or Ser-35) (Verma, Zhao and Chinnadurai 2001) an event that appears to 
result in a gain in function (Verma, Zhao and Chinnadurai 2001). Mutation of the 
phosphorylation sites, in which the threonine and serine residues were changed to 
alanine residues, indicated that phosphorylation of Bik is required for its apoptotic 
activity, without significantly affecting its ability to hetero-dimerise with Bcl-2 and Bcl-
XL (Verma, Zhao and Chinnadurai 2001). The precise mechanism by which 
phosphorylation plays a role in the apoptotic activity of Bik is not known, although it is 
possible that phosphorylation of Bik may play role in interaction with other potential 
cellular targets or that the activity of Bik may be activated by phosphorylation in 
response to different apoptotic stimuli in various human tissues (Verma, Zhao and 
Chinnadurai 2001). A phospho-mimetic form of Bik (designated BikDD) has been 
shown to kill pancreatic cancer cells in an orthotopic mouse model (Xie, et al. 2007). 
The methylation status of bik remains uncertain. While treatment with the DNA 
methylation inhibitor, zebularine, induced genomic de-methylation of a multiple 
myeloma cell line KAS-6/1, and induced the expression of Bik (Pompeia, et al. 2004),  
conflicting reports argue that DNMT1 mediated bik suppression does not involve a 
change in the DNA methylation state or histone modification, maintaining that DNMT1 
is capable of regulating gene expression by a DNA methylation independent pathway 
(Milutinovic, et al. 2004). A closer look at the mechanism of action of zebularine 
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reveals that this drug acts by forming a complex with DNMT1 in the position normally 
incorporated by the base targeted for methylation (Zhou, et al. 2002). Thus, the gene 
targeted to disrupt methylation may also suppress Bik independently of the DNA 
methylation state (Pompeia, et al. 2004). Other studies have indicated a role for DNA 
methylation in transcriptional silencing of bik. Exposure to 5'-aza-2'-deoxycytidine 
resulted in strong up-regulation of bik mRNA in renal cell carcinoma (RCC) cell lines 
(Sturm, et al. 2006) and was shown to be induced by the histone deacetylase inhibitor, 
sodium butyrate in human hepatoma cells (Ogawa, et al. 2004). Increases in bik mRNA 
levels were observed in both HepG2 and Hep3B cells following treatment with 5-aza-2′-
deoxycytidine or histone deacetylase inhibitor sodium butyrate given separately. Bik 
protein however was undetectable (Wang, et al. 1998). A combination treatment of both 
5-aza-2′-deoxycytidine plus depsipeptide has shown a synergistic effect on bik gene 
induction in a variety of cancer cell lines (Dai, et al. 2006). It may therefore be the case 
that control of bik expression by epigenetic mechanisms occurs in a cell type-specific 
manner. The realisation that Bik may rapidly turnover during apoptosis suggests another 
level of control by means of Bik degradation (Marshansky, et al. 2001). It has been 
postulated that the accumulation of Bik protein may be a direct result of its reduced 
degradation in the cell (Marshansky, et al. 2001). Indeed, reports suggest that Bik is one 
of the mediators of proteasome inhibitor-induced apoptosis and that the proteasome 
inhibitors Bortezomib (Nikrad, et al. 2005) and lactacystin (Marshansky, et al. 2001) 
can regulate Bik expression, through stabilisation of the protein. Thus accumulation of 
Bik is sufficient to induce apoptosis indicating that it may be the accumulation of Bik 
rather than the expression per se that determines whether a cell undergoes apoptosis 
(Jiang and Clark 2001b).   
Similar to other BH3-only proteins, Bik binds to pro-survival family members, killing 
cells when over-expressed (Boyd, et al. 1995a). Not unlike other pro-apoptotic members 
of the Bcl-2 family the BH3 domain of bik has proven critical for pro-apoptotic 
activities; dimerisation as well as for cytochrome c release and apoptosis (Boyd, et al. 
1995a, Cosulich, et al. 1997, Hegde, et al. 1998). Since BH3-only pro-apoptotic proteins 
share only the BH3 domain in common (Bouillet and Strasser 2002), it has been 
postulated as to whether the BH3 domain is a death effector module eliciting its cell 
death activity through the inactivation of the anti-apoptotic proteins by hetero-
dimerisation.This will result in disruption of the complex of the death suppressor with a 
caspase activating molecule such as Apaf-1, which in turn results in the activation of 
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caspases and eventually death of the cell (Boyd, et al. 1995a, Kelekar and Thompson 
1998, Lutz 2000, Chittenden 2002) as represented in (Figure 1-17). Regulatory control 
could then be directly associated with the specificity and nature of the interplay between 
Bik and its hetero-dimerising partners (Han, Sabbatini and White 1996b, Elangovan and 
Chinnadurai 1997c). In this regard, the death promoting activity of Bik can be 
suppressed by co-expression of Bcl-2, Bcl-XL and BHRF1, and E1B-19k (Elangovan 
and Chinnadurai 1997c, Boyd, et al. 1995a). Bik also binds with Bcl-XS, a death-
promoting protein that lacks the BH1 and BH2 domains, possibly indicative of a co-
operation effect between the two proteins (Boyd, et al. 1995a). It has long been 
recognised that the relative levels of available Bcl-2 family dimerisation partners in the 
cell may shift the balance of cell fate either in favour of viability or of cell death, 
following exposure to an appropriate stress (Han, Sabbatini and White 1996b). The 
assumption that certain BH3-only ligands possess a degree of specificity for their pro-
survival receptors would render apoptosis of the Bcl-2 family a sophisticated affair, 
with Bik functioning as a naturally dominant negative antagonist whose role in the cell 
is to sequester and inactivate anti-apoptotic genes. 
 
 
Figure 1-17: Model for Apaf-1 regulation by the Bcl-2 family.  
A pro-survival member Bcl-2 family member such as Bcl-XL may bind Apaf-1 and 
prevent it from activating procaspase-9 (or another initiating pro-caspase). A death 
signal may, for example, provoke interaction of a BH3 family member such as Bik, or 
perhaps a Bax family member with Bcl-XL, preventing it from neutralising Apaf-1. In 
the presence of cytochrome c released from mitochondria and ATP, Apaf-1 can then 
binds to procaspase-9 and promote its dimerisation and activation by autocatalysis. 
Caspase-9 subsequently activates effector caspases. Adapted from, (Adams and Cory 
1998)). 
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Association of Bik with anti-apoptotic proteins indeed hinders Bik function (Boyd et al, 
1995). However, mutational analysis of the BH3 domain in bik, suggests that hetero-
dimerisation via the BH3 domain with survival proteins alone is insufficient to explain 
their cell death inducing activity (Elangovan and Chinnadurai 1997c). It has also been 
hypothesised that sequences in the C-terminal region of Bik might also be required for 
the pro-apoptotic activity of Bik, in addition to the activity of the BH3 domain. The 
precise biochemical activity of the C-terminal region of Bik is not known but it is 
conceivable that the C-terminal sequences may function in concert with the BH3 
domain to enforce apoptosis. Another, simpler rationalisation may be that the C-
terminal region plays a role in Bik protein folding is also possible (Elangovan and 
Chinnadurai 1997c). Interestingly, this region is known to contain a sequence motif 
similar to the substrate binding motif of the caspase family, and it was postulated that 
this motif could modulate the substrate-caspase complexes. Indeed one study 
demonstrated that the trans-membrane domain not only decided the sub-cellular 
localisation of Bik, but also had an important role in Bik-induced apoptosis in Hep3B 
cells (Zhao, et al. 2008a).  
 
1.16 EBV regulation of the Cellular Apoptotic Programme  
 
A central component of the overall EBV strategy and its role in the development of 
related malignant disease is the ability of the viral proteins to suppress the cellular 
apoptotic program. In this regard, EBV has developed mechanisms that suppress the 
apoptotic programme of the host in order to delay cell death during the lytic stage of 
infection, until virion numbers have been sufficiently amplified to transmit infection to 
other individuals via saliva, and also to ensure persistence in the host memory B cell 
compartment. EBV genes have been shown to manipulate the cell survival machinery of 
the infected cell by directly regulating the apoptotic death machinery, specifically by 
inducing the expression of several anti-apoptotic proteins such as Bcl-2, Bfl-1, Mcl-1, 
A20, c-IAP-2 and also through the down-regulation of expression of pro-apoptotic 
proteins such as Bax and Bim  (Laherty et al, 1992; Fries et al, 1996; Wang et al, 1996; 
(Loughran, et al. 2011, Spender and Inman 2011, Pegman, et al. 2006a, Pegman, et al. 
2006a, Anderton, et al. 2008, Leao, et al. 2007).  
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Group I BL cell lines which display type I latency, only expressing EBNA1, EBERs 
and BARTs and many EBV-negative BL lines can readily be triggered into apoptosis, 
whereas Group III BL cell lines, which express the complete set of EBV latent proteins, 
are relatively resistant to a variety apoptotic triggers, including growth factor 
withdrawal, Ca2+ ionophore treatment and over-expression of the p53 tumour 
suppressor gene (Henderson, et al. 1991, Okan, et al. 1995). EBV-negative BL cells 
converted to the type III latency state by infection with the B95-8 strain of EBV also 
display elevated thresholds of resistance to apoptotic stimuli (Gregory, et al. 1991), thus 
implicating EBV latent genes in cell survival.   
 
 
1.16.1 EBV up-regulates bcl-2   
 
Type I BLs express little or no Bcl-2 whereas group III BL cells lines display high 
levels of the Bcl-2 protein (Henderson, et al. 1991, Gregory, et al. 1991). Bcl-2 is a 
prototype anti-apoptotic protein that interacts with the mitochondrial membrane and 
inhibits the action of caspases (Hardwick and Soane 2013).  Transfection of individual 
EBV latent genes into EBV-negative BL cell lines has shown that up-regulation of Bcl-
2 expression correlates with the expression of three EBV proteins; LMP1, (Henderson, 
et al. 1991, Rowe, et al. 1994) EBNA-2 (Finke, et al. 1992), and EBNA-3B (Silins and 
Sculley 1995). Significantly, over-expression of Bcl-2 in group I BL cell lines following 
gene transfer results in reduced apoptosis in response to a number of stimuli compared 
with group III cell lines and the inhibition of cell death was correlated to the amount of 
Bcl-2 expressed (Henderson, et al. 1991, Gregory, et al. 1991). Indeed, transfections 
with EBV LMP1 also resulted in enhanced survival of these cells and the ability of 
LMP1 to confer resistance to apoptosis to the type I BLs resulted from its ability to 
induce endogenous Bcl-2 expression (Henderson, et al. 1991, Gregory, et al. 1991). 
While LMP1 and EBNA-2 appear to up-regulate Bcl-2 expression in vitro, the 
recirculating B cells of peripheral blood which are a target of EBV already express 
relatively high levels of Bcl-2.  EBV infection and so expression of LMP1 or EBNA-2 
or the combined expression of both, does not significantly impact Bcl-2 expression. 
Thus it may be that the role of LMP1/EBNA-2 in vivo is to maintain the high 
constitutive level of Bcl-2 rather than to induce it (Martin, et al. 1993). 
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1.16.2 EBV up-regulates A20  
 
A20 is an inducible zinc finger protein that confers resistance to TNFα cytoxicity 
(Laherty, et al. 1992) and is induced in response to a wide variety of stimuli, including 
cytokines such as TNF, IL-1, and CD40 as well as bacterial and viral products such as 
lipopolysaccharide (LPS) and human T-cell leukemia virus type I Tax in many cell 
types including fibroblasts, lymphocytes and endothelial cells (Beyaert, Heyninck and 
Van Huffel 2000). A20 is constitutively expressed in EBV-immortalised B cells and 
transfection experiments have demonstrated that LMP1 induces the expression of A20 
in both lymphocytes and epithelial cells (Fries, Miller and Raab-Traub 1996b). Studies 
of the A20 promoter have shown that LMP1 transcriptionally activates the A20 gene 
through cis-acting NF-κB binding sites with a role for LMP1-inducible binding of an 
NF-κB-like factor to a consensus binding sites within the A20 promoter. A20 has also 
been identified as functioning in a negative feedback loop by inhibiting the activation of 
NF-κB from both CTAR1 and CTAR2 of the LMP1 protein. This effect is mediated by 
the binding of A20 to TRAF2 (Eliopoulos, et al. 1999).     
 
 
1.16.3 EBV up-regulates mcl-1 
 
Mcl-1 is a Bcl-2 family protein which can act a key molecule in apoptosis control, 
promoting cell survival by interfering at an early stage in a cascade of events leading to 
release of cytochrome c from mitochondria (Michels, Johnson and Packham 2005). 
Maximal Bcl-2 up-regulation by LMP1 requires 48-72 hours (Rowe, et al. 1994, Kim, 
Kim and Park 2012). Up-regulation of the Bcl-2 homologue Mcl-1 by LMP1 precedes 
the induction of Bcl-2 and is transient with levels of Mcl-1 decreasing when Bcl-2 
levels begin to increase. Mcl-1 is an anti-apoptotic protein that has been shown to 
contribute to the prolonged existence of chronic lymphotrophic leukaemia B cells and 
its higher expression is correlated with resistance to chemotherapy treatment (Bolesta, et 
al. 2012). It is thought that Mcl-1 functions as a rapidly inducible, short-term effector of 
cell viability (Michels, Johnson and Packham 2005). LMP1 also prevented the decline 
in Mcl-1 levels in response to apoptotic stimulation triggered by elevated cyclic AMP. 
This effect of LMP1 was associated with a delayed cell death in the EBV-negative BL 
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cell line BL41. The maintenance of Mcl-1 expression by LMP1 is likely to be a crucial 
immediate-early response that enables cells to survive until Bcl-2 can be up-regulated 
(Kim, Kim and Park 2012).  
 
1.16.4 EBV up-regulates c-IAP2 
 
C-IAP2 is a multi-functional protein which regulates not only caspases and apoptosis 
but also controls inflammatory signalling and immunity, mitogenic kinase signalling 
and cell proliferation as well as cell invasion and metastasis. C-IAP2 is a member of the 
cellular inhibitor of apoptosis protein family (c-IAP), and was originally identified as a 
molecule recruited to the TNF receptor complex receptor via TRAF1 and TRAF2 
(Zheng, et al. 2010). Its expression is preferentially up-regulated by TNF and other 
stimuli activating NF-κB including IL-1, LPS, and CD30 stimulation (Damgaard and 
Gyrd-Hansen 2011, Geserick, et al. 2009). Transcriptional activation by TNF or IL-1 is 
mediated cooperatively by two NF-κB binding sites bound by the NF-κB p50/p65 
hetero-dimer. In addition, over-expression of CD40 or LMP1 resulted in the c-IAP2 
promoter-driven reporter gene activation (Hong, et al. 2000). It has been postulated that 
the LMP1-inducible c-IAP2 protein functions as a pro-survival factor during EBV-
infection, acting independently of or in concert with TRAF1 and other LMP1-inducible 
anti-apoptotic proteins such as A20 and Bcl-2 (Hong, et al. 2000).   
 
 
1.16.5 EBV up-regulates bfl-1 
 
Studies in our laboratory have revealed the up-regulation of another anti-apoptotic gene, 
bfl-1/A1 during EBV infection. The pro-survival Bcl-2-family member Bfl-1/A1 is a 
transcriptional target of NF-κB that is over-expressed in many human tumours and is a 
means by which NF-κB is known to inhibit apoptosis  (D'Souza, et al. 2004, Loughran, 
et al. 2011). Two EBV proteins LMP1 and EBNA-2 have been shown to up-regulate 
expression of this cellular gene in the laboratory (Pegman, et al. 2006b, D'Souza, et al. 
2004, D'Souza, et al. 2004, Loughran, et al. 2011, Pegman, et al. 2006a, D'Souza, Rowe 
and Walls 2000). In this regard, expression of LMP1 in EBV-negative BL cell lines 
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coincides with a dramatic increase in bfl-1 mRNA (D'Souza, Rowe and Walls 2000) and 
bfl-1 expression was found to protect EBV-positive cells against serum depletion-
induced apoptosis. Moreover, expression of LMP1 in EBV-negative cell lines was 
found to trans-activate the bfl-1 promoter through interactions with components of the 
tumour necrosis factor receptor (TNFR)/CD40 signalling pathway. This process is NF-
κB dependent involving the recruitment of TNFR-associated factor 2 and is mediated to 
a greater extent by CTAR2 relative to the CTAR1 domain of LMP1 (D'Souza, et al. 
2004).  EBNA-2 also up-regulates bfl-1 expression. EBNA-2 trans-activation of bfl-1 
requires CBF1 and there is an essential role for a core consensus CBF1-binding site on 
the bfl-1 promoter. Interestingly bfl-1 expression is induced and maintained at high 
levels by the EBV growth program in an LCL and withdrawal of either EBNA-2 or 
LMP1 does not lead to a reduction in bfl-1 mRNA levels in this context. However the 
simultaneous loss of both EBV proteins results in a major decrease in bfl-1 expression 
(Pegman, et al. 2006b, Loughran, et al. 2011).  
 
 
1.16.6 EBV down-regulates bax.  
 
Bax is a member of the Bcl-2 family that, together with Bak, is required for 
permeabilisation of the OMM (Happo, Strasser and Cory 2012a). EBV LMP1 inhibits 
bax promoter activity through activation of NF-κB signalling via CTAR-1 and CTAR-2. 
The bax promoter harbours 3 κB consensus sites (Grimm, et al. 2005) of which LMP1 is 
known to activate 2, namely κB2 and κB3. LMP1 induced binding of the NF-κB hetero-
dimer p65/p50 to the κB2 site and of the p50/p50 homo-dimer to the κB3 site. Promoter 
mutation analysis revealed that the κB2 site is necessary for inhibition of bax promoter 
activity and the κB3 site for its activation. However, the activation of the bax promoter 
by LMP1 was observed only in the presence of specific inhibitors of p65/p50. In all 
other cases LMP1 inhibited bax promoter activity. Moreover, in cells with impaired Bax 
function or expression the anti-apoptotic activity of LMP1 is significantly reduced 
indicating that Bax is an important target of the anti-apoptotic activity of LMP1 
(Grimm, et al. 2005). 
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1.16.7 EBV down-regulates Bim  
 
Bim is a BH3-only protein whose over-expression in cells leads to cytochrome c release 
through the activation of Bax. All mature B cells express significant amounts of BH3-
only Bim (Happo, Strasser and Cory 2012a). Infection of BL cells with EBV results in a 
significant down-regulation in the expression of all three isoforms of the bim gene 
(Spender and Inman 2011). This down-regulation appears not to require expression of 
EBNA-2 or the LMP proteins (Leao, et al. 2007) and is in fact dependent on the co-
operation of EBNA-3A and EBNA-3C ((Anderton, et al. 2008). It has been reported 
that EBV infection may lead to post-translational modulation of Bim expression, 
involving the phosphorylation of BimEL by the EBV-activated kinase ERK1/2 followed 
by its degradation through the proteasome pathway (Fu, He and Mao 2013). However, a 
pathway in which EBNA-3A and EBNA-3C co-operate to regulate Bim expression at 
the level of transcription has also been described (Anderton, et al. 2008). 
 
 
1.16.8 EBV lytic proteins encoding anti-apoptotic functions 
 
During the lytic cycle of virus replication, repressors of apoptosis can provide a 
selective advantage by protecting the cell from death. EBV encodes its own gene 
products which can delay apoptosis in order to maximise viral production and spread of 
virus progeny to other individuals. These genes include BHRF1, BZLF1 and BALF1.  
As indicated earlier, EBV also encodes a viral homologue of IL-10 (Reviewed in 
(Spender and Inman 2011, Kalla and Hammerschmidt 2012, Forte and Luftig 2011). 
BHRF1 promotes the survival and proliferation of lytically infected cells and the highly 
conserved nature of BHRF1 among different EBV isolates at both the sequence and 
functional level supports the proposed vital role of BHRF1 in delaying cell death, 
thereby maximising the production of progeny virus and facilitating the establishment of 
virus persistence (Kvansakul, et al. 2010a). BZLF1 has been shown to interact with p53 
and inhibit its trans-activating function in lymphoid cells, thereby providing a 
mechanism for preventing p53-mediated apoptosis (Morrison, et al. 2004, Zuo, et al. 
2011). The BALF1 ORF in EBV possesses significant sequence similarity to other anti-
apoptotic viral Bcl-2 homologs and the cellular Bcl-2 and Bcl-XL. A recombinant GFP-
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BALF1 fusion protein co-localises with mitochondrial dyes and suppresses apoptosis 
but not through to promotion of cell-cycle progression, and hetero-dimerises with Bax 
and Bak (Bellows, et al. 2002, Hsu, et al. 2012a). While the growth stimulatory and 
anti-apoptotic genes induced by the initial EBV infection almost certainly prolong 
survival in the lytic stage of the lifecycle, it is also likely that they may augment the 
likelihood of the virus-infected cell progressing into the memory B-cell pool. Taken 
together, these interactions account, at least in part, for the ability of EBV to induce cell 
proliferation and survival which is essential for both EBV-induced immortalisation of B 
cells and establishment of life-long persistence in the memory B cell compartment.  
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1.17 The Germinal Centre Reaction 
 
 
The Germinal Centres (GCs) are structured microenvironments of secondary lymphoid 
tissues [spleen, peripheral lymph nodes and mucosal-associated lymphoid tissue 
(MALT)] where antigen-activated B cells undergo proliferation, class switch 
recombination (CSR), somatic hypermutation (SHM), antigen selection, and affinity 
maturation (Figure 1-18) (Allen, et al. 2007).  Primary B cell follicles consist of naïve 
B-cell regions next to areas containing T-cells, macrophages and follicular dendritic 
cells (FDCs). The recognition of antigen by the BCR coincide with cognate priming of 
T-helper cells by antigen presenting dendritic cells, which initiates the T-cell dependent 
differentiation of B cells. GCs come to be the main sites for generating effector plasma 
cells proficient in secreting high affinity immunoglobulins and for differentiation of 
memory B cells which facilitate a faster and effective response to antigen re-occurrence. 
In this instance B cells accumulate somatic hypermutations in the variable regions of 
their immunoglobulin genes that encode the antigen binding site. This procedure 
potentially increases the affinity and specificity of BCR for antigen (affinity maturation) 
but also imposes negative selection of autoreactive and low affinity receptors (activation 
induced cell death). The GC reaction is therefore a second main place of apoptotic 
elimination of large numbers of unwanted B cells (Spender and Inman 2011). The 
centroblasts differentiate further into non-proliferating centrocytes and transfer to the 
GC area which contains FDCs and T-cells. Centrocytes carrying the highest affinity 
mutated receptors outcompete others for limiting amounts of foreign antigen displayed 
on the FDCs and for survival signals provided by the GC T-helper cells, thus 
guaranteeing their continued survival and differentiation (Vinuesa, et al. 2010). 
 
Since it’s a high risk procedure for generating autoreactive or non-functional clones, B 
cells transferring through germinal center for development and activation are prone to 
programmed cell death (Kurosaki 2000, Benschop and Cambier 1999). Apoptotic 
pathways accountable for the removal of B cells inside the GC signal through the TGFβ 
receptor (Spender, et al. 2009), B cell receptors (Romero-Camarero, et al. 2013), and 
FAS (Reviewed in (Klein and Dalla-Favera 2008, Hao, et al. 2008)).  
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Figure 1-18: Germinal centre reaction 
Antigen-activated B cells differentiate into centroblasts which then undergo clonal expansion in 
the dark zone. During proliferation cells go through the process of SHM. Subsequently 
centroblasts differentiate into centrocytes and migrate to light zone, where the modified antigen 
receptor, is selected for enhanced binding to the antigen by means of FDCs and T-cells. The 
newly generated centrocytes that produce autoreactive or non-functional antibodies undergo 
apoptosis and are eliminated, and the other subset of centrocytes undergo immunoglobulin CRS. 
Antigen selected centrocytes eventually differentiate into memory B cells or plasma cells. 
Adapted from, (Klein and Dalla-Favera 2008). 
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1.18 EBV-infected B cells and the germinal centre reaction 
 
Central to EBV biology is the ability of the infected B cell to survive transit through a 
GC. Naïve B cells are the key targets of new EBV infection in vivo. Following primary 
infection of naive B cells EBV expresses its entire latency gene complex (Latency type 
III) thus driving expansion of the infected B cell pool. B cells enter lymphoid follicles 
where they proliferate and express only three viral proteins (Latency type II). EBV 
ensures the transit of some infected cells into the long-lived memory B cell 
compartment by mimicking the physiological process of antigen-driven memory-cell 
development during transit through a germinal centre.  
 
EBNA-2 subverts aspects of the Notch signalling pathway thus blocking B cell 
differentiation and allowing cell proliferation (Lucchesi, et al. 2008a). EBNA1 binds to 
the latent viral DNA replication origin and maintains the viral genome in the EBV 
positive cells after cell division (Thorley-Lawson 2001a). LMP1 is a viral homologue of 
CD40 which allows activation of B cells without the need to engage with CD40L on the 
CD4+ T cell. LMP-1 expression mimics CD40-CD40L signal transduction and bypasses 
the need for CD4+ T cell help. LMP2A is a B cell receptor functional homologue.  It 
mimics B cell receptor signalling and coupled to LMP1 signalling promotes the B cell 
to undergo affinity maturation, isotype switching and differentiation into memory and 
effector B cells (Odumade, Hogquist and Balfour 2011, Mancao and Hammerschmidt 
2007). 
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1.19 B Cell Receptor signalling and the escape of EBV-infected B cells 
 
BCR signalling is initiated by phosphorylation of the cytoplasmic immunoreceptor 
tyrosine based activation motifs (ITAMs) of CD79A/Igα and CD79B/Igβ (Figure 
1-19) (Yang and Reth 2010). This phosphorylation is mainly catalysed by the Src 
family kinase LYN and results in the recruitment and activation of the tyrosine kinase 
SYK (Kurosaki 2000, Craxton, et al. 1999, Kulathu, Grothe and Reth 2009). Activation 
of SYK is an important event in BCR signalling  causing the formation of a plasma 
membrane-associated signalling complex that contains multiple tyrosine kinases 
(including LYN, SYK and the Tec-family kinase BTK) and adaptor molecules (for 
instance BLNK), which mediate activation of downstream signalling pathways. 
Activation of phospholipase Cγ2 (PLCγ2) (Gorjestani, et al. 2011)(Gorjestani, et al. 
2011) leads to the production of inositol-1,4,5-triphosphate (IP3) and diacylglycerol 
(DAG) (Gorjestani, et al. 2011) which are required for the subsequent release of 
intracellular Ca2+ (iCa2+) (Lyubchenko 2010) and activation of protein kinase C (PKC), 
respectively. Increased iCa2+ and PKC activity induce activation of (Spender and Inman 
2012) mitogen-activated protein kinase (MAPK)-family kinases, including extracellular 
regulated kinase (ERK), c-JUN NH2-terminal kinase (JNK), p38 MAPK, and 
transcription factors important for B-cell fate comprising nuclear factor of activated T 
cells (NFAT) and MYC (Chung, et al. 2012). Activation of inhibitor of κB kinase (IKK) 
leads to phosphorylation and proteasomal degradation of inhibitor of κB (IκB) and 
activation of the nuclear factor-κB (NF-κB) transcription factor. In contrast to p38 
MAPK and JNK, ERK can also be activated independently of PLCγ2, via a RAS/ RAF1 
pathway (Imamura, et al. 2009). Activation of phosphatidylinositol 3-kinase (PI3K) 
requires LYN-dependent phosphorylation of the cytoplasmic domain of CD19 leading 
to recruitment of the p85 adaptor subunit of PI3K and production of the lipid 
phosphatidylinositol-3,4,5-triphosphate (PIP3). PIP3 recruits a number of BCR 
signalling components to the plasma membrane including the serine/threonine kinase 
AKT where it is activated. Active AKT is important for BCR-induced survival and 
proliferation pathways and acts by inactivation of Bad and forkhead family transcription 
factors, enhanced activation of NF-κB and inhibition of GSK3, a negative regulator of 
Myc and D-type cyclins  (Downward 2004). The activation of positive BCR signalling 
pathways is countered by inhibitory phosphatases including SH2 domain-containing 
tyrosine phosphatase-1 (SHP-1) and SH2 domain-containing phosphatidyl 5-
phosphatase (SHIP)-1 and -2. These phosphatases are activated downstream of LYN 
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and therefore LYN plays both positive and negative roles in signal transduction via the 
BCR (reviewed in (Kurosaki 2000, Packham and Stevenson 2010). Figure 1-19 shows 
the details of these interactions. 
 
 
 
Figure 1-19: The BCR signalling pathway.  
The major signalling pathways activated downstream of the BCR are shown. See text for details 
and abbreviations. Adapted from, (Packham and Stevenson 2010). 
  
 
Studies have revealed BCR cross linking with antibodies to membrane bound IgM but 
not IgD on the surface of B cells results in suppression of the PI3K/pp70S6X signalling 
pathway followed by decreased levels of cyclin D2 (Banerji, et al. 2001) and c-myc by 
NF-κB inactivation and subsequent elevation of p27Kip1 protein expression and its 
accumulation resulting in growth arrest or apoptosis (Carey and Scott 2001)(Banerji, et 
al. 2001). In contrast Jiang and Clark observed sIgM and sIgD ligation led to the 
induction of bik mRNA but that only sIgM ligation (and not sIgD ligation) exerted a 
proapoptotic effect by inducing the expression of Bik, via strong activation of PI3K 
(Beckwith, et al. 1996) and calcium influx resulting in apoptosis (Jiang and Clark 
2001a).  
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Overall, EBV transformation of resting B lymphocytes to LCLs mimics antigen-induced 
resting B cell clonal expansion in lymph node germinal centers, where antigen binding 
to surface Ig (sIg) induces c-myc-mediated proliferation (Murn, et al. 2009) and T cell 
CD40 ligand (CD40L) activates B lymphocyte CD40 receptors to up-regulate NFκB, 
MAP kinases, and anti-apoptotic Bcl-2 family protein expression (Vrazo, et al. 2012, 
Elgueta, de Vries and Noelle 2010). The important point about EBV is that it encodes a 
homologue of the B cell receptor, LMP2A, and coupled to LMP1 signalling promotes B 
cells to undergo affinity maturation, isotype switching and differentiation into memory 
and effector B cells (Odumade, Hogquist and Balfour 2011, Mancao and 
Hammerschmidt 2007). LMP2A signalling does not cause B cell to grow, but delivers 
the tonic signal that is essential for the survival of all B cells (Thorley-Lawson 2001b). 
 
Figure 1-20: Signalling relationship between LMP2A and the BCR 
LMP2A comprise of cytoplasmic amino-terminal and carboxy-terminal domains associated by 
12 transmembraine sequences with no significant extracellular domain. The amino-terminal 
domain of LMP2A contains the same ITAMs found in the α- and β-chains of the BCR. Together 
LMP2A and BCR associate with LYN. Phosphrylation of tyrosine residues within the ITAM by 
LYN leads to recruitment of the SYK tyrosine kinase and canonical downstream BCR 
signalling events. Adapted from, (Thorley-Lawson 2001b). 
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1.20 TGFβ1 signalling in the GC 
 
TGFβ has an apoptosis and anti-proliferative inducing capacity and this effect plays a 
critical role in the maintenance of B and T lymphocytes homeostasis including the fate 
of B cells in the GC (Schuster and Krieglstein 2002a). TGFβ, a pleiotropic cytokine, 
initiates a signalling cascade by binding and bringing together the membrane bound 
receptors, type II and type I transmembrane serine/threonine kinases (TβRI and TβRII). 
The complex is formed of two TβRI and TβRII. In addition endoglin and betaglican, 
also called accessory receptors, bind TGFβ with low affinity and present it to the TβRI 
and TβRII (Shi and Massague 2003). Upon TGFβ interaction with the highly active 
membrane bound TβRII, type I receptor (TβRI/ALk5) gets recruited and phosphorylated 
at its characteristic SGSGSG sequence (called the GS domain) which results in the 
activation of type I receptor by type II receptor. The GS domain acts as a Smad binding 
site and subsequently the activated form of TβRI phosphorylates and activates the 
receptor regulated Smads (Smad2/3) by its catalytic domain. Phosphorylated R-Smad(s) 
then undergo hetero-oligomerisation with common Smad (Smad4), where they 
translocate to and accumulate in the nucleus in conjugation with DNA binding 
transcriptional co-factors and transcriptional co-activators and co-repressors. This 
allows for positive or negative regulation of gene transcription in a cell-specific and 
context-dependent manner (Figure 1-21) (Shi and Massague 2003, Massague 1998). 
 
77 
 
                  
 
 
Figure 1-21: TGF-β signalling pathway 
TGFβ links to the membrane-bound type-2-receptor and activates the kinase function of the 
type-2-receptor with subsequent stimulation of the kinase-function of the type-1-receptor. The 
so-called receptor-Smad-proteins (Smad 2 and Smad 3) link to the receptor complex and are 
phosphorylated by the type-1-receptor. The phosphorylated R-smad-proteins form a complex 
with the co-operative Smad 4. This complex is able to penetrate the nucleus. Here the activated 
R-Smads get recruited to DNA promoters with transcription factors, transcription co-
activator/co-repressors and control transcription processes. Adapted from, (Ikushima and 
Miyazono 2011b). 
 
 
 
 
 
Over the past 30 years, experiments designed to investigate the effect of TGFβ mediated 
responses in human B cell lines based on their origin, their phenotype and their EBV 
carrier state have suggested that the phenotypic shift of BL cells from group I toward a 
group III phenotype is consistent with increased resistance to the anti-proliferative and 
proapoptotic activities of TGFβ induced signalling (Altiok, et al. 1991). The mechanism 
by which EBV confers TGFβ resistance has been investigated by many groups, however 
it needs to be determined more clearly in a cell type and context specific way. Various 
mechanisms that have been suggested include; (i) loss or down regulation of the TGFβ 
TGFβ1 
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receptors type I/II and thus inactivation of the TGFβ signalling pathway at a very early 
stages,  (Kumar, et al. 1991, Inman and Allday 2000, Fukuda, Kurosaki and Sairenji 
2006) (ii) LMP2A inhibits TGFβ -mediated apoptosis through activation of the PI3-
K/Akt pathway which results in survival signals both in B cells and epithelial cells 
(however this effect was not derived through alteration of expression levels of type I 
and type II TGFβ1 receptors) (Fukuda and Longnecker 2004), (iii) in centroblasts 
isolated from GCs, several of the apoptotic genes regulated by TGFβ signalling have 
been characterised. These include members of the Bcl-2 family acting upstream of BAX 
and BAK in the intrinsic apoptosis pathway. The mechanism of action of TGF-β in 
centroblasts isolated from GCs involves the induction of an apoptotic program by 
transcriptional downregulation of the anti-apoptotic protein BCL-XL while also 
upregulating the proapoptotic BH3-only proteins PUMA and Bik. The increase in BH3-
only proteins and the loss of BCL-XL expression lead to mitochondrial membrane 
depolarisation and intrinsic apoptosis (Spender and Inman 2011, Spender, et al. 2009).  
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 Vitamin D 1.21
 
1α,25-dihydroxy vitamin D3 (1α,25-(OH)2D3), the active form of vitamin D, is a key 
player in calcium and bone metabolism, nevertheless 1,25(OH)2D3 as well has a 
physiological role outside its recognized role in skeletal homeostasis. Receptors for 
1,25(OH)2D3 are present in various immune cells, including monocytes, macrophages 
and dendritic cells, as well as T and B lymphocytes, thus suggesting a role for 1α,25-
(OH)2D3 in both innate and adaptive immune responses (Chen,S. 2007, Pan,L. 2010). 
Further, immune cells express vitamin D-activating enzymes, allowing local conversion 
of inactive vitamin D into 1α,25-(OH)2D3 within the immune system (Morgan,J.W. 
2000). It has been shown that vitamin D deficiency, especially in early life, increases 
the risk of autoimmune diseases later on and is associated overall with an increased risk 
of infections (Handel,A.E. 2010). It has long been known that multiple sclerosis (MS) is 
associated with an increased Epstein-Barr virus (EBV) seroprevalence and high immune 
reactivity to EBV and that infectious mononucleosis increases MS risk (Ascherio,A. 
2007, Magliozzi,R. 2013). It has been show MS risk is associated with low vitamin D 
status prior to disease (Adams,J.S. 2008). 
Most commonly, vitamin D3 (cholecalciferol) synthesis occurs cutaneously following 
ultraviolet irradiation of skin and it can also be taken in the diet (Deeb, et al. 2005) 
(Figure 1.22). The CYP27A1 gene, which encodes mitochondrial and microsomal 25-
hydroxylases (25-OHase) (Haussler, et al. 1998a), hydroxylates cholecalciferol in the 
liver (Haussler, et al. 1998a) to 25-hydroxycholecalciferol [25(OH)D3] which is 
subsequently 1α-hydroxylated in the kidney by mitochondrial 1α-hydroxylase (encoded 
by the gene CYP27B1), leading to the hormonally active 1α,25-(OH)2D3 (calcitriol) 
(Haussler, et al. 1998a). There are examples of tissue-specific regulation of vitamin D3 
synthetic enzymes in the literature. The active metabolite of vitamin D3 (hereafter 
1α,25-(OH)2D3) functions in an autocrine and paracrine manner. It has significant 
implications for vitamin D3 function and signalling where it contributes to maintaining 
plasma calcium and phosphate homeostasis through the regulation of intestinal 
absorption, cell differentiation and maturation, as well as the innate immune system 
(Deeb, Trump and Johnson 2007a, Morris and Anderson 2010). 
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Figure 1-22: Vitamin D3 metabolism 
During exposure to sunlight, 7-dehydrocholesterol in the skin absorbs solar UVB 
radiation and is converted into cholecalciferol (vitamin D3). Together with vitamin D3 
originating from the diet, it enters the circulation and is metabolised to 25-
hydroxyvitamin D3 [25(OH)D3] in the liver by vitamin D 25-hydroxylase. This is the 
form that circulates in the highest concentrations and reflects solar and dietary exposure. 
25(OH)D3 re-enters the circulation and is converted into 1α,25-(OH)2D3 in the kidney 
by 25(OH)D3-1-hydroxylase, where it contributes to calcium and phosphorus 
homeostasis as well as modulation of the innate immune system. Adapted from (Deeb, 
Trump and Johnson 2007b).  
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Vitamin D3 and its activated metabolites are highly lipophilic and are therefore 
generally found in circulation bound to vitamin D-binding protein (DBP). The main 
function of DBP is to transport vitamin D3 and its metabolites. In addition, it exerts 
several other important physiological functions, including fatty acid transport, 
macrophage modulation, osteoclast activation, and chemotaxis (Gomme and Bertolini 
2004, Meier, et al. 2006, Speeckaert, et al. 2006). 1α,25-(OH)2D3, is generally believed 
to enter target cells by diffusion and then form a complex with a cytoplasmic/nuclear 
vitamin D receptor (VDR), where it causes transcriptional activation and repression of 
target genes. The VDR is a member of the steroid hormone receptor superfamily and 
regulates gene expression in a ligand-dependent manner (Evans 1988). VDR has been 
found in the small intestine, colon, osteoblasts, activated T and B cells, pancreatic beta 
cells of the islets of Langerhans, brain, heart, skin, gonads, prostate and breast cells 
(Holick 2004, Morgan, et al. 2000a). 1α,25-(OH)2D3–VDR-dependent transcriptional 
activity is modulated through synergistic ligand-binding and dimerisation with retinoic 
X receptor (RXR). The activated 1α,25-(OH)2D3–VDR–RXR complex specifically 
binds to vitamin D response elements (VDREs) which are composed of two 
hexanucleotide repeats interspaced with varying numbers of nucleotides (for example, 
GGTCCA-NNN-GGTCCA, where N is any nucleotide; this is denoted DR3), in the 
promoter regions of target genes (Carlberg, et al. 1993) (Figure 1.23). The genes 
regulated upon binding with the VDR include those genes important for calcium 
metabolism such as osteocalcin, osteopontin, 25-hydroxy-vitamin D3-24-
hydroxylase enzyme (CYP24A1) and calbindin (Haussler, et al. 1998b) and also genes 
involved in cellular proliferation and differentiation including c-myc (Salehi-Tabar, et 
al. 2012), c-fos, p21, p27 and HoxA10 (Nguyen, et al. 2011).  
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Figure 1-23: A schematic diagram of the vitaminD3 signalling pathway. 
25(OH)D3, binds to DBP, by which it gets transported into the cell (major pathway), 
while 1α,25-(OH)2D3 is generally believed to enter target cells by diffusion (minor 
pathway). Binding of 1α,25-(OH)2D3 to VDR, results in the heterodimerisation of the 
VDR with the retinoid RXR. This complex then binds to the VDRE specific sequence 
and exerts transcriptional activation or repression of the target genes. Adapted from 
(Pierrot-Deseilligny and Souberbielle 2013). 
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1.22 Objectives of the study 
 
The modulation of anti- and pro-apoptotic proteins by EBV plays a central role in the 
overall virus strategy and in the development of virus-associated malignancies.  
Previous work in our laboratory has demonstrated that EBV down-regulates the cellular 
bik gene in B cells proliferating due to the EBV growth programme, with a key role for 
EBNA-2 in this regulation. Significantly, restoration of Bik expression in LCLs leads to 
apoptotic cell death. The down-regulation of bik by EBNA-2 also highlighted the 
protective effect of EBNA-2 in EBV-infected cells.  
Having established that the cellular bik gene is an important target for down-regulation 
by latent EBV genes in the mediation of an increased anti-apoptotic threshold of EBV-
infected cells, it was the main focus of the current study to  
• Establish the mechanism by which bik is induced and regulated in B cell lines 
that model the GC in response to the major eliminating signals involved in GC 
hemostasis. 
• Define the significance of the loss of bik expression to the survival of EBV 
negative cell lines in response to induced programme cell death.  
• Clarify the mechanisms by which the EBV growth programme/EBNA-2 
interferes with the signalling pathways which are involved in the regulation of 
this proapoptotic gene. 
• Investigate a role for Vitamin D3 in regulating bik expression in B cells. 
 
Regulation of bik by EBV would have implications for the biology of EBV, as EBV-
mediated down-regulation of this gene may contribute to the survival of its host, since 
cells similar to LCLs are present in the circulation and during primary infection by the 
virus (D'Souza, Rowe and Walls 2000). Additionally, systematic studies into the 
contribution of bik to cell survival will provide important information about both 
normal B cell development and potential routes to B cell malignancy. The suppression 
of bik may contribute to the development of EBV-associated autoimmune diseases, for 
instance SLE and MS (Magliozzi, et al. 2013, Niller, Wolf and Minarovits 2008) and B 
cell malignancies, such as post-transplant lymphoproliferative disorders and BL 
tumours.  
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In summary, this thesis presents the novel finding that EBV down-regulates the cellular 
pro-apoptotic bik gene by down-regulating the transcriptional co-activator, Smad3, 
which also acts as the TGFβ signalling mediator. Significantly, Smad3 knockdown in 
EBV-negative cell lines coincided with decreased bik mRNA and Bik protein 
expression levels. The EBV latent transcription factor EBNA-2 plays a key role and this 
down-regulation is independent of the cellular transcription factor CBF1. Furthermore, 
for the first time, the bik gene has been identified to be the target of the 1α,25-(OH)2D3 
intrinsic apoptotic pathway. Cholecalcitriol induced bik expression through a PI3K-
dependent pathway. Here, it has been shown that the bik gene is the common target for 
major intrinsic apoptotic pathways in germinal centre B cell models. A broader 
knowledge of the role and regulation of the bik gene will undoubtedly enhance the 
understanding of EBV biology and of EBV associated diseases. Collectively, these 
findings suggest that modulation of bik expression by EBNA-2 through down-
regulation of Smad3 may be a contributory factor in the development of EBV-
associated B-lymphomas. 
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2.1 Biological Materials 
 
2.1.1 Cell lines 
 
Table 2-1: Cell lines used in the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cell Lines 
 
EBV 
Status 
Cell 
Classification 
Description 
    
BJAB 
 
- Burkitt-like 
lymphoma 
cell line 
BJAB is a B cell derived 
from a patient with EBV-
negative African Burkitt's 
lymphoma. The cells do not 
contain detectable amounts 
of EBV DNA, nor do they 
express the EBV-determined 
nuclear antigen EBNA. 
However the cells have the 
characteristics of B-type 
lymphocytes and carry 
receptors for EBV (Menezes 
et al, 1975).  
ER/EB 2-5 + 
 
LCL An LCL established by co-
infecting B cells with a 28 kb 
mini-EBV plasmid that only 
expresses oestrogen-
responsive EBNA-2, together 
with the EBV P3HR1 strain 
in which its own EBNA-2 
gene is deleted (Kempkes et 
al, 1995a). 
Ramos  - Type I BL EBV negative B Lymphocyte 
cell line derived from an 
American Burkitt's 
Lymphoma patient (DSMZ). 
    
    
87 
 
The BL-like cell line, BJAB was obtained from Professor Martin Rowe, University of 
Wales, Cardiff, Wales. The oestrogen-responsive cell line ER/EB2-5 was a gift from Dr. 
Ursula Zimber-Strobl, GSF-National Research Centre for Environment and Health, 
Munich, Germany. The BL cell line, Ramos (ACC 608) was bought from the Leibniz 
Institute DSMZ - German Collection of Microorganisms and Cell Cultures GmbH.  
 
2.1.2 Antibodies used in the study 
 
Table 2-2: Antibodies used in the study 
Antibody Name/Code Description Supplier 
Mouse Anti-Bik Mouse Anti-Human 
Bik Clone C33-1 
(557040) 
Monoclonal IgG raised against 
amino acids 40-114 
BD Biosciences 
Rabbit Anti-Smad3  
 
Ab28379 Rabbit polyclonal IgG to Smad3 - 
ChIP Grade 
Abcam 
Mouse Anti-Smad4 
 
Ab3219 Mouse monoclonal IgG1 [SMD46 
(same as DCS-46)] to Smad4 - ChIP 
Grade 
Abcam 
Mouse Anti- 
β-Actin  
Mouse Anti- β - Actin 
Clone AC-15 
Monoclonal IgG raised against β-
cytoplasmic actin N-terminal 
peptide 
Sigma 
Goat Anti-Mouse 
IgG Alkaline 
Phosphatase (AP) 
Conjugate 
Anti-GAPDH                          
 
 
Anti-Mouse-HRP    
 
 
 
Anti-Rabbit-HRP                      
Anti-Mouse IgG (AP) 
Conjugate S3721 
 
(FL-335): sc-25778 
 
 
A8924 
 
 
 
A4914 
Affinity-purified goat anti-mouse 
antibody 
 
Rabbit polyclonal IgG, raised 
against amino acids 1-335 
representing full length GAPDH of 
human origin 
 
A8924 anti-mouse IgG (whole 
molecule) peroxidase conjugate is 
an affinity isolated goat polyclonal 
antibody and was adsorbed with rat 
serum proteins. 
 
Anti-Rabbit IgG (whole molecule)-
Peroxidase antibody. Antibody 
adsorbed with human serum 
proteins.  
Promega 
 
 
 
Santa Cruz 
Biotech 
 
 
 
Sigma 
 
 
 
 
 
Sigma 
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2.1.3 Bacterial strains used in the study 
 
Table 2-3: Bacterial strains used in the study 
Bacterial Strain Genotype 
E. coli JM109 endA1, recA1, gyrA96, thi, hsdR17 (rk-, mk+), relA1, supE44, 
λ-, ∆(lac-proAB), [F´, traD36, proA + B + , lacl q Z∆M15] 
 
 
2.1.4 Expression and Reporter Constructs 
 
Table 2-4: Plasmids used in this study 
Plasmid Source Description 
 
pSG5  
 
 
pSG5-EBNA-2 
 
 
 
 
 
 
 
 
pSG5-EBNA-2 
WW323SR 
Stratagene 
 
 
 
 
Lindsay Spender, 
Ludwig Institute for 
Cancer Research, 
Imperial College School 
of Medicine, London.   
 
 
 
Professor Diane 
Hayward, Johns Hopkins 
School of Medicine, 
Baltimore, Maryland 
21231, USA. 
The pSG5 Vector is a eukaryotic 
expression vector, harbouring the 
SV40 promoter and the ampicillin 
resistance gene. 
pSG5-EBNA-2 expresses the wild 
type EBNA-2 gene (from the EBV 
strain B95.8) cloned into pSG5 
(Spender, et al. 2001b). 
 
 
 
 
pSG5-EBNA-2 WW323SR is 
identical to pSG5-EBNA-2 except 
that EBNA-2 has had two tryptophan 
residues mutated to serine and 
arginine residues at positions 323 
and 324 respectively. pSG5-EBNA-2 
WW323SR therefore, does not bind 
RBP-Jκ/CBF1 (Ling et al, 1993a). 
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Table 2-5: Oligonucleotides used in this Study 
Target Primer Sequence 
Bik F 
Bik R  
Hes1 F  
Hes1 R 
BZLF-1 F 
BZLF-1 R               
5’-ggaggccctagaagaaaagactac-3’  
5’-ggaacagaggaggtaaagtgtgat-3’ 
5’-cctcccaggatagctattg-3’ 
5’-tttgcctgaggacttgaagc-3’ 
5’-catgcagcagacattcatca-3 
5’-gacgaactgaccacaacactaga-3’ 
 
All oligonucleotides were synthesised by and obtained from MWG-Biotech, Ebersberg, 
Germany. 
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2.1.5 Bioinformatics software 
 
A number of web-based bioinformatics tools listed in Table 2-6 were used routinely in 
this study. 
 
Table 2-6: Web-based bioinformatics tools used in this study 
 Source Use 
BLAST http://www.ncbi.nlm.nih.
gov/BLAST 
Comparison of nucleotide or 
protein sequences to GenBank 
sequence database. Statistical 
significance of matches 
calculated. 
BioSeq File Format 
converter 
http://bioinformatics.org/
JaMBW/1/2/index.html 
Conversion of nucleotide 
sequences to other formats 
including FASTA and 
GenBank.   
 
NEBcutter V2.0 http://tools.neb.com/NEB
cutter2/index.php 
Identification of restriction 
enzyme sites along a DNA 
sequence, and prediction of 
fragment sizes. 
NetPrimerLaunch http://www.premierbiosof
t.com/netprimer/netprlau
nch/netprlaunch.html 
Primer analysis software for 
prediction of primer properties 
including, Tm, GC content, 
probability of primer-
dimer/hairpin formation. 
TESS http://dot.imgen.bcm.tmc.
edu/ 
 
Nucleic Acid Sequence 
Searches, to identify putative 
transcription factor binding 
sites. 
Translate tool http://www.expasy.org/to
ols/dna.html 
Translation of a nucleotide 
(DNA/RNA) sequence to a 
protein sequence. 
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2.1.6 Chemical and Molecular Biology Reagents  
 
Table 2-7: Chemical and molecular biology reagents used in this study 
Supplier Product/Code 
  
Abcam ChIP kit (ab500), Mouse IgG1, Rabbit Control IgG - 
ChIP Grade (ab46540), Smad3 antibody-ChIP Grade 
(ab28379), Smad4 antibody [SMD46 (same as DCS-
46)] - ChIP Grade (ab3219). 
Amersham Rainbow Molecular Weight Markers (RPN800). 
Amaxa GmBH Cell Line Nucleofector Kit T (VCA-1002), Kit V 
(VCA-1003). 
Applied Biosystems Bcl-2-interacting killer (apoptosis-inducing) Assay 
(Hs00154189_m1), Silencer® Negative Control # 1 
siRNA (5 nM) (AM4611), Silencer®BIK, si1989 1 
siRNA (5 nM) (4390824), Silencer®BIK, si1990 1 
siRNA (5 nM) (4390824), TaqMan(R) Gene 
Expression Assays, Inventoried Assay ID: 
Hs99999905_m1 GAPDH, Custom Silencer® Select 
Smad3 57 and Smad3 56 (5 nM) (4390827). 
ASP Presept Disinfectant Tablets (SPR25).  
BD Biosciences Annexin V-PE kit code 559763, FACS flow 
(342003). Bik, Purified Mouse Anti-Human Bik, 0.5 
mg/ (557040). 
BDH Bromophenol blue (44385), EDTA (280254D), 
Glycine (444495D), Hydrochloric acid (28507BF), 
Isopropanol (296946H), Methanol (29192BL), 
Nitrocellulose membrane (436107E), Sucrose 
(102745C). 
Bioline SensiMix Probe One-Step Kit 250 rxns QT725-02, 
SensiMix SYBR no ROX One step kit 250rxn 
QT235-02. 
 
Biosciences Bis-AcrylaGel (EC-820), HiYield Gel/PCR DNA 
Fragment Extraction Kit (YDF100). PBS 1X (1490-
094), RPMI 1640 Glutamax (61870-010). 
Cambridge Biosciences Goat F(ab')2 anti-human IgM (2022-01).*** 
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Eppendorf Perfectprep Gel Cleanup (955152000). 
Fermentas GeneRuler 100bp DNA Ladder Plus (SM0323), 
GeneRuler 1kb DNA Ladder Plus (SM1333), 
PageRuler Plus Prestained Protein Ladder (SM1811), 
ProteoJET mammalian cell lysis reagent (K0301), 
ProteoJET cytoplasmic and nuclear protein extraction 
kit (K0311), Restriction enzymes. 
Invitrogen 1 Kb DNA ladder (15615-016), 100 bp DNA ladder 
(15628-019), Foetal calf serum (10270-106), HEPES 
(15630-056), Glutamax 1640 (61870-010), RPMI 
1640 (31870-025), Trypan blue (15250-061), SYBR 
Gold Nucleic Acid Gel Stain (S11494), SYBR Safe 
DNA Gel Stain (S33102).    
Labkem  Nitrocellulose Membrane (436107E). 
Labscan Chloroform (A3505E).  
Lennox Chemicals IMS (B0982). 
Merck Calcium chloride (23821000), Magnesium chloride 
(1058321000), Potassium Hydroxide (50321000).  
Msc: Medical supply Co ltd MMLVR (M1701), Rnasin (N2111), Anti-Mouse IgG 
(H+L), AP Conjugate (S3721). 
Mirus Ingenio™ Electroporation Kits & Solution 0.2 cm 
cuvette, for 50 reactions (MIR 50115). 
National diagnostics Acrylagel (EC810), Bis-acrylagel (EC820). 
Millipore 
 
Amicon Ultrafilter (UFC8 00508), Immobilon 
Western Chemiluminescent HRP Substrate 
(WBKLSOO50), SNAP i.d. Antibody collection trays 
(WBAVDABTR), SNAP i.d. Double well blot 
holders (WBAVDBH02), Transforming Growth 
Factor-β1, recombinant human (GF111).* 
Oxoid Agar (L13), PBS tablets (BR14), Tryptone (L42), 
Yeast extract (L21). 
Pierce SuperSignal® West Pico Chemiluminescent Substrate 
(34080). 
Promega dNTPs (U1330), Magnesium chloride 25mM 
(A3511), M-MLV reverse transcriptase & RT buffer 
(M1701), RNasin (N2111), Wizard® PCR Preps DNA 
purification system (A7170), CellTiter 96® Aqueous 
One solution Cell Proliferation Assay 
(MTS)(G35882). 
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Roche Leupeptin (1017128).  
Qiagen EndoFree Plasmid Max kit (12362), Qiagen® Plasmid 
Purification Kit (12143), Quantitect TM SYBR® Green 
PCR Kit (204143).  
Santa Cruz Biotechnology Anti-Rabbit IgG, HRP Conjugate (sc-2030), stored in 
4oC. 
Sigma-Aldrich Chemical Co.  3M sodium acetate, pH5.2 (S7899), Agarose 
(A5093), Albumin from bovine serum (A7906-50G), 
Ampicillin (A9518), Aprotinin (A4529), Ammonium 
Persulfate (215589), Bovine serum albumin (A9647),  
Copper (II) Sulphate pentahydrate (31293), DEPC 
(D5758), DMSO (D8779), β-oestradiol (E8875),  
Glucose (G7528), Glycerol (G5516), L-glutamine 
(G7513), Manganese Chloride (M3634), 
Penicillin/streptomycin (P0781), PMSF (P7626), 
Ponceau S (P7170), Potassium chloride (P4504), 
potassium phosphate monobasic (p5655) Puromycin 
(P8833), RNase A (R6513), RNAZap (R2020), 
Sodium chloride (S3014), Sodium hydroxide (S5881), 
Sodium phosphate (S5136), Tetracycline (T7660), 
TEMED (T7024), Tri Reagent (T9424), 3,3’,5,5’-
Tetramethylbenzidine (TMB) (T0565), Triton® X-
100 (T8787), Trizma® Base (T1503), Tween 20 
(P1379), Water (Molecular Grade) (W4502), Mouse 
Anti-β-Actin A1978, Sodium Citrate (S1804). Phenol: 
chloroform: isoamyl alcohol (25:24:1) (P3803), 
1α,25-Dihydroxyvitamin D3 10 µG (D1530)**. 
VWR International limited Transforming Growth Factor-β1, recombinant human (514-4131)* 
* Lyophilised human recombinant transforming Growth Factor-β1 (TGFβ1) was 
centrifuged prior to opening and reconstituted in water at a concentration of 0.1-1.0 
mg/mL, and stored at -20°C to -80°C.  
**
 The lyophilised powder of cholecalciferol (1α,25-Dihydroxyvitamin D3 10 µg) was 
centrifuged prior to opening and reconstituted in 100% ethanol at a concentration of 10 
µM, and stored at -80°C.   
***
 Anti-IgM antibody was stored at 4˚C.  
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2.2 DNA Manipulation* 
 
2.2.4 DNA Storage 
 
DNA samples were stored in Tris-EDTA (TE) buffer (pH 8.0) at 4˚C. EDTA was used 
to chelate heavy metal ions that are needed for DNase activity while storage at pH 8.0 
minimises deamidation.  DNA was also stored in sterile distilled H2O (dH2O) at -20˚C.  
 
2.2.2 Phenol/chloroform extraction and ethanol precipitation 
 
The standard method to concentrate nucleic acid samples, remove proteins or change 
the buffers in which a sample was dissolved is a phenol/chloroform extraction followed 
by ethanol precipitation. DNA partitions into the aqueous phase, denatured proteins 
collect at the interface and lipids partition into the organic phase. Nucleic acids are 
routinely recovered from aqueous solutions using ethanol precipitation in the presence 
of sodium acetate. An equal volume of phenol/chloroform/isoamyl alcohol (25:24:1) 
was added to the DNA solution, mixed by vortexing and centrifuged for 5 min at 13,000 
x g at room temperature.  The upper aqueous phase was removed, avoiding any material 
at the interphase, and placed in a sterile microfuge tube. An equal volume of 
chloroform/isoamyl alcohol (24:1) was added to the aqueous phase (to remove any 
residual phenol), vortexed as before, and centrifuged for 5 min at 13,000 x g at room 
temperature. Again the upper aqueous phase was removed to a fresh tube. One-tenth 
volume of 3 M sodium acetate (pH 5.2) was added to the solution of DNA to aid 
precipitation, mixed and followed by 2 and a half volumes of 100 % (v/v) ethanol.  This 
mixture was vortexed and incubated at -20˚C for a minimum of 20 min. When dealing 
with very small quantities of DNA, samples were precipitated in ethanol at -20oC 
overnight. The DNA samples were then centrifuged for 20 min at 12,000 x g at 4˚C, the 
supernatant was removed and pellets were washed with 300 µl 70 % (v/v) ethanol to 
remove excess salts.  The tube was centrifuged for 5 min at 10,000 x g, the supernatant 
was removed and pellets were air dried for approximately 10 min. Pellets were re-
suspended in an appropriate volume of sterile TE (pH 8.0) or dH2O and were stored at 
4˚C or -20˚C respectively (Chomczynski,P. 1987). 
*
 Preparations of all solutions used in DNA manipulation are outlined in the Appendix.  
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2.2.3  Restriction digestion of DNA 
 
Restriction enzymes bind and cleave double-stranded DNA at specific sites within or 
adjacent to a particular sequence, which is known as the recognition site. Restriction 
digestion of DNA was carried out for identification purposes, plasmid linearization or to 
excise fragments from plasmid DNA. Restriction digestion patterns were predicted for 
DNA sequences using the NEBCutter or the WebCutter 2.0 bioinformatics tool (Table 
2-6). All restriction enzymes used were supplied with incubation buffers at a 
concentration of 10X (working concentration 1X). Some enzymes required the addition 
of Bovine Serum Albumin (BSA) to the reaction to stabilize the enzyme, (working 
concentration 1X). DNA digestion reactions were performed according to 
manufacturer’s instructions (New England Biolabs) and incubated for 3 h at the 
optimum enzyme temperature (between 37˚C and 50˚C, usually 37˚C).  
 
2.2.4 Preparation of competent cells 
 
Competence is the ability of a cell to take up extracellular DNA from its environment. 
E. coli cells are more likely to incorporate foreign DNA if the cultures are treated to 
make them transiently permeable to DNA. In this regard, a modified rubidium chloride 
(RbCl2) method was employed to prepare competent cells. E. coli JM109 cells were 
streaked from a glycerol stock on to a Luria-Bertani (LB) (Appendix) agar plate and 
incubated at 37˚C overnight. An isolated colony was then picked using a sterile 
inoculating loop and used to inoculate 2.5 mL of LB broth, which was incubated at 
37˚C in a shaking incubator at 200 rpm overnight. This culture was then used to 
inoculate 250 mL of sterile LB broth supplemented with 20 mM MgSO4. The 250 mL 
culture was incubated in a 1 L flask at 37˚C until the optical density (O.D.) of the 
culture was between 0.4 and 0.8, at 640 nm (approximately 4-5 h). The cells were then 
transferred to two sterile 250 mL centrifuge tubes and collected by centrifugation at 
4,500 x g, 4˚C for 5 min. The cells were then gently re-suspended in 0.4 of their original 
volume in ice-cold TFB1 (Appendix) (100 mL for 250 mL culture). Cells were kept on 
ice for all subsequent steps and pipettes, tubes and flasks were chilled. The re-
suspended cells were then incubated on ice at 4˚C for 5 min followed by centrifugation 
at 4,500 x g at 4˚C for 5 min. Cells were then gent
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original volume of ice-cold TFB2 (Appendix) (10 mL for a 250 mL culture). These cells 
were then dispensed into 100 µL aliquots and incubated on ice for 1 h.  Prior to storage, 
the aliquoted cells were snap frozen in a dry ice/isopropanol bath. E. coli JM109 
competent cells prepared by this method and stored at -80˚C are stable for 1 year 
(Sambrook J, Russell DW 2001).  
 
2.2.5 Transformation of E. coli with plasmid DNA 
 
A 95 µL aliquot of competent cells was placed in a pre-chilled microfuge tube 
containing 5 µL DNA (~100 ng/10 µL). The contents of the tube were mixed gently by 
flicking and incubated on ice for 30 min, during which time an aliquot of SOC medium 
(Appendix) was pre-heated to 37˚C. After 30 min on ice the cells were heat-shocked in 
a water bath at 42˚C for 55-65 s, and were then removed immediately to ice for a further 
2 min. A 900 µL aliquot of preheated SOC was added to the cells which were then 
incubated at 37˚C in a shaking incubator for 1 h 30 min. The cells were then collected 
by centrifugation for 3 min at 6,000 x g, following which 900 µL of supernatant was 
removed and discarded.  The cells were re-suspended in the remaining supernatant and 
plated out, along with the controls, on LB plates containing antibiotic at the appropriate 
concentration, and incubated overnight at 37˚C. Plasmids carrying the antibiotic 
resistance gene confer this resistance to the transformed cells and thus only transformed 
cells will yield colonies. These colonies were subsequently used to prepare broth 
cultures for DNA mini-preparations (Sambrook J, Russell DW 2001). 
 
2.2.6 Small scale preparation of plasmid DNA (Miniprep) 
 
A single bacterial colony was used to inoculate 5 mL of LB medium containing the 
appropriate antibiotic and incubated with shaking (200 rpm) overnight at 37˚C. An 
aliquot (1.5 mL) of this culture was transferred to a sterile microfuge tube and 
centrifuged for 30 s at room temperature; the remainder was stored at 4˚C. The 
supernatant was removed from the tube using a pipette tip, leaving the cells as dry as 
possible. The cells were then re-suspended in 100 µL of solution I (Appendix) by 
vortexing. Two hundred microlitres of freshly prepared lysis solution [solution II 
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(Appendix)] was then added, and the tube contents were mixed by inverting the tube 
rapidly a number of times. Ice-cold neutralisation solution III (150 µL; Appendix) was 
added to stop the reaction and the tubes were vortexed gently for 10 s. The lysate was 
centrifuged for 5 min at 12,000 x g, and the supernatant was transferred to a fresh tube, 
taking care not to carry over any of the white precipitate. A phenol chloroform 
extraction and ethanol precipitation was carried out as described previously in Section 
2.2.2. The pellet was air-dried, then re-suspended in 20 µL of dH2O. One microlitre of 
DNase-free RNase A (20 µg/mL) was also added, and the mixture was vortexed, 
incubated at 37˚C for 1 h and then stored at 4˚C (Adapted from Maniatis et al, 1982). 
 
2.2.7 Glycerol Stocks 
 
Glycerol stocks enable long term storage of bacteria, since glycerol prevents water in 
the broth from forming ice crystals that can puncture and kill the bacterial cells. 
Glycerol stocks of bacterial cultures were prepared by adding 0.5 mL of a 50% (v/v) 
glycerol solution to 0.5 mL of the overnight bacterial culture of interest, mixing and 
storing at -80˚C for future use. 
 
2.2.8 Qiagen® plasmid DNA purification protocol (Midiprep) 
 
Plasmid DNA was isolated and purified using the Qiagen® Plasmid Midi Kit. The 
process of plasmid isolation involves the lysis of the cells by a treatment with lysozyme 
followed by SDS which denatures proteins after the lysis of the membranes. The 
precipitation of the SDS-protein complex with high-molarity salt specifically subtracts 
the chromosomal DNA from the supernatant, since it remains attached to the 
mesosome. A glycerol stock of the bacteria of interest was streaked on an LB agar plate 
(containing the appropriate antibiotic) and incubated overnight at 37˚C. An isolated 
colony from this plate was used to inoculate a 5 mL starter culture (with the appropriate 
antibiotic) and incubated in a shaking incubator at 225 rpm 37˚C for 8 h.  100 µL of the 
starter culture was used to inoculate 50 mL of LB (containing the appropriate antibiotic) 
in a 250 mL sterile flask and incubated overnight in a shaking incubator at 37˚C.  It was 
important that the O.D. of the culture was between 1 and 1.5 at 600 nm.  The bacterial 
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culture was transferred to a centrifuge tube and the bacterial cells were harvested by 
centrifugation at 6,000 x g for 15 min at 4˚C using a JA-20 rotor in a Beckman 
centrifuge.  The supernatant was decanted and the cells were re-suspended completely 
in 4 mL of Buffer P1 containing RNase A (100 µg/mL). The bacterial cells were then 
lysed by addition of 4 mL Buffer P2 and incubation at room temperature for 5 min.  
Following incubation, 4 mL of pre-chilled Buffer P3 was added (to precipitate genomic 
DNA, protein, cell debris and SDS), mixed gently by inverting the tube 5-6 times and 
incubated on ice for 15 min.  The mixture was then centrifuged for 1 h 30 min at 16,000 
x g at 4˚C and the supernatant saved. The Qiagen-tip 100 was equilibrated by applying 
4 mL of QBT buffer and allowing the column to empty by gravity. The column does not 
dry out at this stage, as the flow of buffer will stop when the buffer reaches the upper 
filter.  Following equilibration, the supernatant from the previous centrifugation step 
was applied to the filter and allowed to flow through. The Qiagen-tip was washed with 
2 x 10 mL of Buffer QC. DNA was then eluted with 5 mL of Buffer QF. DNA was 
precipitated by adding 0.7 volumes of room-temperature isopropanol. The 
DNA/isopropanol mixture was then aliquoted and centrifuged immediately at 13,000 x 
g for 45 min at 4˚C and the supernatant was carefully removed using pipettes.  The 
resulting pellet was washed with 70% (v/v) ethanol (13,000 x g for 15 min at 4˚C), 
allowed to air dry for 5 min and re-dissolved in 30 µL of TE or dH2O.  DNA was then 
quantified by spectrophotometric analysis, and the quality of the DNA was checked by 
agarose gel electrophoresis (Adapted from the manufactures protocol Qiagen® Plasmid 
Purification Handbook, 2005). 
 
 
2.2.9 Qiagen® EndoFree plasmid purification protocol (Maxiprep) 
 
Endotoxins are frequent contaminants in plasmid DNA prepared from bacteria. In order 
to improve transfection efficiency, endotoxin-free plasmid DNA was isolated and 
purified using the Qiagen® EndoFree Plasmid Midi Kit from Promega according to the 
manufacturers protocol (EndoFree® Plasmid Purification Handbook, 2005). Endotoxin-
free DNA was then quantified by spectrophotometric analysis, and the quality of the 
DNA was checked by agarose gel electrophoresis. 
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2.2.10 Determination of Nucleic Acid Sample Concentration 
 
The concentration of isolated nucleic acids can be determined spectrophotometrically. 
Nucleic acids absorb UV light maximally at an abosorbance of 260nm, thus optical 
absorbance can be used as an accurate measurement of its concentration. Pure DNA at 
50 µg/mL in aqueous solution has an A260 of 1, while 40 µg/mL of pure RNA also has 
an absorbance reading of 1 at this wavelength. Absorbance is also useful as a measure 
of the purity of DNA. The ratio of A260/A280 of a pure dsDNA preparation should be 
between 1.65 and 1.85. Higher values are often due to RNA contamination and lower 
values to protein and phenol contamination.  Pure DNA and RNA have A260/A280 ratios 
of 1.8 and 2.0 respectively. Absorbances were read on the Shimadzu UV-160A 
spectrophotometer using a quartz cuvette and nucleic acid concentrations were 
determined according to the following equations: 
 
 
 
Concentration of DNA (µg/µL) = Absorbance (260 nm) x 50 x dilution factor   
                                                                                          1000                                                                                                          
 
Concentration of RNA (µg/µL) = Absorbance (260 nm) x 40 x dilution factor
             1000 
 
The NanoDrop® ND-1000 Spectrophotometer was also used to determine nucleic acid 
sample concentrations. An undiluted 1 µL sample was pipetted onto the end of a fibre 
optic cable (the receiving fibre). A second fibre optic cable (the source fibre) was then 
brought into contact with the liquid sample, causing the liquid to bridge the gap between 
the fibre optic ends. (The gap is controlled to both 1 mm and 0.2 mm paths by the 
computer). A pulsed xenon flash lamp provided the light source and a spectrometer was 
used to analyse the light after passing through the sample. The instrument is controlled 
by special software run from a PC, and the data was logged in an archive file on the PC. 
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2.2.11 Agarose gel electrophoresis of DNA 
 
DNA has a negative charge in solution, and the magnitude of this charge is relative to 
the DNA fragment length. DNA will migrate to the positive pole in an electric field and 
thus DNA fragments can be separated based on size by passing through a porous gel 
under an electrical current. This is the basis for agarose gel electrophoresis and it is the 
standard method used to separate, identify, and purify DNA fragments. The appropriate 
quantity of agarose was added to 100 mL 1X TAE buffer based on the percentage 
agarose gel required. Increasing the percentage agarose (1.8-2.0%) in the gel was 
generally used to improve resolution of smaller DNA fragments while separation of 
larger DNA molecules was best achieved by using lower percentage gels (0.7-1.0%).  
The agarose was completely dissolved by boiling with intermittent mixing and after 
sufficient cooling (~60˚C) the gel was cast into the Hybaid horizontal gel 
electrophoresis system.  A comb was inserted for formation of the wells.  The gel was 
left to polymerise before filling the chamber with 1X TAE and removing the comb.  
Sample buffer, containing bromophenol blue as a tracking marker (Appendix), was 
added to each sample before loading up to 20 µL of the sample containing the nucleic 
acid per well.  DNA sample buffer was also added to 500 ng of a 1 Kb or 100 bp ladder, 
which was loaded as a size marker.  The gel was run at constant voltage (5 V/cm, 
usually 100V), for 1 to 2 h. After completion, the gel was stained in ethidium bromide 
(0.5 mg/mL) for 30 min, destained in dH2O for 15 min and viewed under UV 
illumination (Sambrook J, Russell DW 2001). 
 
2.2.12 Eppendorf Perfectprep® Gel Cleanup 
 
Extraction and purification of dsDNA fragments from TAE agarose gels was achieved 
using the Eppendorf Perfectprep® Gel Cleanup kit following the manufacturers’ 
protocol (Perfectprep® Gel Cleanup Manual, 2002). The purified DNA was eluted in 30 
µL of molecular biology grade water and stored at 4˚C or -20˚C. 
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2.2.13 DNA Sequencing 
 
Sequencing of plasmid DNA was performed to ensure the nucleic acid fidelity and ‘in-
frame’ insertion of DNA fragments following cloning. Plasmid DNA as prepared in 
Section 1 was quantified (Section 1) and 1-2 µg (typically 1-2 µL) was transferred to a 
sterile 1.5 mL microfuge tube. The DNA was lyophilised in a Savant DNA110 speed 
vac on the low heat setting for 15-20 min or until the solvent had evaporated. The 
lyophilised DNA was sent to MWG-Biotech, Ebersberg, Germany for sequencing. 
Sequencing forward and reverse primers were supplied by MWG-Biotech for most 
commercially available cloning systems. In the absence of existing sequencing primers 
(as in the case of the pRTS-1 vectors), a forward and/or reverse primer was designed 
and purchased and 100 pmol of primer was transferred to a sterile microfuge tube and 
sent with each sequencing reaction to MWG-Biotech. Sequencing results were obtained 
electronically as linear nucleotide sequences. 
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 Cell Culture Methods 2.3
 
All cell culture techniques were performed in a sterile environment using a Holten 
laminar flow cabinet. Cells were visualised with an Olympus CK2 inverted phase 
contrast microscope. 
 
2.3.1 Culture of cells in suspension 
 
All media compositions and media supplements are given in the Appendix. The cell 
lines BJAB, ER/EB 2-5, and Ramos were maintained in RPMI 1640 supplemented with 
10% foetal bovine serum (FBS), 2 mM L-glutamine, 100 µg/mL streptomycin and 100 
U/mL penicillin. Cultures were seeded at a density of 2 x 105 to 5 x 105 cells per mL in 
25 cm2 flasks and expanded in 75cm2 flasks. Cells were sub-cultured two or three times 
per week by harvesting the cells into a sterile centrifuge tube and centrifuging at 1000 x 
g for 5 min at room temperature. The cells were gently re-suspended in a suitable 
volume of fresh supplemented media and replaced into the tissue culture flask.  All cell 
lines were incubated in a humid 5% CO2 atmosphere at 37˚C in a Heraeus cell culture 
incubator. 
 
2.3.2 Media supplements 
 
Supplements were added to the growth media of certain cell lines either to select cells 
containing transfected plasmids, activate the function/or induce expression of a gene of 
interest or to improve cellular proliferation. The oestrogen-responsive ER/EB2-5 cell 
line was maintained in supplemented medium containing 1 µM oestrogen. To abolish 
functional EBNA-2 activity, ER/EB2-5 cells were washed 4 times in PBS, with a 
further 2 washes 24 h later and replaced in estrogen-free supplemented medium.   
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2.3.3 Cell counts 
 
Cell counts were carried out using an improved Neubauer haemocytometer slide. 
Trypan blue exclusion dye was used to establish cell viability. A volume of 10 µL of 
trypan blue was added to 90 µL of a cell suspension and mixed. A sample of this 
mixture was added to the counting chamber of the haemocytometer and cells were 
visualised by light microscopy. Viable cells excluded the dye and remained clear while 
dead cells stained blue. Cell numbers were determined by multiplying the average cell 
count (of 3-5 individual counts) by the dilution factor (usually 1.1) and again by the 
volume of the haemocytometer chamber (1 x 104 cells/mL). Thus, cell counts were 
expressed as the number of cells per mL. 
 
2.3.4 Cell storage and recovery 
 
In order to prepare stocks of suspension cells for long-term storage, 1 x 107 cells in 
exponential phase were centrifuged, the excess media was discarded and the cells were 
re-suspended in 750 µL of supplemented RPMI to which 150 µL of FBS was added, and 
then placed on ice for 10 min. DMSO was added to a final concentration of 10% (v/v), 
mixed gently and transferred to a sterile cryotube. In the case of adherent cells, one 
confluent 75 cm2 flask of cells was used per cell stock. Adherent cells were washed with 
1X PBS, followed by trypsinisation and re-suspended in 900 µL of FBS and 100 µL of 
DMSO. The cells were mixed gently and added to a sterile cryotube. The cryotubes 
were slowly lowered into the gas phase of liquid nitrogen and then immersed in liquid 
nitrogen in a cryofreezer (Cooper Cryoservices). Cells were recovered from liquid 
nitrogen by thawing rapidly at 37˚C and transferring to a sterile centrifuge tube 
containing 5 mL of pre-warmed supplemented media. The cells were centrifuged at 100 
x g for 5 min, then re-suspended in 5-10 mL of fresh supplemented media, transferred to 
a culture flask and incubated at 37˚C in 5% CO2. 
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2.4  Transient transfections 
 
Transient transfection of cells was performed by electroporation or nucleofection. In all 
cases, cells were seeded at a density of 2-5 x 105 per mL of media 24 h prior to 
transfection. After this time in culture, cells were counted again as it was essential for 
cell numbers to have almost doubled before beginning the transfection, thus ensuring 
that cell growth was in logarithmic phase, allowing for optimal DNA uptake during 
transfection. The same quantity of total DNA was used per transfection.  
 
2.4.1 Electroporation of B lymphocytes 
 
Transfection of Ramos and BJAB cell lines was carried out by electroporation. During 
the electroporation method of transfection, the application of brief high voltage electric 
pulses to the cells leads to the formation of nanometre-sized pores in the plasma 
membrane. DNA is taken directly into the cell cytoplasm either through these pores or 
as a consequence of redistribution of membrane components that accompanies the 
closure of the pores. Total DNA (10-20 µg per transfection) dissolved in 30 µL TE 
buffer (pH 8.0) was transferred into a sterile electroporation cuvette. A total of 1 x 107 
cells were used per transfection. Cells were centrifuged at 100 x g for 5 min and the 
supernatant discarded. The cells were then washed in PBS, centrifuged at 100 x g for 5 
min and the supernatant again discarded. For each 1 x 107 cells, 220 µL of serum-free 
media was used for re-suspension and the cells transferred to the DNA-containing 
electroporation cuvettes. The cell/DNA mix was incubated at room temperature for 5 
min. Each cell/DNA mix was then pulsed at 220-250 V (BJAB, 250 V and Ramos 220 
V) with a capacitance of 960 µF (using a capacitance extender) and resistance set to 
infinity using a Biorad Gene Pulser. Immediately after electroporation the cuvettes were 
placed on ice until the cell/DNA mix was transferred into 5 mL supplemented media in 
a 6 well dish, and the contents were mixed by gently rocking back and forth. Care was 
taken to ensure that cells were stored no longer than 10 min after electroporation to 
avoid reduction in cell viability/gene transfer efficiency. Transfected cells were 
harvested 48 h later.  
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2.4.2 Nucleofection of B lymphocytes 
 
The Nucleofector technology is based on electroporation. It consists of the Nucleofector 
device II (Amaxa), which delivers a cell-specific combination of electrical parameters, 
and Nucleofector Solutions, in which the cells are contained while the unique electrical 
program is executed. Optimised conditions for nucleofection of BJAB cells yielded 
higher percentage transfection efficiency, when compared to cells transfected using the 
electroporation technique and Ingenio transfection buffer. The Nucleofector solution 
specific to the particular cell line under investigation (Solution T/V for BJAB/IB4) was 
pre-warmed to room temperature and 50 mL of supplemented media was pre-warmed to 
37ºC. Supplemented medium (2 mL) was aliquoted into the appropriate number of wells 
of a 6 well plate and pre-incubated at 37˚C/5% CO2/humidified atmosphere. A total of 
~7 µg DNA was prepared in sterile 1.5 mL microfuge tubes for each sample. For each 
transfection, 2.5 x 106 (IB4)/ 5 x 106 (BJAB) cells were collected by centrifugation at 90 
x g for 10 min and the supernatant was discarded completely so that no residual medium 
remained. The cells were resuspended in room-temperature solution in question to a 
final concentration of 5 x 106 /100 µL (BJAB). Care was taken to ensure cells were 
stored in Nucleofector solution for no longer than 15 min to avoid reduction in cell 
viability/gene transfer efficiency. A volume of 100 µL of cell suspension was mixed 
with the DNA and the nucleofection sample was transferred to an Amaxa-certified 
cuvette, taking care to avoid bubbles. The cuvette was placed in the nucleofection 
chamber and pulsed on program T-016 (BJAB) or O-006 (Ramos). Immediately after 
this, 500 µL of pre-warmed medium was added to the cuvette. The contents were then 
gently transferred to the prepared 6-well plates, mixed gently and incubated at 37˚C 5% 
CO2 humidified atmosphere until cells were harvested (Parametes used here are 
obtained from Lonza's Optimized Protocols for the Amaxa™Nucleofector™ 
Technology). Electroporation conditions were optimized using a protocols on the Gene 
Pulser MXcell electroporation system (Bio-Rad). 
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2.5 Flow cytometric analysis 
 
Flow cytometry may be defined as a technology to measure properties of cells as they 
move, or flow, in liquid suspension. Most flow cytometers can measure two kinds of 
light from cells, light scatter and fluorescence. Light scatter is the interaction of light 
and matter. All materials, including cells, will scatter light. In the flow cytometer, light 
scatter detectors are located opposite the laser (relative to the cell), and to one side of 
the laser, in-line with the fluid-flow/laser beam intersection. The measurements made 
by these detectors are called forward light scatter and side light scatter, respectively. 
Forward light scatter provides information on the relative size of individual cells, 
whereas side light scatter provides information on the relative granularity of individual 
cells. Fluorescence is the property of a molecule to absorb light of a particular 
wavelength and re-emit light of a longer wavelength. The wavelength change relates to 
an energy loss that takes place during the process. BD FACSCalibur and BD 
FACSAria-II cell sorter instruments were used for these experiments and FLOWJO 
version 7.6.5 was used for fcs raw data analysis (According to BD Biosciences technical 
book). 
 
2.5.1 Annexin V/ vital dye staining 
 
In normal live cells, phosphatidyl serine (PS) is located on the cytoplasmic surface of 
the cell membrane. However, in apoptotic cells, PS is translocated from the inner to the 
outer leaflet of the plasma membrane, thus exposing PS to the external cellular 
environment. The human anticoagulant, Annexin-V, is a 35–36 kDa Ca2+-dependent 
phospholipid-binding protein that has a high affinity for PS and can be used to identify 
apoptotic cells by binding to PS. Fluorescent dyes that bind to nucleotides and penetrate 
only damaged cellular membranes were used (vital dyes). Intercalation complexes are 
formed by propidium iodide or 7-amino-actinomycin (7AAD) with double-stranded 
DNA, which affects amplification of the fluorescence. 
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2.5.2 AnnexinV-PE/7AAD 
 
The Annexin-PE Apoptosis Detection Kit (Becton Dickinson) contains recombinant 
Annexin-V conjugated to the fluorochrome, phycoerythrin (PE) and the vital dye 
7AAD. Viable cells with intact membranes exclude 7AAD, whereas the membranes of 
dead and damaged cells are permeable to 7AAD. Cells that stain positive for Annexin-
V-PE and negative for 7AAD are undergoing apoptosis. Cells that stain positive for 
both Annexin-V-PE and 7AAD are either in the end stage of apoptosis, are undergoing 
necrosis, or are already dead. Cells that stain negative for both Annexin-V-PE and 
7AAD are alive and not undergoing measurable apoptosis. For experiments performed 
here apoptotic cells include the sum of the cells in the upper right and lower right 
quadrants of flow cytometry plot of Annexin-V-PE vs 7AAD. To perform the assay, 
cells were harvested and washed twice in ice-cold PBS. The cells were re-suspended in 
1X Annexin-binding buffer at a concentration of ~1 x 106 cells/mL. A volume of 5 µL 
of Annexin-V-PE solution and 5 µL of 7AAD solution was added to 100 µL of cell 
suspension. The cells were incubated at room temperature for 15 min in the dark and 
400 µL of 1X Annexin-binding buffer was then added and the samples were analysed 
within 1 h by flow cytometry (According to the BD Biosciences Apoptosis assay kit as 
outlined in the product technical data sheet). 
 
2.5.3 Cell Viability Determination using MTS Assay 
 
An MTS assay was performed according to manufacturer’s instructions (Promega). The 
principle behind this assay is that the MTS compound [3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoyxphenyl)-2-(4-sulfophenyl)-2H tetrazolium, inner salt] is provided to 
cells for a fixed amount of time. The compound is reduced to formazan by live cells at a 
rate proportional to the number of cells present. The formazan can be detected by its 
absorbance at 495 nm. Changes in cell viability would be detectable by changes in 
absorbance detection at 495 nm. 
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2.6 RNA Analysis 
 
2.6.1 RNase-free environment 
 
Because RNA is easily degraded by ubiquitous RNases, standard procedures were 
employed to avoid this potential hazard (Sambrook et al, 1989). Prior to working with 
RNA, any apparatus or surfaces to be used were treated to remove RNase. The 
apparatus/surface was washed in detergent and rinsed well in DEPC-treated H2O then in 
100% (v/v) ethanol and finally allowed to air dry. Any apparatus to be used were also 
immersed in a 3% (v/v) solution of hydrogen peroxide (Sigma-Aldrich) for 15 min, and 
were then rinsed thoroughly in DEPC-treated upH2O and allowed to dry. Because hands 
are a major source of RNase contamination, gloves were used at all times and changed 
frequently. 
 
2.6.2 RNA analysis by gel electrophoresis 
 
In order to examine RNA transcripts/ascertain the integrity of RNA, isolated samples 
were run on 1.5% (w/v) agarose gels. The appropriate amount of agarose was dissolved 
in DEPC-treated H2O and prepared according to Section 2.2.13 The RNA samples (1 
µL) were prepared for electrophoresis by adding 3 µL of RNA sample buffer 
(Appendix) and made up to 15 µL in DEPC-treated H2O. The samples were heated to 65 
°C for 10 min prior to loading on the gel.  The gel was run in 1X TAE as described in 
Section 2.2.13. As ethidium bromide is included in the RNA sample buffer, the gels did 
not require further staining and could be visualised directly on a UV trans-illuminator.   
 
2.6.3 RNA extraction from cultured cells 
 
Prior to RNA isolation, the condition of cells was reviewed by phase contrast 
microscopy.  A cell count was performed as described in Section 2.3.3.   
 
109 
 
2.6.4 RNA extraction using Tri-reagent   
 
Cells grown in suspension were centrifuged at 100 x g for 5 min, washed once in PBS 
and the cells were lysed by repeat pipetting in Tri Reagent (Sigma-Aldrich). A volume 
of 1 mL of Tri reagent was used per 1 x 107 cultured cells. The lysate was left at room 
temperature for 5 min, after which time the procedure could be halted by storing 
samples at –80 ˚C. Phase separation was achieved by adding 200 µL of chloroform per 
1 mL of lysate. The samples were covered and shaken gently but thoroughly for 15 s or 
until completely emulsified.  Samples were incubated at room temperature for 15 min.  
The resulting mixture was centrifuged at 13,000 x g for 20 min at 4 ˚C. During 
centrifugation, the mixture separated into a lower red, phenol-chloroform phase, an 
interphase and a colourless upper aqueous phase. The aqueous phase, which contained 
the RNA, was removed to a fresh tube and RNA was precipitated by addition of 500 µL 
of ice-cold isopropanol per mL of Tri reagent used initially. The samples were 
incubated for 10 min on ice and then centrifuged at 13,000 x g for 15 min at 4 ˚C. The 
resulting RNA pellet was washed using 1 mL of 75% (v/v) ethanol by inverting the tube 
5 times.  The pellets were then centrifuged at 13,000 x g for 5 min at 4 ˚C, and the 75% 
(v/v) ethanol was aspirated.  Pellets were air dried and dissolved in DEPC-treated 
upH2O.  The resulting RNA preparation was heated at 60˚C and mixed gently to ensure 
a homogeneous solution prior to aliquoting. An aliquot was removed for 
spectrophotometric (Section 2.2.10) and gel electrophoretic analysis (Section 2.7.2) and 
the remainder of the purified RNA was stored at – 80 ˚C (Rio,D.C. 2010).  
 
2.6.5 Total RNA isolation from cells using QIAgen RNeasy™ kit  
 
RNA was extracted from small numbers of cultured cells (< 5 x 105) using an RNeasy 
kit (QIAgen) according to the manufacturer’s protocol (RNeasy Mini Handbook, 2006). 
An aliquot of purified RNA was removed for spectrophotometric (Section 2.2.10) and 
gel electrophoretic analysis (Section 2.7.2) prior to RT-qPCR. 
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2.6.6 Quantification of mRNA from cultured cells by RT-qPCR 
 
The quantification of mRNA purified from cultured cells was performed in a two-step 
procedure.  In the first step, cDNA was prepared from RNA by reverse transcription 
(RT) with random hexamers serving as primers.  During the second step, cDNA was 
amplified by real time quantitative PCR (qPCR). Real-time qPCR is increasingly being 
adopted for RNA quantification based on its ability to detect the amount of PCR 
product present at every cycle (i.e. in real time), as opposed to the endpoint detection by 
conventional PCR methods, thus allowing the real-time progress of the reaction, 
especially its exponential phase, to be viewed.  The real-time PCR approach is based on 
the detection and quantification of a fluorescent reporter, where the signal increases in 
direct proportion to the amount of PCR product in a reaction.  TaqMan gene expression 
assays were used in this study for comparative gene expression analysis, normalising 
with gapdh endogenous control mRNA levels (Applied Biosystems, Table 2-9).  
 
2.6.7 Reverse transcription 
 
In this process mRNA was transcribed into cDNA using Moloney Murine Leukemia 
Virus (M-MLV) reverse transcriptase.  Initially, 2 µL of random hexamers was added to 
2 µg RNA and the volume brought up to 10 µL with DEPC H2O. The mixture was 
heated to 70˚C for 5 min, to destabilise secondary mRNA structures, and then placed on 
ice. Then, the RT reactants were added in the order listed in Table 2-8.  
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Table 2-8: MMLV RT reactants 
Component Volume 
Reverse Transcriptase buffer (5X) 
dNTP mix (20 mM) 
MgCl2 (25 mM) 
BSA (4 µg/µL) 
DEPC H2O  
RNasin ribonuclease inhibitor 
M-MLV reverse transcriptase (200 U/µL) 
8 µL 
1 µL 
4 µL 
1 µL 
13 µL 
2 µL 
1 µL 
The reactions were placed in a Hybaid thermocycler at 37˚C for 1 h and 95 ˚C for 2 min 
followed by storage at 4˚C. 
 
 
2.6.8 Reverse transcription quantitative PCR (RT-qPCR) 
 
The cDNA generated by RT was quantified by real time PCR using the TaqMan gene 
expression assays (Applied Biosystems), which consisted of  two unlabelled primers for 
amplifying the sequence of interest (final concentration of 900 nM each) and one dual 
labelled TaqMan MGB probe (6-FAM dye- and TAMRA-labelled) for detecting the 
sequence of interest (final concentration of 250 nM). The PCR reaction exploits the 5’-
3’ nuclease activity of the DNA polymerase system to cleave a TaqMan probe during 
PCR as illustrated in (Figure 2-1). Quantification of a cDNA target was normalised for 
differences across experiments/samples using an endogenous control as an active 
reference (gapdh). The PCR reaction mix was prepared for each sample (in triplicate) 
by addition of the reagents listed in (Table 2-9) to the individual wells of a 96-well 
reaction plate (Applied Biosystems) followed by the addition of 2 µL of cDNA to give a 
total reaction volume of 25 µL. 
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Figure 2-1: The TaqMan assay 
 
When the probe is intact, the proximity of the reporter dye to the quencher dye results in 
suppression of the reporter fluorescence primarily by Förster-type energy transfer 
(Lakowicz, 1983). During PCR, if the target of interest is present, the probe specifically 
anneals between the forward and reverse primer sites. The 5’–3’ nucleolytic activity of 
the DNA polymerase system cleaves the probe between the reporter and the quencher 
only if the probe hybridises to the target. The probe fragments are then displaced from 
the target, and polymerisation of the strand continues. The 3´ end of the probe is 
blocked to prevent extension of the probe during PCR. This process occurs in every 
cycle and does not interfere with the exponential accumulation of product. The increase 
in fluorescence signal is detected only if the target sequence is complementary to the 
probe and is amplified during PCR. Because of these requirements, any non-specific 
amplification is not detected (Adapted from Applied Biosystems White Paper on 
TaqMan gene expression assays 
http://docs.appliedbiosystems.com/pebiodocs/00106737.pdf). 
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Table 2-9: Real time qPCR reactants 
Component   Volume/Reaction 
Assay 1.25 µL 
2X TaqMan PCR master mix* 12.5 µL 
Nuclease Free H2O 9.25 µL 
Total 23 µL 
 
The plate was covered with an optical adhesive cover and centrifuged at 2,000 x g for 2 
min to eliminate air bubbles. Amplification and detection were performed with an ABI 
Prism 7500 sequence detection system under the following conditions: 10 min at 95 °C 
to activate AmpliTaq Gold DNA polymerase, and 45 cycles of 15 s at 95°C and 1 min 
at 60°C. During amplification, the ABI Prism sequence detector monitored real-time 
PCR amplification by quantitatively analysing fluorescence emissions. The reporter dye 
(FAM) signal was measured against the internal reference dye (ROX) signal to 
normalise for non-PCR-related fluorescence fluctuations occurring from well to well. 
The threshold cycle represented the refraction cycle number at which a positive 
amplification reaction was measured and was set at 10 times the standard deviation of 
the mean baseline emission calculated for PCR cycles 3 to 15. The results were 
analysed according to the Comparative CT method (∆∆CT) as described by (Livak and 
Schmittgen, 2001). 
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2.7 Protein Analysis  
 
2.7.1 Preparation of cellular proteins 
 
Proteins were isolated from both suspension and adherent cells for analysis by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) and by western blotting. Prior to 
isolation, cells were washed in PBS. Suspension cells were centrifuged at 100 x g for 5 
min and the supernatant removed. Ice-cold PBS (10 mL) was added; the cells were 
centrifuged again at 100 x g and all of the supernatant removed. Adherent cells were 
washed twice with 10 mL of ice-cold PBS, and the cells were scraped into 1 mL of 
PBS.  The crude cell suspension was centrifuged at 100 x g for 5 min. For both 
suspension and adherent cells, the cells were re-suspended in ice-cold suspension buffer 
(Appendix) using 200 µL of suspension buffer for every 1 x 107 cells and the cell 
suspension transferred to a microfuge tube. An equal volume of 2X SDS gel loading 
buffer (Appendix) was immediately added to the cell suspension, after which the sample 
became extremely viscous. The sample was then subjected to sonication for 1 min on 
full power (using a Vibra Cell Sonicator) to shear the DNA. The lysate was clarified by 
centrifugation at 500 x g for 7 min at 4oC. The supernatant (cytoplasmic protein extract) 
and the pellet (nuclei pellet) were aliquoted and stored at –70 ˚C until required for 
analysis. The ProteoJET™ Cytoplasmic and Nuclear Protein Extraction Kit was also 
used according to the manufacturer’s instructions. 
 
2.7.2 SDS-polyacrylamide gel electrophoresis of proteins 
 
During polyacrylamide gel electrophoresis (PAGE), proteins are driven by an applied 
current through a polyacrylamide gel. PAGE is carried out in the presence of the 
negatively charged detergent sodium dodecylsulphate (SDS), which binds to all types of 
protein molecules. Electrostatic repulsion between the bound SDS molecules causes the 
proteins to unfold into a similar rod-like shape, and since the amount of SDS bound is 
proportional to the molecular weight of the polypeptide and is sequence independent, 
SDS-polypeptide complexes migrate through polyacrylamide gels in accordance with 
the size of the polypeptide. 
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2.7.3 Preparation of SDS-polyacrylamide gels 
 
SDS-PAGE was performed using 10% (v/v) resolving gels and 5% (v/v) stacking 
polyacrylamide gels prepared as detailed in Appendix. An ATTO protein gel 
electrophoresis system was used in this study. Glass plates were washed with detergent, 
rinsed first with tap water, then with dH2O and finally wiped in one direction with tissue 
soaked in 100% (v/v) ethanol. The gasket was placed around the ridged plate; the plates 
were assembled and secured with clamps. The resolving gel was then poured to within 2 
cm of the top of the larger plate and overlaid with 100% (v/v) ethanol. When set, the 
ethanol was removed and the stacking gel was poured. A clean comb that had been 
wiped in 100% (v/v) ethanol was inserted and the gel was allowed to polymerise for at 
least 20 min. The electrophoresis tank was filled with 1X Tris-glycine running buffer 
(Appendix) to a level of about 5 cm deep. After polymerisation, the gaskets and clamps 
were removed and the pre-poured gels were lowered into the buffer at an angle to 
exclude air bubbles from the gel-buffer interface.  The tank was completely filled with 
1X running buffer and the comb removed from the gel. Un-polymerised gel was 
removed by gently rinsing the wells with 1X running buffer and the wells were then 
straightened using a loading tip. The gel plates were fixed firmly in place with the 
pressure plates. The chamber formed by the inner plates (notched plate facing inwards) 
was filled with 1X running Buffer, the samples were loaded and the electrodes attached. 
The gels were electrophoresed at a constant current of 30 mA per gel until the blue dye 
front had reached the bottom of the gel. When complete, the plates were removed, 
separated and the gel was placed in transfer buffer prior to Western blotting (Section 
2.8.4) (Protocol is derived from cold spring harbour protocols). 
 
2.7.4 Western blotting 
 
During western blotting, electrophoretically separated proteins were transferred from 
the polyacrylamide gel to a solid support, usually a nitrocellulose membrane, and 
probed with antibodies that reacted specifically with antigenic epitopes displayed by the 
target protein attached to the solid support. The bound antibody, unless conjugated, was 
detected by a secondary immunological reagent, conjugated to either the alkaline 
phosphatase (AP) or horseradish peroxidase (HRP) enzyme for detection. 
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Transfer of protein to nitrocellulose filters 
 
Following gel electrophoresis, gels were equilibrated in transfer buffer (Appendix) for 
at least 15 min. Equilibration facilitated the removal of electrophoresis salts and 
detergents. Salts, if not removed, increase the conductivity of the transfer and the 
amount of heat generated during transfer. Nitrocellulose membrane was cut to the 
dimensions of the gel, along with 6 pieces of 3 mm filter paper that were required for 
the gel/membrane sandwich. Protein transfer was carried out on the Bio-Rad Trans-
Blot® SD semi-dry electrophoretic transfer cell. A pre-soaked sheet of filter paper was 
placed onto the platinum anode. A pipette was rolled over the surface of the filter paper 
to exclude all air bubbles. This step was repeated with two more sheets of filter paper.  
Then, the pre-wetted blotting membrane was placed on top of the filter paper and all 
bubbles rolled out. The equilibrated gel was carefully placed on top of the nitrocellulose 
membrane, aligning the gel on the centre of the membrane. Any air bubbles were again 
rolled out. Another 3 sheets of pre-wetted filter were placed on top of the gel, with care 
taken to remove air bubbles. The cathode was placed on top of the stack and the safety 
cover replaced on the transfer unit. Gels were transferred for 30 min at 17 V (Protocol is 
derived from cold spring harbour protocols).    
 
Staining of proteins immobilised on nitrocellulose filters 
 
Ponceau S is a negative stain, which binds to positively charged amino acid groups of 
proteins. It also binds non-covalently to non-polar regions of proteins. Ponceau S 
staining was employed to determine whether uniform transfer of proteins to the 
nitrocellulose membrane had taken place. Transferred protein was detected as red bands 
on a white background. This staining technique is reversible to allow further 
immunological analysis. Following electrophoretic transfer, the nitrocellulose 
membrane was immersed in 20 mL Ponceau S solution (Sigma-Aldrich) and stained for 
5 min with constant agitation. After proteins were visualised, the membrane was 
washed in several changes of dH2O until all the stain had been washed away. The 
membrane was then used for immunological probing.   
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Immunological probing 
 
Following Ponceau S staining, the membrane was incubated in blocking buffer 
(Appendix) for 3 h at room temperature followed by incubation with the appropriate 
primary antibody (diluted in blocking buffer, see Table 2-10) at 4 ˚C overnight.   
 
Table 2-10: Incubation Conditions for Antibodies Used in Western Blotting 
Primary 
Antibody 
Name Dilution 
In Blocking 
Buffer 
Secondary Antibody Dilution 
In Blocking 
Buffer 
Anti-β-Actin Anti-actin AC-15 1/10,000 AP-conjugated Anti-
mouse IgG 
1/20,000 
Anti-Bik Clone C33-1 
(557040) 
1/200 Anti-Goat-HRP 1/5000 
Anti-Smad3 Ab28379 1/500 Anti-Rabbit-HRP 1/5000 
Anti-EBNA-2 PE2 1/100 AP-Conjugated Anti 
Mouse IgG  
1/5000 
Anti-Smad4 Ab3219 1/500 AP-Conjugated Anti 
Mouse IgG  
1/5000 
Anti-GAPDH (FL-335): sc-
25778 
1/5,000 Anti-Rabbit-HRP 1/10,000 
 
 
After overnight incubation, the membrane was washed three times in TBS-T (0.1% 
(v/v) Tween-20 in TBS (Appendix) for 15 min. The filter was then incubated with the 
appropriate secondary antibody (Table 2-10) for 1 h 30 min at room temperature, 
followed by three 15 min washes in TBS-T. (Conjugated primary antibodies were 
developed following three washes in TBS-T, and needed no further incubation step).  
All of the above incubations were carried out with constant agitation.  The membrane 
was then placed in a clean container and covered with 5-bromo-4-chloro-3-indolyl 
phosphate/Nitro Blue Tetrazolium (BCIP/NBT, Sigma) or 3,3’,5,5’-
tetramethylbenzidine (TMB, Sigma), which are used for the colourimetric detection of 
alkaline phosphatase- or hydrogen peroxidase-conjugated molecules respectively. When 
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incubated with alkaline phosphatase or hydrogen peroxidase, bound enzyme catalysed 
the production of a coloured product that was easily observable. The membrane was 
then rinsed in distilled water to stop the reaction and photographed.  
 
 
2.8 Chromatin Immuno-precipitation (ChIP) 
 
Chromatin immunoprecipitation (ChIP) was performed by using a ChIP kit and 
according to the manufacturer’s instructions (ab500, Abcam Inc). In brief, about 3 x 106 
cells were fixed in 1% formaldehyde before lysis. Chromosomal DNA was sheared by 
using a sonifier (Branson 450) to an optimal DNA fragment size of 200–1000 bp. Anti-
target antibody was used in the immunoprecipitation to pull down the target protein and 
DNA complex. Rabbit and mouse IgG were used as negative controls. After DNA 
purification, 0.5 µL each of input DNA, target-enriched DNA, or rabbit IgG-enriched 
DNA were subjected to PCR analysis. In the case of the bik promoter, a 420 bp 
fragment was amplified, PCR primers were used to investigate EBNA-2 recruitment to 
the BZLF1 and Hes 1 promoters. Primer sequences are listed in (Table 2-5). 
 
 
 Statistical analysis 2.9
 
Statistical analysis was performed using t test followed by paired t test two-tailed using 
GraphPad Prism version 5.00 for Windows, GraphPad software, La Jalla California 
USA, www.graphpad.com.
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Chapter 3 :                                                                        
EBV inhibits TGFβ1-induced 
apoptosis by inhibiting bik 
upregulation through the canonical 
Smad pathway                                                           
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Transforming growth factor-β (TGFβ), a multifunctional cytokine family of growth 
factors, comprises more than 30 structurally related factors found in nematodes, fruit 
flies and humans. They include the bone morphogenetic proteins (BMPs), the closely 
related growth and differentiation factors (GDFs), the activins, Nodals, and 
transforming growth factor-beta proteins. Three almost structurally identical isoforms, 
TGFβ 1, 2, and 3, have been found in humans. This growth factor superfamily regulates 
a diverse array of cellular responses during the development and adult stages of 
eukaryotes (Massague 1998, Ikushima and Miyazono 2011b). The TGFβ signal 
transduction pathway can be modulated by many other signalling cascades and, 
depending on the cell type and cellular context, TGFβ can regulate and control cell 
growth, differentiation, embryonic development, adult stem cell differentiation, 
apoptosis, morphogenesis, immune regulation, wound healing and inflammation. This 
pathway has also been linked to cancers, fibrosis, autoimmune diseases and 
developmental disorders in humans (Meulmeester and Ten Dijke 2011, Inman 2011, 
Tian, Neil and Schiemann 2011, Chou, et al. 2010, Lasfar and Cohen-Solal 2010). 
A role for TGFβ signalling in regulating the intrinsic mitochondrial apoptosis pathway 
during B cell development has been established. B cell subsets show significant 
upregulation of bik transcripts during differentiation as they progress through the GC 
reaction from naive, centroblast, centrocyte and through to memory cells (Klein, et al. 
2003). In human B cells, bik has been identified as a direct transcriptional target of 
TGFβ/Smad signalling and is required for TGFβ-induced apoptosis in Burkitt’s 
lymphoma cell lines (Spender, et al. 2009). Increases in bik mRNA levels have also 
been observed in TGFβ-treated CD77+ tonsillar B cells (centroblast), demonstrating 
that bik is also regulated by TGFβ in primary B cells. BL is an example ofmalignant B 
cells having retained the normal responses of GC B cells to external stimuli. TGFβ1 has 
been shown to have a growth inhibitory and pro-apoptotic effect on the EBV-negative B 
cell lymphoma BJAB, (Kehrl, et al. 1989) and also on Ramos, an EBV-negative BL cell 
line (Altiok, et al. 1991)(Spender, et al. 2009). 
In the present study, experiments were therefore designed with a view to investigating a 
potential role and mechanism for EBV/EBNA-2 modulation of bik during TGFβ 
signalling in this cellular background. The BL-derived EBV negative cell line Ramos, 
which possesses a GC phenotype (group I), in addition to BJAB, an EBV negative B 
cell lymphoma cell line, and ER/EB2-5, a conditional LCL, were used as model systems 
for this purpose. 
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 TGFβ1 induces apoptosis in a dose-dependent manner in EBV-3.1
negative B cell lines. 
 
Ramos (Figure 3-1) and BJAB (Figure 3-2) cell lines were treated with various 
concentrations of TGFβ1 (Millipore, GF111). Cell survival profiles were analysed at 24 
h and 48 h after this treatment by 7-AAD/Annexin-V staining and subsequent flow 
cytometric analysis.  
 
 
 
 
 
 
  
 
 
Figure 3-1: TGFβ1 induces apoptosis in Ramos cells.   
(A) Representative FACS profiles of Ramos cells 24 h following treatment with various 
concentrations of TGFβ1, as indicated above each scatterplot. Quadrant markers were 
based on stained/unstained controls. Cells in the lower left quadrant are viable (7-AAD-
/Annexin V-), cells in the lower right quadrant are early apoptotic (7-AAD-/Annexin 
V+), cells in the upper right quadrant are late apoptotic (7-AAD+/Annexin V+) and cells 
in the upper left quadrant are necrotic/mostly nuclear debris (7-AAD+/Annexin V-), and 
the numbers shown are the percentages of cells in each quadrant. (B) Bar chart 
representation of the experiment shown in A (three independent experiments). Data are 
±SD**P (0.001 to 0.01) vs untreated control. 
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Figure 3-2: TGFβ1 induces apoptosis in BJAB cells.   
BJAB cells were treated with various concentrations of TGFβ1 as indicated above each 
scatterplot. (A) Representative cell viability/apoptosis FACS profiles 24 h after 
treatment with TGFβ1 are shown. The cells in each quadrant are as described in the 
legend to Figure 3-1 and the values shown represent the percentage number of cells in 
each quadrant. (B) Bar chart representation of the experiment shown in A (three 
independent experiments). Data are ±SD**P (0.001 to 0.01) vs untreated control. 
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TGFβ1 was observed to induce apoptosis in a dose-dependent manner. A greater 
proportion of BJAB cells (Figure 3-2) were seen to enter early apoptosis in contrast to 
Ramos (Figure 3-2) where the cells stained with Annexin-V-PE but not with the DNA 
vital stain, 7AAD. Programmed cell death induced by TGFβ1 ligation was a faster 
process in BJAB (Figure 3-2) in comparison to Ramos cells (Figure 3-1). Cell 
proliferation and metabolic activity was measured by cellTiter 96 Aqueous One 
Solution cell proliferation Assay (MTS). The overall metabolic activity was greatly 
decreased upon TGFβ1 treatment, by 3-fold in BJAB and to lesser extent of 1.3 fold in 
Ramos after 48 h (Data not shown).   
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3.2 TGFβ1 mediates apoptosis by upregulting bik mRNA and protein 
 
In order to investigate if TGFβ1 exerts its apoptotic effect by regulation of bik, Ramos 
and BJAB cells were treated with 25 ng/mL or 100 ng/mL TGFβ1 (Millipore, GF111) 
for 24 h. Total RNA and protein were harvested and relative bik mRNA levels were 
detected by RT-qPCR using RNA prepared 24 h after treatment. Bik mRNA levels were 
assayed in triplicate and normalised to gapdh mRNA levels. Relative quantification 
levels were calculated relative to the control untreated samples. Bik protein expression 
was analysed by Western blot and Bik protein relative density values were obtained 
using ImageJ.  
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Figure 3-3: Bik mRNA and protein expression levels rise in response to TGFβ1 
treatment in Ramos. 
Ramos cells were treated with 25 ng/mL or 100 ng/mL TGFβ1. (A) Relative bik mRNA 
levels were detected by RT-qPCR using RNA prepared 24 h after treatment. Bik mRNA 
levels were assayed in triplicate by RT-qPCR and normalised to gapdh mRNA levels. 
Relative quantification levels were calculated relative to the control. Data are ±SD **P 
(0.001 to 0.01) of three independent experiment. (B) Representative Western blot 
showing Bik protein. Trans-activation of bik in response to BCR ligation (anti-IgM) is 
also shown (see section B above). (C) Bik protein relative density values (from (B)) were 
obtained using ImageJ and were normalized to untreated control. (ref: Rasband, W.S., ImageJ, 
U. S. National Institutes of Health, Bethesda, Maryland, USA, http://imagej.nih.gov/ij/, 1997-
2011.) 
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Figure 3-4: Bik mRNA and protein expression levels rise in response to TGFβ1 
treatment in BJAB. 
BJAB cells were treated with 25 ng/mL or 100 ng/mL TGFβ1 (A) Relative bik mRNA 
levels were detected by RT-qPCR using RNA prepared 24 h following treatment with 
TGFβ1 as described in the legend to (Figure 3-3). Data are ±SD **P (0.001 to 0.01) of 
three independent experiment. (B) Representative Western blot showing Bik protein 
expression at the same time point. Trans-activation of bik in response to BCR ligation 
(anti-IgM) is also shown (see section B above).  
 
 
Bik mRNA levels increased in both Ramos (Figure 3-3 A) and to a greater extent in 
BJAB (Figure 3-4 A) cells following treatment with TGFβ1, in a dose-dependent 
manner.  Bik protein levels also increased in both cell lines (Figure 3-3 B and C; Figure 
3-4 B and C). However, this effect was more profound in BJAB. Bik is a 
phosphoprotein and it is phosphorylated on consensus Casein Kinase II (CKII) 
phosphorylation sites (Thr-33 and/or Ser-35). Phosphorylation is required for efficient 
Bik-mediated apoptosis (Verma, Zhao and Chinnadurai 2001). Bik appears as a double 
band, 27 kDa/26k Da in size, in some cell lines and a single band in others. Western 
blots using the Ramos cell line showed a single band for Bik, whereas BJAB 
demonstrated a double band. When the latter was stimulated with TGFβ1 ligand, it was 
the higher molecular weight band that was affected. 
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3.3 Transient bik down-regulation inhibits apoptosis induced by 
TGFβ1 
 
In order to investigate if bik is essential for TGFβ1-mediated apoptosis, the bik gene 
was transiently knocked down in Ramos (Figure 3-5) and BJAB(Figure 3-6) cells using 
siRNA specific to bik (siRNA1980 and siRNA1990). In these transfection experiments, 
both anti-bik siRNAs were able to inhibit bik expression as reflected in decreased bik 
mRNA and protein levels, whereas the control siRNA did not. Twenty four hour after 
transfection, siRNA-transfected cells were then left untreated or treated with 10 ng of 
TGFβ1 for 24 h. The cell survival profile was determined after 24 h by 7AAD/Annexin-
V-PE staining and subsequent flow cytometric analysis. As can be seen (Figure 3-7 and 
Figure 3-8) TGFβ1 was again seen to induce apoptosis in both cell lines. This effect was 
more pronounced in BJAB, which had 36.9% ±SD 4.530 apoptotic cells when 
compared to Ramos (26% ±SD 7.365 apoptotic). In transfected cells a significant level 
of apoptosis was observed before treatment, (which can be attributed to the harsh 
transfection conditions). Enforced downregulation of bik resulted in an increase in the 
percentage of viable cells in both cell lines (approximately 10%) before TGF β1 
treatment. Transient bik knockdown was seen to protect cells from apoptosis mediated 
by TGFβ1 in Ramos and BJAB cells. This is in contrast to the control siRNA 
transfection where TGFβ1 induced apoptosis in Ramos (from 50% ±SD 3.717 before to 
82% ±SD 4.028 after) (Figure 3-7), and BJAB (from 42% ±SD 2.101 to 72% ±SD 
4.319 after) (Figure 3-8). Total Bik protein level was also monitored 24 h after TGFβ1 
treatment in both cell lines after bik transient knockdown. Transient bik knockdown was 
seen to inhibite the TGFβ1-mediated Bik induced upregulation opposed to cells 
transfected with control siRNA (Figure 3-11).  
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Figure 3-5: Transient bik knockdown in the Ramos cell line. 
Ramos cells were transfected with two different anti-bik siRNAs (si1989, si1990), or 
negative control siRNA (siNeg). (A) The level of bik mRNA shown for 24 h post 
transfection was quantitated by RT-qPCR as before. Relative quantification levels were 
calculated relative to the siNeg control. Data are ±SD **P (0.001 to 0.01) of three 
independent experiment. (B) Representative Western blot showing Bik protein 
expression from extracts prepared at 24 h (upper panel) and 48 h (lower panel) 
following transfection of Ramos cells. 
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Figure 3-6: Transient bik knockdown in the BJAB cell line. 
BJAB cells were transfected with two different anti-bik siRNAs (si1989, si1990), or 
negative control siRNA (siNeg). (A) The level of bik mRNA shown for 24 h post 
transfection was quantitated by RT-qPCR as before. Relative quantification levels were 
calculated relative to the siNeg control. Data are ±SD **P (0.001 to 0.01) of three 
independent experiment. (B) Representative Western blot showing Bik protein 
expression from extracts prepared at 24 h (upper panel) and 48 h (lower panel) 
following transfection of BJAB cells. 
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Ramos cells were transfected with each of two different bik siRNAs (si1989, si1990) or 
negative control siRNA (siNeg). (A) Representative cell viability/apoptosis FACS 
profiles 24 h after treatment with TGFβ1. The cells in each quadrant are as described in 
the legend to Figure 3-1 and the values shown represent the percentage number of cells 
in each quadrant. (B) Bar chart representation of the percentage of viable cells in 
experiment shown in A (three independent experiments). Data are ±SD **P (0.001 to 
0.01). 
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Figure 3-7: Bik knockdown in Ramos leads to a reduction in the loss of cell viability 
due to TGFβ1 treatment. 
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BJAB cells were transfected with each of two different bik siRNAs (si1989, si1990) or 
negative control siRNA (siNeg). (A) Representative cell viability/apoptosis FACS 
profiles 24 h after treatment with TGFβ1. The cells in each quadrant are as described in 
the legend to Figure 3-1 and the values shown represent the percentage number of cells 
in each quadrant. (B) Bar chart representation of the percentage of viable cells in 
experiment shown in A (three independent experiments). Data are ±SD **P (0.001 to 
0.01). 
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Figure 3-8: Bik knockdown in BJAB leads to a reduction in the loss of cell viability 
due to TGFβ1 treatment. 
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Cell proliferation was also monitored 24 h after TGFβ1 treatment in both cell lines after 
bik transient knockdown using the cellTiter 96 Aqueous One Solution cell proliferation 
assay (MTS). It can be seen that bik knockdown led to an overall increase in cell 
metabolic activity in untreated transfected cells in both cell lines and a partial reversal 
of the growth inhibitory effect of TGFβ1 when compared to cells transfected with siNeg 
in the case of Ramos cells (Figure 3-9). Bik down-regulation due to specific siRNA 
treatment significantly restored the cell metabolic rate that was lost due to TGFβ1 in 
BJAB (Figure 3-10). The proliferative effect of bik knockdown was more evident in 
BJAB than Ramos, where cells transfected with anti-bik siRNA and treated with TGFβ1 
are seen to have an increase in cell proliferative activity in comparison to the untreated 
samples (Figure 3-10). 
 
 
 
 
   
 
 
 
 
 
Figure 3-9: Bik knockdown leads to a decrease in the loss of metabolic activity seen 
upon treatment of Ramos with TGFβ1. 
Proliferation of RAMOS cells following transfection with bik siRNAs (si1989 & 
si1990) and scrambled siRNA (siNeg) and in response to treatment with 10 ng of 
TGFβ1 was monitored at the time points indicated using the cellTiter 96 Aqueous One 
Solution cell proliferation assay (MTS). The proliferation of transfected untreated cells 
(white bars) and treated with TGFβ1 (black bars) was measured relative to the 0 h 
untreated sample. Data are ±SD *P ≤ 0.05 of three independent experiment. 
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Figure 3-10: Bik knockdown leads to a decrease in the loss of metabolic activity 
seen upon treatment of BJAB with TGFβ1. 
The proliferation of BJAB cells that were transfected with bik siRNAs (si1989 & 
si1990), and scrambled siRNA in response to 10 ng/mL of TGFβ1 was measured at the 
indicated time point using the CellTiter 96 Aqueous One Solution cell proliferation 
assay (MTS). The proliferation of transfected cells untreated (white bars) and treated 
with TGFβ1 (black bars) was measured relative to 0 h untreated sample. Data are ±SD 
*P ≤ 0.05 and **P (0.001 to 0.01) of the independent experiment. 
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Figure 3-11: Bik knockdown inhibited the TGFβ1-mediated Bik protein induction.  
Cells were transfected with each of two different bik siRNAs (si1989, si1990) or 
negative control siRNA (siNeg). Twenty four hour after transfection cells were treated 
with 10 ng/mL of TGFβ1. Representative Western blot showing Bik protein expression 
from extracts prepared at 24 h following treatment of (A) BJAB and (B) Ramos cells 
with TGFβ1. 
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3.4 Ectopic EBNA-2 inhibits TGFβ1-mediated apoptosis in Ramos 
cells. 
 
It has been shown recently that EBNA-2 down-regulates the expression of bik (D. 
Walls, unpublished results). Therefore, experiments were set up in order to investigate if 
EBNA-2 expression might inhibit the observed pro-apoptotic effects of TGFβ1. 
RAMOS cells were transfected with 1µg each of plasmids expressing either EBNA-2 or 
the non-CBF1-binding EBNA-2 mutant, WW323SR. Forty-eight hours after 
transfection, cells were treated with 10 ng TGFβ1. The cell survival profile was then 
determined 24 h after treatment using 7AAD/Annexin-V-PE staining and subsequent 
flow cytometric analysis by FACS Calibur.  
It can be seen that ectopic EBNA-2 or its non-CBF1 binding mutant, EBNA-2 
WW323SR in Ramos cells partially rescued these cells from apoptosis induced as a 
result of harsh conditions of transfection (Figure 3-12). Treatment of the control 
transfected cells with TGFβ1 efficiently led to apoptosis and significantly decreased the 
percentage of viable cells (from 30% ±SD 1.656 before to 10% ±SD 2.198 after). 
However, ectopic EBNA-2 or its non-CBF1 binding mutant, EBNA-2 WW323SR, 
decreased the effect of TGFβ1-mediated apoptosis (Figure 3-12). 
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RAMOS cells were transfected with 1µg of each plasmid as indicated underneath the 
graph. Forty-eight hours after transfection, cells were treated with 10 ng TFGβ1. (A) 
Representative cell viability/apoptosis FACS profiles 24 h after treatment with TGFβ1. 
The cells in each quadrant are as described in the legend to Figure 3-1 and the values 
shown represent the percentage number of cells in each quadrant. (B) Bar chart 
representation of the relative percentage of viable cells in the experiment shown in A 
(average of three independent experiments). Data are ±SD **P (0.001 to 0.01). 
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Figure 3-12: EBNA-2 rescues cells from apoptosis induced by TGFβ1 in Ramos 
cells. 
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3.5 TGFβ1 mediates apoptosis through the canonical Smad pathway 
 
It was observed here that TGFβ1 was able to induce the expression of bik mRNA and 
protein in Ramos (Figure 3-3) and BJAB (Figure 3-4), which coincided with apoptosis 
and an overall decrease in metabolic activity in the cell population. 
It has been shown elsewhere that TGFβ1-mediated signalling leads to the recruitment of 
the Smad protein complex, Smad2/3/4, to the bik promoter, coinciding with activation 
of that promoter and an increase in the level (Figure 1.12). In order to investigate the 
Smad3 protein level, its location in the cell and the associated relative bik expression in 
response to TGFβ1 mediated signalling, Ramos cells were treated with or without 10 ng 
of TGFβ1 for a duration of 24 h. RT-qPCR showed elevated bik mRNA in response to 
TGFβ1 (Figure 3-13 A). Over 24 h, the bik mRNA basal level first decreased between  
0 and  4 h and began increasing to its basal level at the 24 h time point in the absence of 
TGFβ1, however the transcriptional level of bik mRNA was higher at both time points 
in the presence of TGFβ1 (Figure 3-13 A).  
As described before, TGFβ1 binding to its receptors results in activation of receptor-
regulated R-Smads (Smad2/3) by phosphorylation of the XserX motif in their C-
terminus, leading to their translocation from the cytoplasm to the nucleus. Hence, 
subsequent translocation of Smad3 from the cytoplasm to the nucleus is indicative of 
Smad3 activation, reflecting TGFβ1 signalling. 
 
In order to confirm activation of the TGFβ1 signalling pathway, Smad3 protein 
expression levels in nuclear and cytoplasmic fractions were evaluated by Western blot 
before and after treatment with TGFβ1. The level of Smad3 protein was detected using 
anti-Smad3 and was normalised to the levels of Gapdh protein. It can be seen that from 
the 0 to 24 h time points, the level of Smad3 protein starts to decrease in the 
cytoplasmic fraction and accumulates in the nuclear fraction in the presence of TGFβ1. 
This event was most clearly seen at the 4 hour time point, when comparing the two 
cytoplasmic fractions in the presence and absence of TGFβ1 (Figure 3-13 B). It can be 
concluded from the observations made, that Smad3 translocated from the cytoplasm to 
the nucleus in response to TGFβ1 signalling. 
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Figure 3-13: TGFβ1 induces bik and the translocation of Smad3 from the 
cytoplasm to the nucleus in Ramos cells. 
Ramos cells were treated without or with 10 ng of TGFβ1 for different lengths of time 
as indicated. (A) RT-qPCR shows elevated bik mRNA levels at 0 h, 4 h and 24 h in the 
presence of TGFβ1 as indicated. (B) Western blot of Smad3. Protein extracts of nuclear 
and cytoplasmic fractions were prepared and the level of Smad3 protein was detected 
using anti-Smad3 (ab28379). Data are ±SD *P ≤ 0.05.  
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The extent of recruitment of Smad3 and Smad4 to the bik promoter in the presence and 
absence of TGFβ1 was next investigated. Binding of Smad3 and Smad4 to the bik 
promoter was determined by chromatin immunoprecipitation (ChIP) assay. Ramos and 
BJAB cells were treated with 10 ng TGFβ1 for 4 h. Cells were then treated with 1% 
formaldehyde in order to cross-link endogenous nuclear proteins and DNA. Samples of 
sonicated chromatin were then individually immunoprecipitated with anti-Smad3 
(ab28379), anti-Smad4 (ab3219), no antibody (beads only) and isotype control IgG 
respectively. DNA isolated from immunoprecipitated material was then amplified by Q-
PCR using primers that target a 420-bp sequence from the human bik promoter 
(Spender, et al. 2009) (Figure 3-14 C). These experiments showed that the level of 
Smad3 bound to the bik promoter increased ten-fold in Ramos cells following treatment 
with TGFβ1 (Figure 3-14 A). This effect was also observed in BJAB cells but the 
magnitude of the increase was just two-fold (Figure 3-14 B). 
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Figure 3-14: ChIP assay for Smad3 showing increased binding of Smad3 to the bik 
promoter in BJAB and Ramos cells following treatment with TGFβ1. 
Recruitment of Smad3 to the bik promoter was determined by chromatin immunoprecipitation 
(ChIP) analysis. (A) Ramos and (B) BJAB cells were treated without (grey bar) or with 10 
ng/mL TGFβ1 (black bar) for 4 h. Cells were then treated with 1% formaldehyde to cross-link 
endogenous proteins and DNA. Samples of sonicated chromatin were immunoprecipitated with 
anti-Smad3 (ab28379, no antibody (beads only) and isotype control IgG respectively. DNA 
isolated from immunoprecipitated material was amplified by Q-PCR with primers to amplify 
the 420 bp sequence of human bik promoter. (C) Smad binding region previously identified 
within the human bik promoter (Spender, et al. 2009). Straight arrows indicate position of PCR 
primers used in ChIP assays shown in A and B; the bent arrow shows the location of the bik 
transcription start site. Data are ±SD ***P < 0.001. 
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In order to investigate any potential interplay between EBNA-2 and TGFβ1-mediated 
Smad recruitment to the bik promoter, the EBV-negative BL cell line Ramos was used. 
Ramos cells were transfected with plasmids expressing either EBNA-2 or the 
corresponding empty vector, pSG5. Forty eight hours after transfection, 10 ng TGFβ1 
was added for a duration of 4 h and then cells were harvested and treated with 1% 
formaldehyde. Samples of sonicated chromatin were separately incubated with anti-
Smad3, anti-Smad4 and anti-EBNA-2 antibodies. DNA isolated from 
immunoprecipitated material was amplified by Q-PCR with primers to amplify a 420-bp 
sequence upstream of human bik promoter that has previously been shown to interact 
with Smads [(Spender, et al. 2009) Figure 3.14C]. 
The following observations were made regarding Ramos cells expressing EBNA-2, 
when compared to their counterparts’ transfected with empty vector: (i) the level of 
Smad3 bound to the bik promoter decreased ten-fold in the presence of EBNA-2. (ii) 
EBNA-2 was detectable by ChIP on the bik promoter in cells expressing EBNA-2 
(Figure 3-15). 
 
 
Figure 3-15: EBNA-2 expression leads to a reduction in the level of Smad3 bound 
to the bik promoter in Ramos cells 
Ramos cells were transfected with pSG5 (white bars) or pSG5EBNA-2 (black bars). 
Forty eight hours after transfection, 10 ng/mL TGFβ1 was added for duration of 4 h. 
Cells were then harvested and ChIP was performed as described before. DNA isolated 
from immunoprecipitated material with anti-Smad3 and anti-EBNA-2 was amplified by 
Q-PCR. Data are ±SD *P ≤ 0.05, **P (0.001 to 0.01). 
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Ramos and BJAB cells were then transfected with 1µg pSG5 or plasmids expressing 
either EBNA-2 or its non-CBF1-binding mutant, WW323SR. Forty-eight hours after 
transfection, cells were treated with 10 ng TGFβ1 for 4 h. Cells were harvested and 
treated with 1% formaldehyde to cross-link endogenous proteins and DNA. Samples of 
sonicated chromatin were then individually incubated with anti-Smad3 and anti-Smad4 
or isotype control antibodies. DNA isolated from immunoprecipitated material was 
amplified by Q-PCR as described before. Total RNA was also extracted and RT-qPCR 
was used to detect the bik mRNA level in Ramos (Figure 3-16) and BJAB (Figure 
3-17). 
These transfections showed that ectopic expression of EBNA-2 or its non-CBF1 binding 
mutant, WW323SR, resulted in down-regulation of bik mRNA. Treatment with TGFβ1 
led to up-regulation of bik mRNA in Ramos (by 7-fold Figure 3-16 C) and BJAB cells 
(by 9-fold Figure 3-17 C) transfected with the empty vector, pSG5. Whereas in both cell 
lines expressing EBNA-2 or its mutant, WW323SR, TGFβ1 treatment was seen to have 
no significant effect on bik mRNA expression level (Figure 3-16 C and Figure 3-17 C). 
TGFβ1 treatment of control (data not shown) and transfected cells with pSG5 led to 
significant increases in binding of Smad3 to the bik promoter in Ramos (approximately 
2.6-fold Figure 3-16 A) and in BJAB (by 4.8-fold Figure 3-17 A) and Smad4 in Ramos 
(by 1.8-fold Figure 3-16 B) and in BJAB (by 3.1-fold Figure 3-17 B) to the bik 
promoter where the same samples showed bik mRNA up-regulation in response to this 
treatment (Figure 3-16 C and Figure 3-17 C). It could also be seen that bik down-
regulation due to ectopic EBNA-2 or its non-CBF1 binding mutant coincided with less 
Smad3 and Smad4 binding to the bik promoter in the presence of TGFβ1 (Figure 3-16 A 
and B) (Figure 3-17 A and B). 
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Figure 3-16: EBNA-2 abrogates the TGFβ1-mediated recruitment of Smad3/4 to 
the bik promoter and subsequent bik trans-activation in Ramos cell. 
Ramos cells were transfected with pSG5 or EBNA-2 or WW323SR. Forty-eight hours 
after transfection, cells were treated with and without 10 ng/mL TGFβ1 for a duration of 
4 h. Cells were then harvested and immunoprecipitated with (A) anti-Smad3 and (B) 
anti Smad4. DNA isolated from immunoprecipitated material was amplified by Q-PCR 
as before with primers to target the 420-bp sequence upstream of the human bik 
promoter transcription start site. (C) Represents relative RT-qPCR analysis for bik 
expression in the presence or absence of TGFβ1 in transfected cells. Data are ±SD *P ≤ 
0.05, **P (0.001 to 0.01). 
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Figure 3-17: EBNA-2 abrogates the TGFβ1-mediated recruitment of Smad3/4 to 
the bik promoter and subsequent bik transactivation in BJAB cell. 
BJAB cells were transfected with pSG5 or EBNA-2 or WW323SR. Forty-eight hours 
after transfection, cells were treated with (+/black) and without (-/white) 10 ng/mL 
TGFβ1 for a duration of 4 h. Cells were then harvested and immunoprecipitated with 
(A) anti-Smad3 and (B) anti Smad4. DNA isolated from immunoprecipitated material 
was amplified by Q-PCR as before with primers to target the 420-bp sequence upstream 
of the human bik promoter transcription start site. (C) Represents relative RT-qPCR 
analysis for bik expression in the presence or absence of TGFβ1 in transfected cells. 
Data are ±SD *P ≤ 0.05, **P (0.001 to 0.01). 
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Total protein was harvested from the same experiment shown in (Figure 3-18) and 
analyzed for Smad3 expression by Western blot. The Smad3 protein level was 
significantly lower in BJAB cells expressing either ectopic EBNA-2 or its non-CBF1 
binding mutant, WW323SR (Figure 3-18 A and B). These results indicated a role for 
EBNA-2 in inhibiting TGFβ1-mediated effects by Smad3 down-regulation and that the 
EBNA-2-CBF1 interaction was not essential for this effect. 
 
 
 
 
 
 
 
 
 
 
Figure 3-18: Inhibition of TGFβ1-mediated Smad3 up-regulation by EBNA-2 and 
WW323SR in BJAB. 
BJAB cells were transfected with pSG5, EBNA-2 or WW323SR. Forty-eight hours 
after transfection, cells were treated with 10 ng TGFβ1 for 4 h. (A) Cells were then 
harvested and whole cell lysate was prepared and subjected to Western blot analysis 
determining the Smad3 and β-actin protein. (B) Bik protein relative density values 
shown were obtained from ImageJ and were normalised to untreated cells transfected 
with pSG5. 
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Next, siRNA technology was used to directly down-regulate endogenous Smad3 so as to 
evaluate its contribution to the transcriptional regulation of bik. In this regard, Ramos 
and BJAB cells were treated with two different anti-Smad3 siRNAs (si56 and si57) or 
negative control siRNA (siNeg). Twenty-four hours after transfection cells were treated 
with 10 ng/mL TGFβ for a further 4 h. Transfected cells stimulated with TGFβ1 were 
then harvested and analysed for Smad3 and Bik protein and bik mRNA levels. 
It can be seen that both anti-Smad3 siRNAs significantly inhibited Smad3 expression, 
whereas the control siRNA (siNeg) did not (Figure 3-19 A and B upper panel). Smad3 
knockdown also coincided with a moderate decrease in the level of Bik protein in 
response to TGFβ1 (Figure 3-19 A and B middle panel). Treatment of transfected cells 
with anti-Smad3 siRNA reversed the TGFβ1 stimulatory effect on bik in comparison to 
cells transfected with control siRNA (siNeg) (Figure 3-19 C and D). These observations 
imply a direct regulatory role for Smad3 in regulating bik expression. 
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Figure 3-19: Knockdown of Smad3 results in bik down-regulation. 
BJAB and Ramos cells were transfected with two different anti-Smad3 siRNAs (si56 
and si57) or negative control siRNA (siNeg). Twenty-four hours after transfection, cells 
were treated with 10 ng/mL TGFβ1 for an additional 4 h. Western blots showing Smad3 
(upper panel), Bik (middle panel) and β-actin (lower panel) in BJAB (A) and Ramos 
(B). Relative bik mRNA level were determined by RT-qPCR using RNA prepared 24 h 
after treatment of transfected BJAB (C) and Ramos cells (B). Fold differences were 
calculated relative to bik level in the siNeg transfected cell pool (assigned value of 1). 
Data are ±SD *P ≤ 0.05, **P (0.001 to 0.01). 
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3.6 The EBV growth programme diminishes TGFβ1-mediated 
recruitment of Smad3/4 to the bik promoter 
 
 
3.6.1 Bik is down-regulated by EBNA-2 in ER/EB 2-5 cells. 
 
ER/EB2-5 is a conditional LCL in which the function of EBNA-2 can be controlled by 
the presence or absence of oestrogen (Kempkes, et al. 1995b). This was achieved by 
fusing the N-terminus of EBNA-2 to the hormone-binding domain of the oestrogen 
receptor. Essentially, this ER/EBNA-2 fusion gene was then used to complement the 
EBNA-2 deletion in the EBV P3HR1 viral genome (Kempkes, et al. 1995b). The 
resulting ‘conditional’ LCL, designated ER/EB2-5, generated after immortalising 
resting B cells with this recombinant EBV, therefore requires the presence of oestrogen 
for EBNA-2 function and hence cell proliferation. Addition of oestrogen results in 
EBV-infected B cells with a phenotype similar to those found in a typical LCL. Cells 
growing in the absence of oestrogen cease to proliferate due to the expression of only 
non-functional ER/EBNA-2 and the shut-off of the EBV growth programme (see Figure 
3-20). 
 
Figure 3-20: Schematic diagram of ER/EB2-5. 
ER/EB2-5 is an LCL that contains a mini-EBV plasmid expressing a chimeric EBNA-2 
oestrogen receptor fusion protein plus the P3HR1 viral genome, thus complementing the latter’s 
EBNA-2 deletion. EBNA-2 expression and proliferation are dependent on the presence of 
oestrogen. Adapted from, (Kohlhof, et al. 2009). 
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In order to address a role for EBNA-2/Smads in bik regulation in this context, as 
opposed to BL-derived cell lines, ER/EB2-5 cells were cultured in the presence and 
absence of oestrogen. In these cells, EBNA-2 function, and therefore EB virus-driven 
cell proliferation, is dependent on oestrogen. Cells were harvested at 0, 24, 48, 72 and 
96 h and Western blot analysis (Figure 3.21 A) confirmed that ER/EB2-5 cells grown in 
the absence of oestrogen, only expressed non-functional ER/EBNA-2, while cells 
grown in the presence of oestrogen expressed increased ER/EBNA-2 with an apparent 
higher molecular weight of 120 kDa, confirming the activation of ER/EBNA-2 (due to 
phosphorylation) and the ensuing transcriptional activation of its own gene. Changes in 
bik mRNA levels due to EBNA-2 expression over time in ER/EB2-5 are shown in 
Figure 3.21 B. Bik mRNA levels were seen to increase dramatically over time (44-fold 
at 48 h) in ER/EB2-5 cells upon inactivation of EBNA-2. The amount of bik mRNA 
was also seen to greatly increase by 72 h (80-fold when compared to time 0 h).  A 
reduction in bik levels (approximately 12.5-fold) was observed 48 h following the 
addition of oestrogen to the culture medium (Figure 3.21 B). A further decrease was 
seen at 72 h (0.7-fold), and levels of bik mRNA remained stably-repressed from this 
point on, similar to that observed at 0 h in cycling cells. It has been shown elsewhere 
that TGFβ1 is able to reactivate the viral lytic cycle (Iempridee, et al. 2011). Thus, in 
order to rule out the effect of EBV lytic gene expression on the Smad canonical 
signalling pathway, ER/EB2-5 cells were left untreated with TGFβ1 in this experiment. 
ER/EB2-5 cells grown in the absence or presence of oestrogen for periods of 48 and 72 
h were harvested, fixed and ChIP was performed for Smad3 and Smad4 as described 
before. DNA isolated from immunoprecipitated material was detected by Q-PCR as 
described before. It can be seen that expression of activated ER/EBNA-2 abrogated the 
observed TGFβ1-induced increase in Smad3 (Figure 3.21 C) and Smad4 (Figure 3.21 
D). This effect was best seen at the 48 h time point.   
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Figure 3-21: Repression of bik and decreased Smad3/4 recruitment to the bik 
promoter in response to the activation of ER/EBNA-2 in the conditional LCL 
ER/EB2-5. 
ER/EB2.5 cells were cultured in the presence (active/cycling) and absence (EBV growth 
programme is repressed) of oestrogen. Cells were harvested at indicated time points 
from both activated and repressed phenotype. (A) Western blots indicating the 
expression of ER/EBNA-2 and β-actin proteins. (B) RT-qPCR analysis showing relative 
bik mRNA levels. Cells were harvested at 48 h and 72 h time points and ChIP was 
performed as described before. Chromatin was immunoprecipitated with (C) anti-
Smad3 antibody and (D) anti-Smad4 antibody. DNA isolated from immunoprecipitated 
material was amplified by Q-PCR as described before. Data are ±SD *P ≤ 0.05, **P 
(0.001 to 0.01), ***P < 0.001. 
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To investigate if EBNA-2 might be interacting with the bik promoter in the absence of 
extraneous TGFβ1, ER/EB2-5 cells were cultured in the presence and absence of 
oestrogen for a period of 48 h, chromatin was then harvested and ChIP was performed 
as described before. It can be seen that the level of Smad3 binding to the bik promoter 
decreased by 0.6-fold in the presence of oestrogen (EBV growth programme-dependent 
cell proliferation) and that EBNA-2 interaction with the bik promoter was increased by 
1.3-fold (Figure 3-22). 
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Figure 3-22: Less Smad3 is bound to the bik promoter during the EBV growth 
programme in ER/EB2-5 cells. 
ER/EB2-5 cells, cycling in the presence and absence of oestrogen for 48 h, were 
harvested and ChIP was performed as described before with anti-Smad3 and anti-
EBNA-2 antibodies. DNA isolated from immunoprecipitated material was amplified by 
Q-PCR as before. Data are ±SD *P ≤ 0.05, **P (0.001 to 0.01). 
 
 
In order to investigate a potential role for the EBV growth programme in regulating 
Smad3 levels, protein lysates were prepared from suppressed/cycling ER/EB2-5 cells at 
48 h, 72 h, and 96 h and in the absence of extraneous TGFβ1. It was clear, both from 
whole cell extracts and nuclear fractions, that Smad3 protein levels had decreased 
overall in response to the activation of the EBV growth programme (Figure 3-23). 
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Figure 3-23: Modulation of Smad3 protein expression by the EBV growth 
programme in the conditional LCL ER/EB2-5. 
Protein extracts were prepared from ER/EB2-5 cells cultivated in the presence 
(activation of EBV growth programme) and absence (suppression of EBV growth 
programme) of oestrogen at the time points indicated. The figure shows Western blots 
of Smad3 and GAPDH and β-actin proteins using whole cell lysate (top panel) and 
nuclear fractions (bottom panel). 
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Summary 
 
Transforming growth factor beta, a member of the TGFβ superfamily of ligands, has 
highly pleiotropic properties which are determined by the dose and duration of signal in 
addition to the type and state of the target cell.  
Here, evidence is presented to show that TGFβ1-mediated cell death coincided with the 
up-regulation of the pro-apoptotic BH3-only Bik in both Ramos and BJAB cell lines 
and that transient bik knockdown reversed the apoptotic effects mediated through 
TGFβ1 signalling. Furthermore, transient bik knockdown was seen to reverse the 
reduction in cell metabolic activity that was mediated by TGFβ1. TGFβ1-induced cell 
death is dependent on canonical Smad proteins in these cell lines, by prompting the 
translocation of Smad3 from the cytoplasm to the nucleus (indicative of Smad-
dependent TGFβ signalling). ChIP assays showed that in the presence of TGFβ1, 
Smad3 and Smad4 were recruited to the bik promoter and subsequent RT-qPCR 
analysis confirmed that this coincided with an increase in bik mRNA levels. As recent 
findings in our laboratory indicated an association between EBNA-2 and bik down-
regulation, experiments were designed to investigate a possible role for Smad3 in this 
process. Expression of ectopic EBNA-2 and its non-CBF1 binding mutant in Ramos 
cells had a pro-survival effect when apoptosis was induced through TGFβ1 signalling. 
Furthermore, subsequent ChIP analysis showed that less Smad3 and Smad4 was bound 
to the bik promoter in both cell lines in the presence of TGFβ1, and that this effect was 
not dependent on the ability of EBNA-2 to interact with CBF1. In BJAB, ectopic 
expression of EBNA-2 or its non-CBF1 binding mutant led to a decrease in the level of 
total Smad3. The level of Smad3 protein did not increase in response to TGFβ1 
stimulation, as opposed to the case when BJAB cells were transfected with control 
plasmid (pSG5). 
The conditional LCL ER/EB2-5 was used to investigate the EBV/bik interaction in a 
setting in which the EBV growth programme could be switched on and off. ER/EB2-5 
cells proliferating due to EBV showed a significant decrease in bik mRNA when 
compared to cells where the EBV growth programme was suppressed. Bik down-
regulation in ER/EB2-5 cells proliferating in the presence of oestrogen coincided with 
decreased levels of Smad3 and Smad4 bound to the bik promoter when compared to 
ER/EB2-5 cells, where the EBV growth programme was suppressed. In parallel to these 
observations, the total level of Smad3 protein was seen to be decreased in ER/EB2-5 
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cells proliferating due to the EBV growth programme. These results were obtained in 
the absence of extraneous TGFβ1, as addition of this hormone has been shown to 
activate the EBV lytic cycle (Iempridee, et al. 2011, di Renzo, et al. 1994). It was also 
illustrated here that in the presence of TGFβ1 there was an increase in EBNA-2, along 
with a decrease in Smad3, recruited to the bik promoter in Ramos cells expressing 
ectopic EBNA-2. Likewise, in ER/EB2-5 cells proliferating due to the EBV growth 
programme, the level of EBNA-2 recruitment to the bik promoter increased when 
compared to ER/EB2-5 cells where the EBV growth programme was suppressed. 
 
 
Figure 3-24: A model for EBV inhibition of TGFβ1-mediated cell death. 
TGFβ triggers a signalling cascade through interaction with two transmembrane 
serine/threonine kinase receptors, TβR1 and TβR2. The main intracellular mediators of 
these receptors are a family of proteins known as Smads. Here it has been shown that in 
the presence of EBV growth programme or ectopic EBNA-2, the basal level of receptor 
regulated Smad (Smad3) protein is decreased (possible mechanisms have been indicated 
in figure; see Chapter 6) resulting in decreased recruitment of Smad3 to the bik 
promoter.  
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In summary, the mechanism of action of TGFβ1 in Ramos and BJAB was seen to partly 
involve the induction of an apoptotic program via transcriptional up-regulation of the 
pro-apoptotic protein Bik, in a manner dependent on the Smad canonical pathway. The 
increase in the level of this BH3-only protein contributed to intrinsic apoptosis. TGFβ1-
mediated apoptotic effects were diminished in cells transiently expressing EBNA-2 as a 
likely consequence of Smad3 protein down-regulation and a reduction in the level of 
Smads bound to the bik promoter. Furthermore, evidence was generated to suggest that 
EBNA-2 may be interacting with the bik promoter. Moreover, it was seen that the EBV 
growth programme repressed bik through down-regulation of the basal level of Smad3. 
This coincided with a decreased level of bik promoter-bound Smad3 and an increased 
level of EBNA-2 recruited to the bik promoter (Figure 3-24). 
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Chapter 4 :                                      
The EBV Nuclear Antigen-2 
rescues Ramos cells from BCR-
induced apoptosis                                              
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Germinal centres are highly structured microenvironments essential for the clonal 
expansion of antigen-specific germinal centre B lymphocytes, followed by somatic 
hyper mutation (SHM) and isotype switching. Since it’s a high risk procedure for 
generating autoreactive or non-functional clones, B cells transferring through germinal 
centres for development and activation are prone to programmed cell death initiated 
from the B cell receptor (BCR), FAS and TGFβ receptor signalling pathways, unless 
they receive sufficient pro-survival signals, e.g. from CD40 ligand (Kurosaki 2000, 
Benschop and Cambier 1999). Studies have revealed that BCR cross-linking with 
antibodies to membrane-bound IgM but not IgD, on the surface of B cells results in 
suppression of the PI3K/pp70S6X signalling pathway (Banerji, et al. 2001). In contrast, 
(Jiang and Clark 2001b) have reported that both sIgM and sIgD ligation lead to the 
induction of bik mRNA, but only the former was shown to exert a pro-apoptotic effect, 
with an increase in Bik protein levels and strong activation of PI3K (Beckwith, et al. 
1996) and calcium influx (Jiang and Clark 2001a). Bik plays a decisive role in 
programmed cell death induced by toxins, cytokines (TGFβ, IFN-γ) (Spender, et al. 
2009), BCR cross-linking (Jiang and Clark 2001a) and viral pathogenesis (Boyd, et al. 
1995a)(Chinnadurai, Vijayalingam and Rashmi 2008a). Significant up-regulation of bik 
transcripts has been reported in germinal centre B cells during differentiation from naive 
(IgD+, CD27–) to centroblast transition and its level remained elevated in memory B 
cells, hence it is likely to be an important factor for maintenance of B cell homeostasis 
(Klein, et al. 2003). 
Previously, it has been shown that EBV-infected cells survive apoptotic signals through 
the interaction of the early lytic protein, BHRF1 (Landais, et al. 2005) with Bik protein 
(Boyd, et al. 1995a). EBV transformation of resting B lymphocytes to LCLs mimics 
antigen-induced resting B cell clonal expansion in lymph node germinal centres, where 
antigen binding to surface Ig (sIg) induces myc-mediated proliferation (Murn, et al. 
2009) and T cell CD40 ligand activates B lymphocyte CD40 receptors to up-regulate 
NF-κB, MAP kinases, and anti-apoptotic Bcl-2 family protein expression (Elgueta, de 
Vries and Noelle 2010). Initiation of apoptotic signalling pathways via BCR modulates 
the expression of Bcl-2 family members to regulate the intrinsic mitochondrial 
apoptosis pathway, which can be opposed by appropriate survival signals. Controlling 
expression of the Bcl-2 family of proteins is therefore critical in regulating the GC 
reaction.  
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BCR ligation in the absence of co-stimulatory ligand-receptor interactions is important 
for the elimination of autoreactive B cells. BCR engagement with anti-IgM antibody is 
a model for antigen-induced clonal deletion, with apoptosis induced as a consequence of 
surface IgM (sIgM) cross-linking.  In human B cells, bik is a downstream target of BCR 
signalling (Jiang and Clark 2001a, Craxton, et al. 1999, Craxton, et al. 2000). In B104 
lymphoma cells, which possess the phenotype of mature B cells, sIgM engagement was 
shown to correlate strongly with sustained bik induction and apoptosis (Jiang and Clark 
2001a). Therefore, experiments were set out to investigate whether bik repression could 
confer a survival advantage on BL-derived cells following BCR engagement. The BL 
cell line Ramos and the B cell lymphoma-derived BJAB are examples of malignant 
cells that have retained the normal response of GC B cells to BCR stimulation (Young 
and Staudt 2013). 
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4.1 BCR cross-linking in EBV-negative B cell lines leads to the 
induction of apoptosis 
  
BJAB and Ramos cells were seeded at 5 x 105 cell/mL 24 h prior to treatment with three 
different concentrations of anti-IgM antibody. Twenty-four hours after antibody 
treatment, apoptosis was measured as described previously (in chapter 3). Apoptosis 
was seen to have been induced in both cell lines in a dose-dependent manner (Figure 
4-1 and Figure 4-2). It was observed that Ramos cells (Figure 4-1) were more sensitive 
to apoptosis induced by anti-IgM ligation than BJAB cells (Figure 4-2), since 1 µg/mL 
anti-IgM antibody in Ramos resulted in 55% ±SD 3.593 of cells undergoing apoptosis 
whereas in BJAB this number increased to 14% ±SD 2.600. This is not due to lack of or 
low expression of sIgM as several groups have shown that BJAB expresses sIgM 
(Singer and Williamson 1980, Guerreiro-Cacais, Levitskaya and Levitsky 2010).  
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Figure 4-1: BCR cross linking in Ramos cells leads to apoptosis. 
Ramos cells were treated with various concentrations of anti-IgM antibody, as indicated 
above each scatterplot, for a duration of 24 h. Cell survival profiles were analysed using 
7AAD/Annexin-V staining and subsequent flow cytometric analysis. (A) Quadrant 
markers were based on stained/unstained controls. Cells in the lower left quadrant are 
viable (7AAD-/Annexin-V-), cells in the lower right quadrant are early apoptotic 
(7AAD-/Annexin-V+), cells in the upper right quadrant are late apoptotic 
(7AAD+/Annexin-V+) and cells in the upper left quadrant are necrotic/mostly nuclear 
debris (7AAD+/Annexin-V-). (B) Values presented as a bar chart reflect the percentage 
of cells in each quadrant for triplicate experiments. Data are Mean ±SD *P ≤ 0.05 and 
**P (0.001 to 0.01). 
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Figure 4-2: Apoptosis was induced by BCR cross-linking in BJAB cells. 
BJAB cells were treated with 1, 2, and 4 µg/mL of anti-IgM antibody for 24 h. (A) Cell 
survival profile was analysed using 7AAD/Annexin-V staining and subsequent flow 
cytometric analysis as described in (Figure 4-1) legend. (B) Values presented as a bar 
chart reflect the percentage of cells in each quadrant for triplicate experiments. Data are 
Mean ±SD *P ≤ 0.05 and **P (0.001 to 0.01) of three independent experiment. 
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4.2 BCR ligation leads to bik induction 
  
In order to investigate if BCR cross-linking exerts its apoptotic effect by regulation of 
bik, Ramos and BJAB cells were treated with 0.5 µg/mL or 5 µg/mL anti-IgM antibody 
for a duration of 24 h. Total RNA and protein were harvested and relative bik mRNA 
levels were detected by RT-qPCR using RNA prepared 24 h after treatment. Bik mRNA 
levels were assayed in triplicate and normalised to gapdh mRNA levels. Bik protein 
expression was analysed by Western blot.  
Bik mRNA levels were seen to increase in both Ramos (Figure 4-3) and to a lesser 
extent in BJAB cells (Figure 4-4) following treatment with anti-IgM antibody, and in a 
dose-dependent manner.  Bik protein levels increased also in both cell lines (Figure 4-3 
B and Figure 4-4 C; B and C), with a more pronounced effect in Ramos. Bik is a 
phosphoprotein and it is phosphorylated on consensus Casein Kinase II (CKII) 
phosphorylation sites (Thr-33 and/or Ser-35). Phosphorylation is required for efficient 
Bik-mediated apoptosis (Verma, Zhao and Chinnadurai 2001). Bik appears as a 27 
kDa/26 kDa double band in some cell lines and a single band in others. Western blot 
analysis of the Ramos cell line showed a single band for Bik protein, whereas BJAB 
demonstrated a double band.  When Ramos was stimulated with the TGFβ1 ligand, it 
was the higher molecular weight band that was seen to be affected. These observations 
are consistent with what has already been reported in the literature (Jiang and Clark 
2001a, Spender and Inman 2009a). 
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Ramos cells were treated with 0.5 µg/mL and 5 µg/mL anti-IgM antibody. (A) Relative 
bik mRNA levels were detected by RT-qPCR using RNA prepared 24 h after treatment. 
Bik levels were assayed in triplicate and normalised using gapdh. Relative 
quantification levels were calculated relative to the control. Data are Mean ±SD *P ≤ 
0.05 and **P (0.001 to 0.01) vs untreated control. (B) Western blot showing Bik protein 
expression. (C) Bik protein relative density values shown were obtained from ImageJ 
and were normalised to untreated control.  
 
 
 
 
 
 
Ctrl 0.5 µg 5 µg 
0
2
4
6
Anti IgM Ab
*
**
 - αIgM Ab
 + αIgM Ab
Bi
k
m
RN
A 
re
la
tiv
e 
qu
an
tif
ic
at
io
nA 
B 
Figure 4-3: BCR ligation with anti-IgM antibody leads to bik trans-activation in 
Ramos. 
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BJAB cells were treated with 0.5 µg/mL and 5 µg/mL Anti-IgM antibody. (A) Relative 
bik mRNA levels were detected by RT-qPCR using RNA prepared 24 h after treatment 
as described in the legend of (Figure 4.3). Data are Mean ±SD *P ≤ 0.05 and **P 
(0.001 to 0.01) vs untreated control. (B) Western blot showing Bik and β-actin protein 
expression.  
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Figure 4-4: BCR ligation with anti-IgM antibody leads to bik trans-activation in 
BJAB 
 165 
 
4.3 Transient bik knockdown does not significantly inhibit anti-IgM-
induced apoptosis in EBV negative cell lines 
 
In order to investigate to what extent bik is involved in BCR-mediated cell death, bik 
was transiently knocked down in Ramos (Figure 4-5) and BJAB (Figure 4-6) cell lines 
using anti-bik siRNAs (si1989 and si1990). Protein extracts at 24 h and 48 h post 
transfection were prepared from both cell lines and were analysed by Western blot. 
RNA extracts were prepared at 24 h post transfection and the level of bik mRNA 
expression was analysed by RT-qPCR as described before. In transfection experiments 
with Ramos and BJAB, both anti-bik siRNAs were shown to inhibit bik expression, as 
reflected in decreased bik mRNA and protein levels. In contrast, the control siRNA 
siNeg did not affect Bik expression (Shown in chapter 3, Figure 3.5 and Figure 3.6).     
Cells that were transfected with siRNAs were then left untreated or treated with 0.5 
µg/mL of anti-IgM antibody. The cell survival profile was determined 24 h following 
treatment by 7AAD/Annexin-V-PE staining and subsequent flow cytometric analysis.  
It can be seen that treatment with αIgM led to the induction of apoptosis in both cell 
lines, with a more pronounced effect seen in Ramos cells (Figure 4-5 and Figure 4-6). In 
the transfected cell population, significant apoptosis was observed before treatment 
with/without anti-IgM antibody (Figure 4-5 and Figure 4-6), and transient bik down-
regulation appeared to rescue cells from transfection-induced apoptosis by 
approximately 20% (Figure 4-5 and Figure 4-6). Transient bik knockdown was seen to 
decrease the overall apoptotic level but it did not have a pronounced effect in 
significantly inhibiting apoptosis mediated by BCR cross-linking in both cell lines 
(Figure 4-5 and Figure 4-6). It has previously been shown in purified immature and 
mature B cells from wild type, bim−/−, and vav–bcl-2 transgenic mice that BCR cross-
linking mediates apoptosis through induction of both Bim (Enders, et al. 2003b) and Bik 
(Jiang and Clark 2001b) pro-apoptotic proteins. Thus, while it appears that bik 
knockdown had a pro-survival effect, the induction of Bim might be masking the actual 
effect.  
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Ramos cells were transfected with each of two different bik siRNAs (si1989, si1990) or 
negative control siRNA (siNeg). Twenty-four hours following transfection, cells were 
treated with 0.5 µg/mL of anti-IgM antibody for duration of 24 h. (A) Cell survival 
profile was analysed using 7AAD/Annexin-V staining and subsequent flow cytometric 
analysis as described in (Figure 4-1) legend. (B) Values presented as a bar chart reflect 
the percentage of viable cells for triplicate experiments. Data are Mean ±SD *P ≤ 0.05. 
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Figure 4-5: Transient bik knockdown does not significantly inhibit anti-IgM-
induced apoptosis in Ramos. 
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BJAB cells were transfected with each of two different bik siRNAs (si1989, si1990) or negative 
control siRNA (siNeg). Twenty-four hours following transfection, cells were treated with 0.5 
µg/mL of anti-IgM antibody for duration of 24 h. (A) Cell survival profiles were analysed using 
7AAD/Annexin-V staining and subsequent flow cytometric analysis as described in (Figure 4-1) 
legend. (B) Values presented as a bar chart reflect the percentage of viable cells for triplicate 
experiments. Data are Mean ±SD *P ≤ 0.05 and**P (0.001 to 0.01). 
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Figure 4-6: Transient bik knockdown does not significantly inhibit anti-IgM-
induced apoptosis in Ramos. 
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4.4 Ectopic EBNA-2 inhibits BCR-induced apoptosis in Ramos cells 
 
As previously described, recent findings in our laboratory indicated that Bik repression 
appears to be a feature of LCLs and BL cells expressing all the viral latency-associated 
proteins. These results suggested that bik is a negative transcriptional target of the EBV 
latent protein, EBNA-2 (Chapter 1). In order to investigate to what extent EBNA-2 
expression in EBV negative cells can protect these cells from apoptosis induced by 
BCR cross-linking, a co-transfection strategy involving pMaxGFP with one of pSG5-
EBNA-2, pSG5-EBNA-2 WW323SR or the corresponding control vector pSG5, was 
therefore adopted in order to realise this goal. Forty-eight hours after transfection, cells 
were treated with 0.5 µg/mL anti-IgM antibody for a duration of 24 h and apoptosis was 
measured in the population of cells expressing GFP by using Annexin-V-PE/7AAD 
staining. It can be seen that expression of EBNA-2 rescued Ramos cells from antigen-
receptor-mediated apoptosis with 42% ±SD 5.033 of cells being viable and that the 
EBNA2-CBF1 interaction was not essential for this effect with 44% ±SD 5.000 viable 
cells,  compared to Ramos cells transfected with control vector with decreased viability 
(17% ±SD 5.508 ) (Figure 4-7). The large proportion of necrotic cells present is due to 
harsh transfection conditions. It has been shown previously in our laboratory that 
EBNA-2 negatively regulates the expression of bik. In addition, EBNA-2 trans-
activates the expression of the pro-survival Bcl-2 family members, bcl-2 and bfl-1 
(Pegman, et al. 2006a). Also, EBNA2 has been shown to bind Nur77 and protect against 
Nur77-induced cell death (Lee, et al. 2002).  
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Ramos cells were co-transfected with 0.5 µg pMaxGFP and 0.5 µg of each plasmid as 
indicated underneath the graph. Forty-eight hours after transfection, cells were treated 
with 0.5 µg/mL anti-IgM antibody. (A) Represents the cell viability/apoptosis FACS 
profiles 24 h after treatment with anti-IgM antibody. The cells in each quadrant are as 
described in the legend to Figure 4-1 (B) Bar chart representation of the percentage of 
viable cells in experiment shown in A (average of three independent experiments). Data 
are ±SD **P (0.001 to 0.01). 
A 
B 
Figure 4-7: EBNA-2 inhibits apoptosis induced by BCR cross-linking in Ramos  
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A similar experiment was set up in order to investigate if ectopic EBNA-2 reduces the 
rate or delays the onset of apoptosis induced by BCR cross-linking in BJAB (not 
shown). BJAB cells were co-transfected with pMaxGFP and one of pSG5-EBNA-2, 
pSG5-EBNA-2 WW323SR or the corresponding control vector pSG5. Poor transfection 
efficiency (less than 10%) and a high rate of apoptosis due to transfection was observed 
in all cases. Several factors were changed in order to improve the transfection efficiency 
and cell viability (data not shown). Three transfection reagents were used (TransIT-
LT1, SuperFect, TransIT-2020) instead of the Ingenio Electroporation Kit, which was 
used with either the Nucleofector (Amaxa) or Electroporator (Bio-Rad) instruments. In 
addition, total DNA concentrations (0.5 µg, 1 µg, and 2 µg), GFP expression plasmids 
(pEGFP-N1 and pMaxGFP) and the presence of antibiotics in culture medium 
(penicillin/streptomycin –P/S) were also investigated in order to optimize the 
transfection efficiency and increase the cell viability. In general, transfection efficiency 
increased moderately (from 10% up to 12%) when using pEGFP-N1 and cell viability 
increased significantly when electrical current and P/S were not used. Transfection 
efficiencies were higher when BJAB cells were electroporated or nucleofected 
compared to when these cells were transfected with TransIT-LT1, SuperFect, and 
TransIT-2020 reagents. However, cell viability was significantly lower. BJAB cells 
were efficiently tranfectable with siRNA and cell viability was not seen to be as low as 
when they were transfected with plasmids. 
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4.5 The involvement of PI3K-dependent pathway in BCR-mediated bik 
mRNA expression, and apoptosis. 
 
The activity of phosphatidylinositol-3 kinase (PI3K) is essential for normal BCR-
mediated responses, developmental progression in B lymphopoiesis and for the survival 
of mature B cells (Xu, et al. 2012, Vigorito, et al. 2004). Experiments carried out 
elsewhere showed that the expression of Bik protein is significantly increased after 
sIgM ligation in B104 B lymphoma cells, and furthermore that Bik protein expression is 
PI3K-dependent, since treatment with a PI3K inhibitor, wortmannin (Wm) blocked both 
sIgM-mediated Bik protein production and apoptosis (Jiang and Clark 2001a). In 
contrast, other studies have shown that inhibition of PI3K accelerates apoptosis in BL 
cell lines including Ramos (Curnock and Knox 1998, Spender and Inman 2012a).  
In order to investigate if the PI3K pathway plays a role in the regulation of bik 
following BCR stimulation of GC-derived cells (as opposed to B104 cells, which are 
derived from a mature B cell), the intrinsic apoptotic pathway was again induced in 
Ramos and BJAB cells by treating the two cell lines with anti-IgM antibody. The PI3K 
pan-inhibitor, wortmannin (10 nM), was added 30 min prior to BCR cross-linking with 
0.5 µg/mL anti-IgM antibody and apoptosis was then assessed as before using Annexin-
V-PE/7-AAD double staining. 
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Figure 4-8: The effect of PI3K inhibition on BCR cross-linking mediated apoptosis 
in Ramos cells. 
Ramos cells were treated with wortmannin 30 min before BCR stimulation with anti-
IgM antibody. Apoptosis was assessed using 7AAD/Annexin-V double staining by flow 
cytometry. (A) Representative cell viability/apoptosis FACS profiles 24 h after 
treatment are shown. The cells in each quadrant are as described in the legend to Figure 
4-1 and the values shown represent the percentage of cells in each quadrant. (B) Bar 
chart represents the percentage of the cells in experiment shown in A (average of three 
independent experiments). Data are ±SD **P (0.001 to 0.01). 
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Treatment of Ramos cells with wortmannin or vehicle did not have any obvious effect 
on cell viability (Figure 4-8), whereas apoptosis was increased when BJAB cells were 
treated with wortmannin (25% ±SD 2.000) when compared to untreated cells (9.9% 
±SD 1.504) (Figure 4-9). It can be seen that BCR cross-linking with anti-IgM antibody 
for 24 h led to 75% ±SD 5.000 of Ramos cells undergoing apoptosis (Figure 4-8).In 
comparison, BCR cross-linking mediated a lower level of apoptosis in BJAB cells (23% 
±SD 3.512) (Figure 4-9). Treatment of Ramos cells with wortmannin inhibited the 
apoptotic effect induced by BCR cross-linking with anti-IgM antibody and resulted in 
23% ±SD 3.060 of cells being apoptotic (Figure 4.8). In contrast, in BJAB cells, 
wortmannin did not have any significant impact on delaying or decreasing apoptosis 
induced by BCR cross-linking (Figure 4-9).  
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BJAB cells were treated with anti-IgM antibody. Wortmannin was added 30 min before 
anti-IgM antibody stimulation. Apoptosis was assessed using 7AAD/Annexin-V-
PE double staining by flow cytometry. (A) Representative cell viability/apoptosis FACS 
profiles 24 h after treatment are shown. The cells in each quadrant are as described in 
the legend to (Figure 4-1) and the values shown represent the percentage of cells in each 
quadrant. (B) Bar chart representation of the cells in experiment shown in A (average of 
three independent experiments). Data are ±SD ***P < 0.001. 
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In order to investigate a role for the PI3K signalling pathway in the trans-activation of 
bik upon BCR cross-linking, total RNA from the same experiment was also extracted 
and analysed for bik expression by RT-qPCR. As can be seen, bik mRNA was increased 
by approximately 6.3-fold in Ramos (Figure 4-10 A) and by 3.1-fold in BJAB (Figure 
4-10 B) in the presence of 0.5 µg/mL anti-IgM antibody. However, when PI3K was 
inhibited by wortmannin, prior to BCR stimulation, bik mRNA expression was 
decreased by 3.1-fold in Ramos (Figure 4-10 A) and by 1.5-fold in BJAB cells (Figure 
4-10 B). 
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Apoptosis was induced in (A) Ramos and (B) BJAB cells by treating these cells with 
anti-IgM antibody. The PI3K pan-inhibitor, wortmannin, was added 30 min before anti-
IgM antibody stimulation. Relative bik mRNA levels were detected by RT-qPCR using 
RNA prepared 24 h after treatment. Bik mRNA levels were assayed in triplicate and 
normalised to gapdh mRNA levels. Relative quantification levels were calculated 
relative to the control assigned a value of 1. Data are Mean ±SD **P (0.001 to 0.01). 
 
 
Overall, BCR cross-linking led to the significant induction of apoptosis which coincided 
with bik trans-activation in Ramos cells. An intact PI3K signalling pathway seemed to 
be required for the BCR cross-linking mediated effect in this cell line, as inhibition of 
PI3K by wortmannin significantly decreased the apoptotic effect mediated by BCR 
cross-linking and decreased expression of bik. However, BCR cross-linking in BJAB 
cells induced less apoptosis in contrast to Ramos cells which also coincided with bik 
trans-activation. Although PI3K inhibition also led to bik mRNA down-regulation (to a 
lower extent than that observed in Ramos cells), PI3K pathway inhibition was seen to 
have no significant effect on preventing or enhancing apoptosis due to BCR cross-
linking. 
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Figure 4-10: BCR cross-linking requires PI3K signalling pathway for bik mRNA 
trans-activation. 
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Summary  
 
Here, Ramos and BJAB were used to study the molecular events associated with GC B 
cell receptor-ligation-induced apoptosis. Similarly to TGFβ1, signalling via the BCR 
induced apoptosis more profoundly in Ramos when compared to BJAB, which 
coincided with an increase in Bik protein and mRNA levels in a dose-dependent 
manner. Transient bik knockdown was not sufficient to inhibit the apoptosis mediated 
through BCR cross-liking in both EBV-negative cell lines. Moreover, ectopic EBNA-2 
or its non-CBF1 binding mutant, EBNA-2 WW323SR, rescued Ramos cells from the 
apoptotic effects mediated through BCR cross-linking (Figure 4-11). Here, it has been 
observed that inhibition of the PI3K pathway by wortmannin led to a decreased 
expression level of bik mRNA and the viability of Ramos cells stimulated with anti-IgM 
antibody was augmented. However, while PI3K inhibition in BJAB cells was seen to 
coincide with decreased bik mRNA level, no significant effect was seen in reversing the 
apoptotic effects induced upon BCR stimulation.  
 
 
Figure 4-11: A model for inhibition of BCR-induced apoptosis by EBV. 
BCR engagement in the absence of survival signals (CD40 engagement) can promote 
apoptotic signal transduction pathways such as activation of effector caspases and 
expression of pro-apoptotic genes (bik and bim).  Here, it has been shown that EBNA-2 
negatively modulates bik trans-activation following BCR cross-linking and significantly 
inhibiting apoptosis. 
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Chapter 5 :                                       
A co-operative effect of 1α,25-
(OH)2D3 on BCR- and TGFβ1-
mediated apoptosis                                                
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A role for 1α,25-(OH)2D3 in B cell homeostasis 
 
Vitamin D3 has received increased attention recently for its pleiotropic actions on many 
chronic diseases, including cancer (Holick 2004, Fleet, et al. 2012), cardiovascular 
disease, autoimmune disease, diabetes (Adams and Hewison 2008), and neurologic 
disease (Garcion, et al. 2002, Holick 2007). It has been estimated that vitamin D3 
regulates the expression of over 900 genes (for review see (Wang, et al. 2005)). 
Investigations on B cell responses have found that 1α,25-(OH)2D3 inhibited the on-
going proliferation of activated B cells and induced apoptosis without having any effect 
on initial cell division. The generation of plasma cells and post-switch memory B cells 
was significantly inhibited by 1α,25-(OH)2D3, although the up-regulation of genetic 
programs involved in B cell differentiation was only modestly affected (Chen, et al. 
2007). B cells express mRNAs for proteins involved in vitamin D3 activity, including 
CYP27B1, CYP24A1, and the VDR, each of which has been seen to be regulated by 
1,25(OH)2D3. Importantly, 1α,25-(OH)2D3 has been shown to up-regulate p27, but not 
p18 and p21, both of which may be important in regulating the proliferation of activated 
B cells and their subsequent differentiation. These findings indicate that 1α,25-(OH)2D3 
may play an important role in the maintenance of B cell homeostasis and that the 
correction of vitamin D3 deficiency may be useful in the treatment of B cell-mediated 
autoimmune disorders (Chen, et al. 2007). B cell reactivity with 1α,25-(OH)2D3 is a 
characteristic universally shared by naive, germinal centre and memory B cell 
subpopulations, and cellular activation rather than differentiation, is more defining of 
their biological reactivity to 1α,25-(OH)2D3 (Morgan, et al. 2000b). The apoptotic 
effects of 1α,25-(OH)2D3 are cell-specific and context-dependent and are mediated by 
modulating different signalling pathways, cell cycle regulators and Bcl-2 protein family 
members (Fleet, et al. 2012). Vitamin D3 has been shown to induce apoptosis in prostate 
cancer cells by the intrinsic pathway and by down-regulating Bcl-2, Bcl-xL but not Bax 
and Bad (Guzey, Kitada and Reed 2002). It has been shown that 1α,25-(OH)2D3 has a 
direct effect on the B cell response. It inhibits the on-going proliferation of activated B 
cells and induces their apoptosis, and also the generation of class switched memory B 
cells, plasma cell differentiation, and Ig production (Chen, et al. 2007).  
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Here, experiments were designed to address (i) if 1α,25-(OH)2D3 is able to induce 
apoptosis in Ramos and BJAB -B cell lines that are used as GC B cell models (ii) 
whether the occurrence of such apoptosis coincides with upregulation of bik,, and (iii) 
the possible co-operation of 1α,25-(OH)2D3 with TGFβ1 and BCR signalling pathways 
in regulating apoptosis and bik.  
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5.1  Apoptotic effect of 1α,25-(OH)2D3  
 
In order to investigate a potential apoptotic effect of 1α,25-(OH)2D3, Ramos cells were 
treated with 10 nM and 50 nM concentrations of 1α,25-(OH)
 
for 24 h and 48 h. 
Apoptosis was then measured by Annexin-V-PE/7AAD staining, followed by flow 
cytometry. It was observed that apoptosis was induced in a dose-dependent manner. 
This effect was best seen at the 48 h time point where both 10 nM and 50 nM had 
similar effects, with an approximately 3-fold increase in the apoptotic cell population 
when cells where treated with 50 nM 1α,25-(OH)2D3 compared to control (Figure 5-1). 
The effect of FCS on the apoptotic activity of 1α,25-(OH)2D3 was then examined. The 
induction of apoptosis was maximal when cells were cultured with media supplemented 
with 5% FCS (data not shown). 
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Figure 5-1: 1α,25-(OH)2D3 induces apoptosis in Ramos cells. 
Ramos cells were treated with 10 nM and 50 nM of 1α,25-(OH)2D3 for 24 and 48 h. (A) 
Representative cell viability/apoptosis FACS profiles at 24 h and 48 h following 
treatment. The cells in each quadrant are as described in the legend to (Figure 4.1) and 
the values shown represent the percentage number of cells in each quadrant. (B) Values 
presented as a bar chart reflect the percentage of cells that were undergoing apoptosis 
(three independent experiments). Data are ±SD *P ≤ 0.05 and **P (0.001 to 0.01).  
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5.2  1α,25-(OH)2D3 -mediated apoptosis coincides with bik trans-
activation 
 
Ramos cells were then treated with 0.1 nM, 1 nM, 10 nM, and 100 nM of 1α,25-
(OH)2D3 for 24 and 48 h. Total RNA and protein were harvested at the indicated time 
points for RT-qPCR and Western blot analysis (Figure 5-2). It can be seen that the bik 
mRNA expression level significantly increased in response to 1α,25-(OH)2D3  in a dose- 
dependent manner relative to untreated control. A 4-fold increase in the level of bik 
mRNA can be seen 24 h after treatment with 10 nM of the 1α,25-(OH)2D3 (Figure 5-2 
A). In addition, Western blot analysis showed a 6-fold increase in Bik protein 
expression at the 24 h time point in response to 10 nM of 1α,25-(OH)2D3 (Figure 5-2 B). 
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Figure 5-2: Bik mRNA and protein levels increase in response to 1α,25-(OH)2D3 
treatment (Ramos cells). 
(A) Relative bik mRNA levels were detected by RT-qPCR, as described in the legend to 
Figure 4.3, using RNA prepared at 0 h, 24 h and 48 h following treatment with three 
different concentrations of 1α,25-(OH)2D3 as indicated below each bar chart (average of 
three independent experiments) Data are ±SD**P (0.001 to 0.01). (B) Western blot 
showing Bik protein expression for the 24 h time point in response to 0.1 nM, 1 nM, 
and 10 nM of 1α,25-(OH)2D3.  
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5.3 1α,25-(OH)2D3 and TGFβ1 independently and co-operatively 
induce apoptosis in Ramos and BJAB cells 
 
A number of different experiments have demonstrated cross-talk between the TGFβ1 
and vitamin D3 signalling pathways (Adams and Hewison 2008, Subramaniam, et al. 
2001). The activities of nuclear hormone receptors are mediated, at least in part, through 
the Smad proteins. Smad3 for example, a downstream component of the TGFβ 
signalling pathway, interacts with and acts as a co-activator of VDR (Subramaniam, et 
al. 2001). 1α,25-(OH)2D3-induced phosphorylation of Smad2 and Smad3 proteins is an 
indirect effect of 1α,25-(OH)2D3 and is dependent on TGFβ (Daniel, et al. 2007). 
Smad3 binds the VDR-RXR heterodimer in a ligand-dependent manner, in which an 
intact Smad MH1 domain is required, in contrast to many other Smad interactions, 
which are mediated by the MH2 domain (Leong, et al. 2001). This interaction is 
strongly inhibited by the inhibitory Smad, Smad7 but not by Smad6 (Yanagi, et al. 
1999). 
In order to address a possible co-operation between the 1α,25-(OH)2D3 and TGFβ 
signalling pathways in the GC cell context, Ramos and BJAB were treated with either 
10 nM 1α,25-(OH)2D3 or 10 ng/mL TGFβ1 alone, or co-stimulated with both together 
for 24 and 48 h. Each treatment was again observed to induce apoptosis and combined 
treatments resulted in higher rates of apoptosis when compared to the relevant 
individual treatments (Figure 5-3 and Figure 5-5). The rate of apoptosis was increased 
by 5.5-fold after 48 h in Ramos cells (Figure 5-3 A and B) and by 7-fold in BJAB cells 
(Figure 5-5 A and B) co-stimulated with 10 ng/mL TGFβ1 and 10 nM 1α,25-(OH)2D3, 
when compared to untreated control at the same time point. Total RNA and protein 
were extracted 24 h and 48 h after treatment. Bik mRNA levels were seen to increase in 
cells treated with either TGFβ1 or 1α,25-(OH)2D3. Apoptosis was increased 4-fold in 
Ramos cells (Figure 5-4 A) and by more than 2.7-fold in BJAB cells (Figure 5-6 A) 
when cells were co-stimulated with TGFβ1 and vitamin D3 together. The level of Bik 
protein was also seen to rise in response to either 1α,25-(OH)2D3 or TGFβ1 treatment 
alone and Bik expression was increased when cells were co-stimulated with both of 
these stimuli (Figure 5-4 B and Figure 5-6 B).  
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Figure 5-3: 1α,25-(OH)2D3 and TGFβ1 independently and co-operatively induce 
apoptosis in Ramos cells. 
(A) Representative FACS profiles of Ramos cells 24 h and 48 h following treatment 
with stimuli as indicated above each scatterplot. The cells in each quadrant are as 
described in the legend to Figure 4.1 and the values shown represent percentage number 
of cells in each quadrant. (B) Values presented as a bar chart reflect the percentage of 
cells undergoing apoptosis (three independent experiments). Data are ±SD *P≤ 0.05 and 
***P < 0.001. 
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Figure 5-4: 1α,25-(OH)2D3 and TGFβ1 independently and co-operatively trans-
activate bik in Ramos cells. 
Ramos cells were treated with 10 nM 1α,25-(OH)2D3 and/or 10 ng/mL TGFβ1 for 24 
and 48 h. (A) Relative bik mRNA levels were detected by RT-qPCR, as described in the 
legend to Figure 4.3, using RNA prepared at indicated time points following treatment 
with different stimuli as indicated below each bar chart. (B) Represents Western blot 
showing Bik and β-actin protein expression for 24 h and 48 h time points. Data are ±SD 
*P≤ 0.05 and **P (0.001 to 0.01). 
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Figure 5-5: 1α,25-(OH)2D3 and TGFβ1 independently and co-operatively induce 
apoptosis in BJAB cells.  
BJAB cells were treated with 10 nM 1α,25-(OH)2D3 and/or 10 ng/mL TGFβ1 for 24 
and 48 h. Cell viability/apoptosis was measured 24 h after treatment by FACS as 
described in the legend to Figure 4.1 and values presented as a bar chart reflect the 
percentage of cells undergoing apoptosis for 24 h and 48 h after treatment. Data are 
±SD *P≤ 0.05, **P (0.001 to 0.01), and ***P < 0.001.  
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Figure 5-6: TGFβ1 and 1α,25-(OH)2D3  independently and co-operatively trans-
activate bik in BJAB cells. 
BJAB cells were treated with 10 nM 1α,25-(OH)2D3 and/or 10 ng/mL TGFβ1 for 24 h 
and 48 h. (A) Relative bik mRNA levels were detected by RT-qPCR, as described in the 
legend to Figure 4.3, using RNA prepared at the indicated time points following 
treatment with different stimuli as indicated below each bar chart. (B) Represents 
Western blot showing Bik and β-actin protein expression for 24 h and 48 h time points. 
Data are ±SD **P (0.001 to 0.01) and ***P < 0.001. 
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5.4  Co-operation between the BCR, 1α, 25-(OH)2D3 and TGFβ1 
signalling pathways on induction of apoptosis in Ramos and BJAB 
cells 
 
In order to investigate if 1α,25-(OH)2D3 co-operates with BCR and TGFβ1 signalling 
pathways in inducing apoptosis in a GC cell context, Ramos and BJAB cell lines were 
treated with 1α,25-(OH)2D3, TGFβ1 and anti-IgM antibody separately or in combination 
(as indicated in Figure 5-7 and Figure 5-8) for a period of 48 h. Cell survival profiles 
were then determined as before by 7-AAD/Annexin-V staining and flow cytometric 
analysis. These three stimuli were again seen to induce apoptosis in Ramos and BJAB 
when used individually (Figure 5-7 and Figure 5-8). Among the three stimuli, in order, 
anti-IgM antibody had the strongest and TGFβ1 and 1α,25-(OH)2D3  were observed to 
have the weakest effect in induction of apoptosis in Ramos cells (70% ±SD 1.854, 44% 
±SD 2.147 and 30% ±SD 2.108 apoptotic respectively, see Figure 5-7). Co-stimulation 
of Ramos cells with TGFβ1 and anti-IgM antibody
 
led to a significant induction of 
apoptosis (94% ±SD 3.858), more than was the case when each stimulus was used 
individually (Figure 5-7). Combined treatment of Ramos cells with 1α,25-(OH)2D3 and 
anti-IgM antibody led to 84% ±SD 3.494 apoptosis (Figure 5-7). Similarly, co-
stimulation with TGFβ1 and 1α,25-(OH)2D3 resulted in 52% ±SD 2.152 of cells being 
apoptotic (Figure 5-7). Overall therefore, it can be seen that 1α, 25-(OH)2D3 co-operated 
with anti-IgM antibody and to lesser extent with TGFβ1 to increase the level of induced 
apoptosis in Ramos cells (Figure 5-7). On the other hand, it was observed that, at the 
various effector concentrations used, TGFβ1 had the strongest effect in induction of 
apoptosis in BJAB cells (44% ±SD 1.955 apoptotic), followed by anti-IgM antibody 
(35% ±SD 1.206 apoptotic) and 1α, 25-(OH)2D3 (31% ±SD 1.952 apoptotic) (Figure 
5-8). Co-stimulation of BJAB cells with 1α,25-(OH)2D3 and TGFβ1 led to 50% ±SD 
2.082 of cells undergoing apoptosis, more than was the case when each stimulus was 
used individually. Similarly, combined treatment of BJAB cells with TGFβ1 and anti-
IgM antibody further increased the percentage of apoptotic cells to 57% ±SD 2.608 
when compared to the individual treatment with TGFβ1 and anti-IgM antibody (Figure 
5-8). Combined treatment of BJAB cells with 1α, 25-(OH)2D3 and anti-IgM antibody 
was also seen to have a co-operative effect  as 46% ± SD 1.311 of cells were apoptotic 
after this co-stimulation. 
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Figure 5-7: Co-operative effects of TGFβ1, 1α,25-(OH)2D3 and anti-IgM antibody 
on the induction of apoptosis in Ramos.  
Ramos cells were treated with various stimuli alone or together as indicated below each 
bar chart, for a duration of 48 h. (A) Representative cell viability/apoptosis FACS 
profiles 24 h and 48 h after treatment. The cells in each quadrant are as described in the 
legend to Figure 4.1 and the values shown represent percentage number of cells in each 
quadrant. (B) Values presented as a bar chart reflect the percentage of cells undergoing 
apoptosis (average of three independent experiments). Data are ±SD **P (0.001 to 0.01) 
(See Table 5-1: Statistical significance). 
 
 
 
 
 
 
 
 
 
Figure 5-8: Co-operative effects of TGFβ1, 1α,25-(OH)2D3 and anti-IgM antibody 
on the induction of apoptosis in BJAB.  
BJAB cells were treated with various stimuli alone or together, as indicated below each 
bar chart, for a duration of 48 h. (A) Representative cell viability/apoptosis FACS 
profiles 24 h and 48 h after treatment. The cells in each quadrant are as described in the 
legend to Figure 4.1 and the values shown represent percentage number of cells in each 
quadrant. (B) Values presented as a bar chart reflect the percentage of cells undergoing 
apoptosis (average of three independent experiments). Data are ±SD **P (0.001 to 0.01) 
(See Table 5-1: Statistical significance). 
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Table 5-1: Statistical significance of apoptosis induced by various stimuli in Ramos 
and BJAB. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total RNA from this experiment was prepared 48 h after treatment and bik mRNA 
levels were determined by RT-qPCR. It could be seen that the degree of apoptosis 
correlated with the extent of bik mRNA induction. It was observed that bik mRNA 
levels increased in response to anti-IgM antibody, TGFβ1 and 1α,25-(OH)2D3 
treatments alone or in combination, as indicated in Figure 5-9. As was observed 
previously (Figure 5-6), treatment of cells with 1α,25-(OH)2D3, TGFβ1, and anti-IgM 
antibody coincided with bik trans-activation. 1α,25-(OH)2D3 induced bik to a greater 
extent in Ramos (2-fold) than in BJAB (1.3-fold) (Figure 5-9 A and B respectively). 
1α,25-(OH)2D3 also co-operated with TGFβ1 in inducing  bik to a similar extent in  both 
Ramos and BJAB (3.4-fold and 3.6-fold respectively). When 1α.25-(OH)2D3 was used 
together with anti-IgM antibody, the level of bik mRNA increased 5.5-fold  in Ramos 
compared to a 4-fold increase in BJAB (Figure 5-9 A and B). 
Overall, the co-operative effect of 1α,25-(OH)2D3 with TGFβ1 and anti-IgM antibody 
treatments in induction of apoptosis was more pronounced in Ramos compared to BJAB 
cells. Apoptosis was seen to coincide with bik trans-activation in response to individual 
or combined treatments in both cell lines.  
 
 
Statistical significance of apoptosis 
induced by various stimuli. 
(Ramos) (BJAB) 
0 h vs 48 h control - - 
48 h Ctrl      vs        every each treatment ** 
     
** 
Vit D3               vs        Vit D3  +  TGFβ1 ** ** 
Vit D3               vs         Vit D3  +  αIgM Ab ** ** 
TGFβ1         vs         Vit D3  +  TGFβ1 ** ** 
TGFβ1         vs         αIgM Ab + 
 
TGFβ1 ** ** 
αIgM Ab     vs          αIgM Ab + 
 
TGFβ1 ** ** 
αIgM Ab     vs          αIgM Ab  + Vit D3   ** ** 
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(A) Ramos and (B) BJAB cells were treated with various stimuli alone or together, as 
indicated below each bar chart, for a duration of 48 h. Relative bik mRNA levels were 
detected by RT-qPCR, as described in the legend to Figure 4.3 using RNA prepared at 
indicated time points following treatment with different stimuli as specified above. Data 
are ±SD *P < 0.05 and **P (0.001 to 0.01) (See Table 5-2: Statistical significance of 
bik trans-activation by various stimuli in Ramos and BJAB.. 
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Figure 5-9: Co-operative effects of TGFβ1, 1,25-(OH)2D3 and anti-IgM antibody on 
bik trans-activation in Ramos and BJAB cells.  
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Table 5-2: Statistical significance of bik trans-activation by various stimuli in 
Ramos and BJAB. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Significance of bik trans-activation by 
various stimuli. 
(Ramos) (BJAB) 
0 h vs 48 h control - - 
48 h Ctrl      vs        every each treatment 
Except  48 h Ctrl  vs Vit D3                
** 
     ** 
** 
 
 
 
 
 
 
* 
Vit D3               vs        Vit D3  +  TGFβ1 ** ** 
Vit D3               vs         Vit D3  +  αIgM Ab ** ** 
TGFβ1         vs         Vit D3  +  TGFβ1 ** ** 
TGFβ1         vs         αIgM Ab + 
 
TGFβ1 ** ** 
αIgM Ab     vs          αIgM Ab + 
 
TGFβ1 ** ** 
αIgM Ab     vs          αIgM Ab  + Vit D3   ** ** 
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5.5 A role for PI3K signalling in BCR-, TGFβ1-, and 1α,25-(OH)2D3-
mediated apoptosis 
 
PI3K has diverse roles in the adaptive and innate immune system. Vitamin D3 has been 
shown to be involved in activation of the PI3K/Akt signalling pathway (Deeb, Trump 
and Johnson 2007b, Hughes, et al. 2008). Also, the PI3K pathway is required for 
sustained Bik protein production upon BCR stimulation (Jiang and Clark 2001b). 
TGFβ1 has also been shown to activate PI3K in a non-Smad-dependent pathway (Zhang 
2009).  
Here, experiments were designed to investigate a role for PI3K in the intrinsic apoptotic 
pathways mediated by BCR cross-linking, TGFβ1, and 1α,25-(OH)2D3. Cells were 
treated with 10 nM wortmannin (Wm) 30 min prior to individual treatments for 48 h 
with TGFβ1, 1α,25-(OH)2D3, and anti-IgM antibody or dual sets of combined 
treatments, as indicated below each bar chart (Figure 5-10-Figure 5-13). It was observed 
that PI3K inhibition in Ramos cells significantly decreased BCR cross-linking and 
vitamin D3 mediated apoptosis to 17% ±SD 2.541 and 8%±SD 1.002 respectively, while 
TGFβ- mediated apoptosis was moderately increased to 26%  ±SD 1.311 (Figure 5-10 
B).  
Co-stimulation with anti-IgM antibody/1α,25-(OH)2D3  led to 77% ±SD 1.692 apoptosis 
compared to the control. Interestingly, this effect was reversed after inhibition of PI3K 
signalling, and led to a substantial decrease in apoptosis (34% ±SD 2.380) (Figure 5-11 
B). Combined treatment of Ramos cells with anti-IgM antibody/TGFβ1 after PI3K 
inhibition led to a decrease in the overall level of apoptosis (from before 80% ±SD 
2.409 down to 65% ±SD 2.476 after PI3K inhibition) (see Figure 5-11 B for 
interpretation here). Combined stimulation with 1α,25-(OH)2D3/TGFβ1 resulted in a 
moderate increase in the percentage of apoptotic cells (37% ±SD 2.062) and treatment 
of cells with wortmannin was seen to have no significant effect in altering the level of 
apoptosis (32% ±SD 2.585) (Figure 5-11 B). 
 
 
 
 
 
 
 
 196 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-10: The effect of wortmannin on BCR cross-linking, TGFβ1 and 1α,25-
(OH)2D3-mediated apoptosis in Ramos cells. 
Ramos cells were treated with (black bar) or without (white bar), wortmannin 30 min 
before apoptosis was initiated with the specified stimuli as indicated above each scatter 
plot. (A) Representative cell viability/apoptosis FACS profiles 24 h after treatment with 
TGFβ1. The cells in each quadrant are as described in the legend to Figure 3-1 and the 
values shown represent the percentage number of cells in each quadrant. (B) Bar chart 
representation of the percentage of apoptotic cells in the cell viability/apoptosis FACS 
assay 24 h after treatment (average of three independent experiments). Data are ±SD 
**P (0.001 to 0.01). 
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Ramos cells were treated with (black bars) or without (white bars), wortmannin 30 min 
before, apoptosis was initiated with the specified stimuli as indicated above each scatter 
plot. (A) Representative cell viability/apoptosis FACS profiles 24 h after treatment with 
TGFβ1. The cells in each quadrant are as described in the legend to Figure 3-1 and the 
values shown represent the percentage number of cells in each quadrant. (B) Bar chart 
representation of the percentage of apoptotic cells in the cell viability/apoptosis FACS 
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Figure 5-11: The effect of wortmannin on BCR cross-linking, TGFβ1 and 1α,25-
(OH)2D3 co-operative-mediated apoptosis in Ramos cells. 
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assay 24 h after treatment (average of three independent experiments). Data are ±SD *P 
≤ 0.05 and **P (0.001 to 0.01). 
In comparison to the results seen for the Ramos cells (Figure 5-10 and Figure 5-11), 
inhibition of the PI3K pathway in BJAB cells (Figure 5-12) resulted in overall increased 
apoptosis (from 24% ±SD 1.607 before to 42% ±SD 2.082 after). A significant increase 
in apoptosis was observed when these cells were stimulated with TGFβ1 after inhibition 
of PI3K (76% ±SD 2.000) (Figure 5-12). There were no detectable changes in the level 
of apoptosis due to PI3K inhibition when cells were treated with anti-IgM antibody or 
1α,25-(OH)2D3 (Figure 5-12). When BJAB cells were co-stimulated with anti-IgM 
antibody/TGFβ1 after PI3K inhibition, a significant increase in the relative rate of 
apoptosis was seen when compared to untreated cells (from 64% ±SD 2.589 before to 
85% ±SD 3.686 after). Wortmannin had a similar effect on BJAB cells when they were 
treated with TGFβ1/vitamin D3 (from 68% ±SD 3.092 before to 85% ±SD 1.504 after). 
Co-stimulation with anti-IgM antibody and 1α,25-(OH)2D3 however, resulted in no 
significant changes after wortmannin treatment (Figure 5-13).  
It has previously been shown elsewhere, that Akt is constitutively phosphorylated 
in BJAB cells, and that the PI3K specific inhibitor LY294002 mediated Akt de-
phosphorylation and subsequently the cell growth inhibition (Mori and Sairenji 2006). 
This therefore might explain why BJAB cells are responding differently to PI3K 
inhibition when compared to the Ramos cell line. 
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BJAB cells were treated with (black bar) or without (white bars) wortmannin, 30 min 
before apoptosis was initiated with the specified stimuli as indicated above. Bar chart 
representation of the percentage of apoptotic cells in the cell viability/apoptosis FACS 
assay 24 h after treatment (average of three independent experiments). Data are ±SD *P 
≤ 0.05 and **P (0.001 to 0.01). 
 
 
 
 
 
 
 
 
 
 
 
 
       
       
Figure 5-12: The effect of wortmannin on the BCR cross-linking, TGFβ1 and 
1α,25-(OH)2D3 mediated apoptosis in BJAB cells. 
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Figure 5-13: The effect of wortmannin on BCR cross-linking, TGFβ1 and 1α,25-
(OH)2D3 mediated apoptosis in BJAB cells. 
BJAB cells were treated with (black bar) or without (white bars) wortmannin, 30 min 
before apoptosis was initiated with the specified stimuli as indicated above. Bar chart 
representation of the percentage of apoptotic cells in the cell viability/apoptosis FACS 
assay 24 h after treatment (average of three independent experiments). Data are ±SD 
**P (0.001 to 0.01). 
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Summary  
 
In conclusion, it has been shown here that the stimulation of the EBV-negative cell lines 
Ramos (BL-derived), and BJAB (B cell lymphoma-derived) with 1α,25-(OH)2D3 led to 
apoptosis. It was also shown that 1α,25-(OH)2D3-mediated apoptosis coincided with bik 
mRNA and Bik protein up-regulation in these cell lines. 1α,25-(OH)2D3 was seen to co-
operate with anti-IgM antibody and TGFβ1 to further increase apoptosis in Ramos and 
to lesser extent in BJAB. Augmentation of apoptosis in GC model cell lines through 
combined treatment with 1α,25-(OH)2D3/TGFβ1 was seen to coincide with bik trans-
activation.  
 
Figure 5-14: A model for possible cross-talk between 1α,25-(OH)2D3,  TGFβ1, and 
BCR signalling pathways resulting in bik trans-activation and its inhibition bye 
EBV.  See text for discussion of the interactions involved. 
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Wortmannin treatment alone was seen to decrease the viability of BJAB cells, but no 
effect was seen on Ramos cells. On the other hand, no significant changes in the level of 
apoptosis were seen in BJAB cells treated with an anti-IgM antibody and 1α,25-
(OH)2D3  individually or together after inhibition of PI3K pathway. However inhibition 
of the PI3K pathway was seen to increase the apoptotic effects mediated by TGFβ1 in 
these cells. When BJAB cells were co-treated treated with TGFβ1/1α,25-(OH)2D3, 
apoptosis was increased compared to the counterpart experiment in which PI3K 
pathway was not inhibited. It was observed that pre-treatment with wortmannin led to a 
significant decrease in the proportion of Ramos cells undergoing apoptosis, when 
triggered to do so with anti-IgM antibody and 1α,25-(OH)2D3, individually or in 
combination. Whereas inhibition of the PI3K pathway and subsequent treatment with 
TGFβ1 was seen to increase the rate of apoptosis in Ramos cells. The rate of apoptosis 
induced by combined treatment with 1α,25-(OH)2D3/TGFβ1 after the PI3K pathway 
was inhibited, showed  no detectable change in Ramos cells.  
Overall 1α,25-(OH)2D3 might selectively sensitise Ramos and BJAB cells to the major 
GC intrinsic apoptosis pathways emanating from TGFβ1 and BCR cross-linking, in part 
through trans-activating bik. The PI3K signalling pathway plays an important role in the 
1α,25-(OH)2D3 and anti-IgM antibody with regard to the induction of apoptosis and 
possibly bik regulation in these cells (Figure 5-14). 
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Chapter 6 :                             
General discussion                                         
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Many viruses exploit and manipulate the differentiation state of infected cells, promote 
or block cell cycling and make use of a variety of mechanisms to evade innate cellular 
anti-viral responses and encourage cell survival (reviewed in (Hayward 2004)). Since 
apoptosis is regulated by functional pro-apoptotic and anti-apoptotic proteins, it is not 
surprising that EBV controls the cellular response to apoptosis by regulating both pro- 
and anti-apoptotic genes. Following infection of naïve B cells, EBV induces the naïve B 
cell activation and proliferation to become proliferating lymphoblasts which express the 
EBV growth programme (latency III) orchestrated by the viral transcription factor 
EBNA-2 (Sinclair, et al. 1994b). EBNA-2 subverts aspects of the Notch signalling 
pathway, thus blocking B cell differentiation, and allowing cell proliferation (Lucchesi, 
et al. 2008a). EBNA-2 induction of LMP-1, which mimics constitutively active CD40 
signal (Uchida, et al. 1999) and LMP-2A, a second mimic of functional BCR, (Thorley-
Lawson 2001a) drive the infected cell to proliferate and survive the germinal centre 
reaction (Babcock, Hochberg and Thorley-Lawson 2000, Wahl, et al. 2013). EBV 
residing within the memory and the long-lived peripheral B cell compartment down-
regulate the expression of highly immunogenic viral latency antigens, and only few 
viral gene products (Latency II, Latency 0 and Latency I) are expressed (reviewed in 
Chapter 1). EBNA1 binds to the latent viral DNA replication origin and maintains the 
viral genome in the EBV positive cells after cell division (Thorley-Lawson 2001a). In 
order to survive apoptotic pathways responsible for eliminating B cells within GCs 
(which signal through the TGFβ receptor and BCRs), EBV employs substantial control 
over the expression or function of the Bcl-2 family members (reviewed in Chapter 1 and 
(Spender and Inman 2011)). 
EBNA-2 acts as a pleiotropic modulator of viral and cellular genes that are involved in 
growth control, and plays a decisive role in the induction and maintenance of 
proliferation of the infected cell. EBNA-2, stimulates B cell survival and growth 
proliferation in the setting of EBV infection (reviewed in (Hayward 2004)). This viral 
transcription factor does not bind DNA directly but it is recruited to its site of action 
through complex and cell-context dependent interactions with cellular proteins 
including CBF1 (also known as RBP-Jk, a molecular component of the cellular Notch 
signalling pathway) and others (reviewed in (Zimber-Strobl and Strobl 2001, Hayward 
2004)). EBNA-2 also regulates the expression of genes encoding cell surface and 
soluble proteins that modulate the cell's interaction with the environment, such as the 
receptors CD21, CD23, and CCR7 and the cytokines TNF-α, LT-α and IL-18 
(Burgstahler, et al. 1995, Spender, et al. 2001b, Calender, et al. 1990, Pages, et al. 
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2005), in addition to cellular genes that are implicated in intrinsic growth and survival 
regulation,  like cyclin D2, c-myc, bfl-1 and c-fgr) (Kaiser, et al. 1999, Sinclair, et al. 
1994a, Knutson 1990). Furthermore, in a study which Sindbis virus infection was used 
to induce Nur77 synthesis and apoptosis, it was demonstrated that EBNA-2 could bind 
to Nur77 and protect against Nur77-induced cell death (Lee, et al. 2002). 
In humans, Bik seems to play a key role in B cell homeostasis. It has been shown that B 
cell subsets undergo significant upregulation of bik during differentiation as they 
progress through the GC reaction from naïve, centroblast, centrocyte and through to 
memory cells. It has been reported that the EBV Bcl-2 homolog, BHRF1 blocked 
apoptosis induced by Bik (Boyd, et al. 1995a). However it was subsequently shown that 
the inhibitory effect of BHRF1 was not due to direct interaction with Bik but rather due 
to the inactivation of Bak which, unlike Bax, is required for Bik-mediated apoptosis 
(Shimazu, et al. 2007). Interestingly, Bik also mediates host cell suicide in response to 
protein synthesis shutoff (Shimazu, et al. 2007), a process commonly observed 
following viral infection, and induced by the EBV early lytic gene BGLF5 (Rowe, et al. 
2007). Bik has also been seen to be required for IFN-γ-induced cell death in human 
airway epithelial cells (Mebratu, et al. 2008).  
In our laboratory, preliminary RNA multi-riboprobe nuclease assays had indicated a 
possible correlation between the EBV growth programme and the down-regulation of 
the pro-apoptotic bik gene in BL-derived cell lines and LCLs. Subsequently, it was also 
shown in our laboratory that EBV down-regulates bik. Significantly, restoration of Bik 
expression in the LCL IB4 induced a pathway upstream of the caspases, stimulating the 
induction of apoptosis that is dependent on the functional BH3 domain of Bik. In line 
with literature and previously in our laboratory, PBMC-derived untouched naïve B cells 
were infected with EBV, and any further decrease in the already low level of bik mRNA 
that was present prior to infection was not observed (D Walls; personal 
communication). It is possible therefore, that blocking Bik upregulation may have an 
important role in evasion of host immune responses. These results demonstrated that bik 
is transcriptionally down-regulated by EBNA-2 in EBV-negative cell lines and LCLs 
and that neither c-Myc nor the ability of EBNA2 to interact with CBF1 are required for 
this effect (D Walls; personal communication). This finding was the first indication of 
the transcriptional down-regulation of a pro-apoptotic gene by EBV. To date EBNA-2 is 
known to transcriptionally repress the activity of two other cellular genes, the 
immunoglobulin heavy chain locus (IgM) and c-myc (Maier, et al. 2006, Lucchesi, et al. 
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2008a). EBNA-2 has previously been implicated in the modulation of the anti-apoptotic 
bcl-2 (Finke, et al. 1992). Significantly the overexpression of Bcl-2 in group I BL cell 
lines resulted in diminished apoptosis in response to a number of stimuli, and cell death 
inhibition was directly correlated to the amount of Bcl-2 expressed (Henderson, et al. 
1991, Milner, Johnson and Gregory 1992). It has also been shown in the laboratory that 
EBNA-2 up-regulates the anti-apoptotic bfl-1. EBNA-2 trans-activation of bfl-1 
requires CBF1, and bfl-1 expression is induced and maintained at high levels by the 
EBV growth programme in an LCL (Pegman, et al. 2006a).  
Here, the mechanism and potential role of the EBV-bik interaction was investigated in a 
context that is relevant to EBV namely following the triggering of intrinsic apoptotic 
pathways by TGFβ1, BCR, and 1α,25-(OH)2D3 in a GC B cell setting. EBV negative 
cell lines which are used as GC B cell models were used for this purpose along with a 
conditional LCL, ER/EB2-5, in which the EBV growth programme, driven by EBNA2, 
could be switched on and off.  
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6.1 EBV inhibits TGFβ1-induced apoptosis by inhibiting bik 
upregulation through the canonical Smad pathway 
 
TGFβ signalling mediates a wide range of biological activities in development and 
disease. The TGFβ1 ligand signals through heterodimeric type I and type II receptors 
that are members of the serine/threonine kinase family (Juarez and Guise 2011). Here it 
was shown that stimulation of the EBV-negative B cell lines, BJAB and Ramos with 
TGFβ1 led to induction of apoptosis. This effect was more evident in BJAB in 
comparison to the Ramos cells. The induction of apoptosis by TGFβ receptor ligation 
coincided with increased expression of bik in both cell lines. Transient bik knockdown 
by RNAi in both cell lines led to decreased apoptosis as induced by TGFβ1. Ramos 
cells transiently expressing EBNA-2 or its non-CBF1 binding mutant, EBNA-2 
WW323SR, were also observed to have decreased apoptosis upon TGFβ1 receptor 
ligation compared to cells transfected with control vector.  
It was also confirmed here that treatment of Ramos cells with TGFβ1 induced the 
translocation of Smad3 from the cytoplasm to the nucleus, as determined by Western 
blot. Elevated Smad3 levels were also seen to coincide with increased levels of bik 
mRNA in Ramos and BJAB. On the other hand, Smad3 knockdown resulted in a 
decreased level of bik mRNA and protein. ChIP analysis indicated that upon TGFβ1 
ligation, the level of Smad3 and Smad4 recruitment to the bik promoter increased, 
which coincided with elevated bik mRNA levels in Ramos and BJAB cell lines. 
Conversely TGFβ1 treated Ramos and BJAB cells transiently expressing EBNA-2, or 
its non CBF-1 binding mutant, EBNA-2 WW323SR, led to a decreased level of Smad3 
and Smad4 and also coincided with increased degree of EBNA-2 recruitment to the bik 
promoter. This observation was correlated with a low level of bik mRNA expression as 
determined by RT-qPCR. Similarly, in the conditional LCL ER/EB2-5 cells 
proliferating on EBV growth programme, the level of Smad3 bound to the bik promoter 
was decreased and EBNA-2 was seen to be recruited to the bik promoter. This also 
coincided with a later observation that the total level of Smad3 protein was decreased in 
ER/EB2-5 cells proliferating due to EBV growth programme. Moreover, it was also 
seen that Smad3 levels were decreased in EBV negative BJAB cells expressing ectopic 
EBNA-2 or its mutant, WW323SR.  It has been cited that TGFβ1 can induce apoptosis 
and growth arrest depending on the cell type and the context (Ikushima and Miyazono 
2011a, Schuster and Krieglstein 2002b). Several mechanisms have been suggested 
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through which EBV infected cells may confer resistance to TGFβ-mediated apoptosis or 
growth inhibition (Spender and Inman 2011, Horndasch, et al. 2002). 
It has been observed that the loss, or down-regulation, of the TGFβ receptors type I/II 
results in inactivation of the TGFβ signalling pathway (Kumar, et al. 1991, Inman and 
Allday 2000, Fukuda, Kurosaki and Sairenji 2006). However, receptor down-regulation 
does not always account for the resistance of cells to TGFβ mediated effects, as was 
seen in LCLs treated with TGFβ (Horndasch, et al. 2002). In that study, the complete 
TGFβ signalling cascade was intact and a loss of signalling was not required for 
antagonizing the TGFβ-mediated effects (Horndasch, et al. 2002). In addition to this 
down-regulation of type I/II receptor expression (Inman and Allday 2000, Fukuda, 
Kurosaki and Sairenji 2006) which is associated with insensitivity to TGFβ, there are 
also further checks and controls related to TGFβ  gene expression which act to abolish 
its function. Furthermore, it has also been observed in B cells and epithelial cells, that 
LMP2A mediated activation of the PI3K/Akt pathway confers resistance to TGFβ-
mediated effects, but not the down-regulation of these receptors (Fukuda and 
Longnecker 2004). 
TGFβ exerts its anti-proliferative effects through the targeting of regulatory proteins in 
the cell cycle machinery, for example the dephosphorylation of pRb (the tumour 
suppressor retinoblastoma protein). However, this effect was abolished in the presence 
of EBV or the LMP1 (Arvanitakis, Yaseen and Sharma 1995, O'Nions and Allday 
2003). It was observed that LMP1 was responsible for the induced expression of cyclin 
D2, which is not expressed in normal B cells. It has been suggested that constitutive 
induction of the cell cycle regulators by LMP1 can lead to pRb hyper-phosphorylation 
and uncontrolled cell proliferation (Arvanitakis, Yaseen and Sharma 1995, O'Nions and 
Allday 2003). Among the latent genes, EBNA-2 as well as LMP1 was shown to induce 
the expression of cyclin D2 (Spender, et al. 2001, Sinclair, et al. 1994).  
LMP1 is known to be universally expressed in NPC cells. In these EBV-infected 
epithelial cells LMP1 is involved in blocking TGFβ-mediated effects. LMP1 has been 
shown to prevent TGFβ-induced cell cycle arrest by suppressing the TGFβ-induced 
expression of the transcription factor ATF3. Deprivation of ATF3 induction enables 
TGFβ-mediated expression of Id1, which would otherwise be inhibited by ATF3 (Kang, 
Chen and Massague 2003). The presence of Id1 then inhibits TGFβ-induced cytostasis 
(Lo, et al. 2010).  Induction of Id1 is possibly dependent on cell type. It has been 
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reported that TGFβ represses Id1 expression in epithelial cells (Kang, Chen and 
Massague 2003). Also, it has been shown that TGFβ induces the expression of Id1 in 
both the Ramos and BL-41 cell lines (Bakkebo, et al. 2010). However, ATF3 does not 
appear to be a TGFβ target in B cells, even when B cells are not infected with EBV. 
Also, while Id1 protein is up-regulated by TGFβ in B cells, growth arrest can proceed 
uninterrupted in the presence of Id1 (Spender and Inman 2009b). In the case of the 
EBV-infected gastric epithelial cell line, GT38, it has been shown that the 
TGFβ1/MAPK/p21 pathway is required for TGFβ1-mediated cytostasis, and that 
constitutive MAPK phosphorylation induced by LMP1 conferred resistance to TGFβ 
mediated growth arrest in this cell line (Fukuda, et al. 2002). 
A better understanding of the detailed molecular mechanisms by which Notch and 
TGFβ signalling interact may shed a light on the EBNA-2 interaction with the TGFβ 
signalling cascade. Phosphorylated Smad proteins bind to p300 in TGFβ mediated 
signalling (Nishihara, et al. 1998, Pouponnot, Jayaraman). It has been proposed that 
p300 forms the bridge linking the Smad complex to the transcriptional apparatus of the 
cell. Both Notch (Masuda, et al. 2005) and LMP1 (Mori, et al. 2003) have been shown 
to abrogate TGFβ-mediated growth inhibitory effects, by sequestering p300 from 
receptor activated Smads. In addition, the three viral transcription factors vIRF, (Kaposi 
sarcoma herpes virus), E1A (adenovirus), and EBNA-2 (EBV) are known to trans-
activate myc through a cellular cofactor at the PRF element (plasmacytoma repressor 
factor) which is located on the myc promoter. While all three have the ability to activate 
the myc promoter, each has a unique set of co-adaptor profiles, which can result in 
activation or repression of the target gene. It has been observed that CBP, but not the 
300/CBP-associated factor (P/CAF) and p300 promote vIRF trans-activation, whereas 
p300 but not P/CAF and CBP suppress EBNA-2 trans-activation. In the case of E1A, 
P/CAF promotes trans-activation while p300 and CBP have a suppressive effect 
(Jayachandra, et al. 1999). Smad3 phosphorylation at Thr8, Thr179, and Ser213 via 
cdk2/4 in the nucleus has been reported to inactivate Smad3 (Matsuura, et al. 2004). It 
has been shown elsewhere that cdk2 and cdk4 are active in the presence of EBNA-2 
(Kempkes, et al. 1995a) and hence, it may be the case that the effect of EBNA-2 on 
Smad3 might be mediated by these kinases. It has previously been shown in a BL cell 
line (CA46) that TGFβ exerts G1 cell cycle arrest by transcriptional repression of E2F-1, 
where c-myc is not repressed, (due to chromosomal translocation) and that CDKIs are 
not induced. This is a good example of TGFβ cell-type specific activity (Spender and 
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Inman 2009b). Interestingly, EBNA-2 has been shown to induce E2F upregulation 
(Helin, et al. 1992) (Kempkes, et al. 1995a). 
TGFβ signalling is one of the key signalling pathways required for elimination of 
unwanted B cell in the GC. In order to establish a lifelong persistent infection, EBV 
infected cells may confer resistance to TGFβ-mediated apoptosis or growth inhibition in 
GCs through several mechanisms (as described above) (Spender and Inman 2011, 
Horndasch, et al. 2002). EBV exerts significant control over the expression of the bcl-2 
family. bik is a direct target of TGFβ1 signalling in B cells (Spender and Inman 2011, 
Spender, et al. 2009).. The results presented here show for the first time that EBNA-2 
inhibits bik by effecting a decrease in the level of Smad3 protein, and consequently the 
level of Smad3 interacting with the bik promoter, and that this transcriptional co-
activator from the TGFβ signalling pathway is key to maintaining bik expression in the 
cell lines examined. 
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6.2 EBNA-2 decreases the BCR-induced apoptosis  
 
BCR aggregation due to antigen binding promptly activates the Src family kinases 
(reviewed in (Romero-Camarero, et al. 2013, Craxton, et al. 1999)). Signals originating 
from this complex activate multiple cascades that lead to changes in cell metabolism, 
gene expression and cytoskeletal organisation. The complex BCR signalling pathway 
leads to diverse effects, including cell survival, apoptosis, proliferation, and also 
differentiation into antibody-producing cells or memory B cells. The consequence of the 
response is determined and modulated by the maturation state of the cell, the nature of 
the antigen, the degree and duration of BCR occupancy, and also signals from other 
receptors and transmembrane proteins such as CD45, CD19, CD22, PIR-B, FcγRIIB1 
(CD32), CD40, the IL-21 receptor, and BAFF-R (Kurosaki 2011, Chung, et al. 2012). 
Overall, the EBV transformation of resting B lymphocytes to LCLs mimics antigen-
induced resting B cell clonal expansion in lymph node germinal centres, where antigen 
binding to surface Ig (sIg) induces myc-mediated proliferation (Murn, et al. 2009) and T 
cell CD40 ligand activates B lymphocyte CD40 receptors to up-regulate NF-κB, MAP 
kinases, and anti-apoptotic Bcl-2 family protein expression (Elgueta, de Vries and 
Noelle 2010). It is noteworthy that EBNA-2 is the mediator responsible for 
downregulating sIgM as was observed in a study conducted using LCLs and BL cell 
lines conditionally expressing EBNA-2 (Jochner, et al. 1996b). It has been shown by 
Jiang,A. et al, that membrane bound IgM and IgD ligation in B104 cells (a mature B 
cell phenotype  Chen,W. 1999) led to the induction of bik mRNA, but that only sIgM 
ligation resulted in apoptosis due to the expression of bik, via strong activation of PI3K 
(Beckwith, et al. 1996) and calcium influx (Jiang and Clark 2001a).  
Here it has been shown that BCR stimulation by an anti-IgM antibody led to a 
significant increase in apoptosis in Ramos cells and to lesser extent in the BJAB cell 
line. It is important to note here that BJAB is an EBV-negative B lymphoma cell line 
with a non-translocated c-myc (Marchini, Longnecker and Kieff 1992), while the BL-
derived Ramos cell line carries the translocated c-myc gene. Subsequent Western blot 
and RT-qPCR analysis revealed elevated levels of Bik protein and mRNA in both cell 
lines when treated with various concentrations of anti-IgM antibody. It has been shown 
elsewhere that anti-IgM antibody treatment of BL Ramos and B cell lymphoma BJAB 
cells modulates the expression and protein stability of c-myc, promoting cells to 
undergo apoptosis (Kaptein, et al. 1996, Gururajan, et al. 2005), whereas c-myc-
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deficient B cells are resistant to apoptosis by BCR triggering (Murn, et al. 2009). It was 
observed in the present study that apoptosis was induced due to harsh transfection 
conditions and that transient bik knock-down led to an overall increase in the cell 
survival rate in both Ramos and BJAB after transfection. Although transient bik 
knockdown was seen to decrease the overall level of apoptotsis it did not however have 
a pronounced effect on the rate of apoptosis induced by BCR cross-linking in both cell 
lines. It has previously been shown that BCR cross-linking mediates apoptosis through 
induction of both Bim and Bik (Jiang and Clark 2001b, Enders, et al. 2003a) and so the 
expression of Bim may be the reason for the retention of sensitivity to apoptosis under 
the consitions used. It was also demonstrated here that ectopic EBNA-2 and its non-
CBF1 binding mutant, EBNA-2 WW323SR, could rescue Ramos cells from antigen-
receptor-mediated apoptosis when compared to cells transfected with control vector. 
These observations indicated that EBNA-2 mediated effects on bik in this context 
occurred independently of its ability to interact with the cellular transcription factor 
CBF1. 
In Ramos cells in which the PI3K pathway was inhibited by wortmannin, apoptosis was 
significantly decreased when the BCR was cross-linked with anti-IgM antibody. 
Whereas in BJAB cells wortmannin, did not have any obvious effect on apoptosis 
induced by BCR cross-linking. However, BJAB cells treated with wortmannin did 
exhibit a decrease in cell viability when compared to the control cells in which the PI3K 
pathway was not inhibited. Bik mRNA increased in both Ramos and BJAB cells 
following treatment with anti-IgM antibody and PI3K inhibition with wortmannin 
reversed this effect in Ramos. Although PI3K inhibition also coincided with decreased 
bik mRNA levels in BJAB cells in response to anti-IgM antibody, the extent of bik 
down-regulation was less significant to what that observed in Ramos cells. 
PI3K confers a survival signal to cells, allowing them to survive several apoptotic 
stimuli (Kalimuthu and Se-Kwon 2013). It has been shown that the inositol 
phosphatases and tensin homologue (PTEN) negatively regulate PI3K-mediated 
survival and proliferation of hematopoietic cells by inducing the G1 cell cycle arrest and 
decreasing the level of cyclin D2 (Huang, et al. 2007) and cyclin D3 (Zhu, et al. 2001). 
PTEN is a tumor suppressor gene that is mutated in human cancers. Deletion of PTEN 
has been shown to result in B cells that exhibit enhanced survival and express more 
MCL1 and less Bim. These cells also expressed low amounts of p27kip1 and high 
amounts of cyclin D3 and therefore appeared to undergo proliferative expansion 
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(Miletic, et al. 2010). Many tumour cells are seen to express elevated levels of PI3K 
products following deletion of the phosphatase PTEN, activation of Ras or expression 
of autocrine growth factors. Accordingly, these cells are reasonably resistant to 
apoptosis. The principal mediator in this pathway is Akt, a PI3K activated protein 
kinase (Niiro, et al. 2012). Akt has been shown to have direct effects on the apoptosis 
machinery, for instance affecting the pro-apoptotic Bcl-2 related protein, BAD (Datta, et 
al. 1997). It has also been seen to affect the transcriptional response to apoptotic stimuli, 
for instance by regulating Forkhead transcription factors, and by influencing the activity 
of the p53 family (Downward 2004). In addition, novel connections between the 
metabolic effects of Akt and its control on cell survival have also been made, as 
LY294002 (a PI3K specific inhibitor) down-regulated Akt phosphorylation and cell 
proliferation in a dose-dependent manner (Downward 2004). The survival kinase 
PKB/Akt was highly activated in PTEN-deficient splenic B cells (Suzuki, et al. 2003). It 
has been shown that BJAB has no detectable PTEN protein (Pauls, et al. 2012) and that 
it has elevated PIP3 and PIP2 (Marshall, et al. 2002), with constitutive phosphorylation 
of AKT, whereas Ramos cells have been shown to express a very low level of PTEN 
protein but no detectable pAKT (Mori and Sairenji 2006, Cheung, et al. 2007).  
In summary it was observed that apoptosis was induced in Ramos and BJAB upon BCR 
cross-linking. Apoptosis in these cells coincided with upregulation of bik. BCR-
mediated bik upregulation was likely to be dependent on an intact PI3K pathway in 
Ramos and to lesser extent in BJAB as was in evidence following use of the PI3K pan 
inhibitor, wortmannin. The use of a more specific PI3K inhibitor would clarify this 
issue. The B cell response following BCR cross-linking is dependent on the 
differentiation stage of the B cells. As it has been shown, cross-linking of BCR induces 
proliferation of resting tonsillar follicular mantle (FM) B lymphocytes but prompts 
programmed cell death in the Ramos cell line (Padmore, Radda and Knox 1996). 
Moreover, the balance between the pro- and anti-apoptotic Bcl-2 family members 
directs cellular fate. 
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6.3 A co-operative effect of 1α,25-(OH)2D3 on BCR- and TGFβ1-
mediated apoptosis 
 
EBV infection is usually kept under tight control by EBV-specific immune responses, 
especially by cytotoxic CD8+ T cells which remove proliferating and lytically-infected 
B cells (Hislop, et al. 2007). Impaired CD8+ T cell control of EBV infection leads to 
accumulation of EBV-infected autoreactive B cells in the target organs where they 
generate autoantibodies and provide co-stimulatory survival signals to autoreactive T 
cells which would otherwise be eliminated in the target organ by apoptosis (Pender 
2012). It has been shown that the level of vitamin D modulates the immune response to 
EBV (Holmoy 2008a). Although there are no reports regarding the direct effect of 
vitamin D on CD8+ T cells, they are known to express the highest level of VDR 
compared to other immune cells (Smolders, et al. 2008). 
B cell reactivity with 1α,25-(OH)2D3 is a characteristic universally shared by naïve, 
germinal centre and memory B cell subpopulations, and cellular activation, rather than 
differentiation, is more defining for their biological reactivity to 1α,25-(OH)2D3 
(Morgan, et al. 2000b). The effects of 1,25-(OH)2D3 on B cell responses includes; (i) 
the inhibition of the on-going proliferation of activated B cells and subsequent 
apoptosis, (ii) the inhibition of the generation of plasma cells and post-switch memory 
B cells, and  (iii) up-regulated expression of the p27, but not of p18 and p21, that 
possibly will be important in regulating the proliferation of activated B cells and their 
following differentiation(Chen, et al. 2007). Vitamin D receptor decreases NF-
κB activation by interfering with nuclear transcription factor NF-κB (p65 and p105). 
Therefore, the VDR prevents co-stimulatory signal transduction in naïve B cells, 
namely by decreasing CD40 signalling (Geldmeyer-Hilt, et al. 2011). Vitamin D plays a 
part in regulating autoantibody production. It has been shown that treatment of EBV-
infected cells with 1,25-(OH)2D3, the immunoregulatory hormone, inhibited the 
production of IgM and IgG (Provvedini, et al. 1986). Also a direct inhibitory effect of 
1α,25-(OH)2D3 on IgE production by human B cells has been reported (Heine, et al. 
2002). Recently it has been shown that 1,25-(OH)2D3 induced a reduction of memory B 
cells and anti-DNA antibodies in systemic lupus erythematosus patients (Terrier, et al. 
2012). In a study conducted by Yenamandra,S.P. et al, the expression profile of more 
than forty nuclear receptors were compared in the naïve and EBV-transformed B 
lymphocytes, freshly infected B cells and long-term cultured LCLs (Yenamandra, et al. 
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2009). Nr2F2 and RARA were among the genes that were the most up-regulated and 
ERB, NUR77, PPARG, RXR-B and VDR were the most down-regulated in LCLs 
(Yenamandra, et al. 2009, Yenamandra, Klein and Kashuba 2009). It has been shown 
recently that EBNA-3 blocks the activation of VDR-dependent genes and protects LCLs 
against vitamin-D3-induced growth arrest and/or apoptosis by binding to VDR 
(Yenamandra, et al. 2010). These findings are evidence that 1,25-(OH)2D3 may play an 
central role in the maintenance of B cell homeostasis and that an improvement 
of vitamin D insufficiency may be useful in the treatment of B cell-mediated diseases. 
Here it has been shown that apoptosis was induced in Ramos and BJAB cells by 1α,25-
(OH)2D3. It was observed for the first time that, 1α,25-(OH)2D3 mediated apoptosis 
coincided with up-regulation of bik in both cell lines. Higher levels of apoptosis were 
induced in Ramos cells through BCR cross-linking and to lesser extend with 1α,25-
(OH)2D3 or TGFβ1. On the other hand, in BJAB cells TGFβ1 was observed to have the 
greater impact on the induction of apoptosis in comparison to anti-IgM antibody and 
1α,25-(OH)2D3 treatment. Co-treatment of Ramos cells with 1α,25-(OH)2D3/anti-IgM 
antibody was seen to have a strong co-operative effect regarding the induction of 
apoptosis compared to when these cells were co-treated with 1α,25-(OH)2D3/TGFβ1. 
Similarly apoptosis was induced strongly in Ramos cells when co-treated with anti-IgM 
antibody/TGFβ1. In comparison when BJAB cells were co-treated with either sets of 
1α,25-(OH)2D3/anti-IgM, 1α,25-(OH)2D3/TGFβ1, or anti-IgM antibody/TGFβ1 overall 
apoptosis was increased when compared to BJAB cells that were treated individually 
with each effector.  
The importance of the PI3K pathway in BCR-, TGFβ- and vitamin D3- mediated effects 
and its possible involvement in the cross-talk between the intrinsic signalling pathways 
was then investigated by using wortmannin. PI3K inhibition alone led to no significant 
changes in the viability of Ramos cells. However, the apoptotic effects of anti-IgM 
antibody and 1α,25-(OH)2D3 were significantly decreased, whereas the TGFβ1 
apoptotic effect was enhanced when Ramos cells were treated with wortmannin. It was 
observed that when anti-IgM was used in combination with 1α,25-(OH)2D3 apoptosis 
was increased in Ramos cells to a level greater than that achieved with either effector 
alone Wortmannin was seen to decreased this overall increase of apoptosis which was 
achieved due to co-treatment of Ramos cells with anti-IgM antibody/1α,25-(OH)2D3. A 
similar pattern, but of a lesser magnitude was observed when Ramos cells were co-
stimulated with 1α,25-(OH)2D3/TGFβ1 or anti-IgM antibody/TGFβ1. Thus the PI3K 
pathway, possibly plays a role in BCR- and 1α,25-(OH)2D3-mediated apoptosis and 
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might mediating cross-talk between 1α,25-(OH)2D3 and BCR-signalling. Moreover an 
intact PI3K pathway appears to be required for bik trans-activation in Ramos cells in 
response to 1α,25-(OH)2D3 and BCR cross-linking.  
 
 
 
Figure 6-1: A model for possible cross-talk between 1α,25-(OH)2D3,  TGFβ1, and 
BCR signalling pathways resulting in bik trans-activation and its inhibition bye 
EBV. 
 
In BJAB cells treatment with wortmannin led to an overall decrease in cell viability. 
Unlike in Ramos cells, this drug did not display any pro-survival effect when BJAB 
cells were treated anti-IgM antibody or 1α,25-(OH)2D3. It was observed that TGFβ1-
mediated apoptosis was enhanced when BJAB cells were treated with wortmannin. 
Moreover wortmannin enhanced apoptosis in BJAB cells co-stimulated with 
TGFβ1/1α,25-(OH)2D3 when compared to co-stimulated cells in the absence of 
wortmannin. In contrast in BJAB cells, inhibition of PI3K had no significant effect on 
the extent of apoptosis when cells were co-stimulated with anti-IgM antibody/1α,25-
(OH)2D3. Although 1α,25-(OH)2D3 was able to induce apoptosis in Ramos and BJAB 
cells, 1α,25-(OH)2D3 might be using mediators known to be important in other intrinsic 
apoptosis-associated pathways, for example Smad3 (TGFβ) and PI3K (BCR). A number 
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of different experiments have demonstrated the relationship between the transforming 
TGFβ and vitamin D3 signalling pathway (Adams and Hewison 2008, Subramaniam, et 
al. 2001).  Smad3, a downstream component of the TGFβ signalling pathway, interacts 
with VDR as a co-activator of VDR (Subramaniam, et al. 2001). It has been shown that 
the 1α,25-(OH)2D3-mediated phosphorylation of Smad2 and Smad3 is an indirect effect 
of 1α,25-(OH)2D3 and is dependent on the presence of the TGFβ (Daniel, et al. 2007). 
Smad3 has been shown to bind to the VDR-RXR heterodimer in a ligand-dependent 
manner (Leong, et al. 2001). Vitamin D3 has been shown to be involved in the 
activation of the PI3K/Akt signalling pathway (Deeb, Trump and Johnson 2007a, 
Hughes, et al. 2008) and PI3K pathway has been shown to be required for sustained Bik 
protein production upon BCR stimulation (Jiang and Clark 2001a). Additionally TGFβ1 
has also been shown to activate PI3K in a non-Smad-dependent pathway (Zhang 2009). 
The accumulating evidence provided above indicates an interconnected network of 
apoptotic signals potentially emanating from TGFβ1, BCR and 1α,25-(OH)2D3, and that 
the interactions implied above may be important to achieve the optimal selection 
by apoptotic elimination of unwanted germinal centre B cells and maintaining 
homeostasis. It remains possible that the EBV growth programme inhibits the existing 
cross-talk by modulating the key mediators (Smad3 or PI3K) of these major apoptotic 
signalling pathways and increasing the apoptotic threshold (Figure 1-6). These 
molecular and cellular pathways should not be considered in isolation. They should be 
viewed as an array of interconnecting signals, all contributing to the final outcome, 
thereby allowing fine control of the cell fate and homeostasis. 
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Conclusions 
 
EBV infection impacts on cell death and survival pathways in GC B cells. 
Interconnected signalling pathways, regulate the apoptosis of GC B cells. Establishment 
of a persistent latent EBV infection demands that the infected host B cells transit 
through the GC where networks of pro-apoptotic signalling molecules implement a 
harsh selection system over the differentiating B cells. Few B cells survive this course 
to differentiate fully. To guarantee the EBV-infected host cell survival, EBV has its own 
array of pro-survival mechanisms which can potentially dominate external stimuli 
promoting cell death such as, TGFβ, BCR cross-linking and apoptosis-induced 
activation by 1α,25-(OH)2D3 which are mediators of intrinsic apoptotic pathways.  
One mechanism by which EBV promotes tumourigenesis is by altering the balance 
between pro- and anti-apoptotic proteins thereby leading to enhanced cell survival. In 
this context, previous studies have demonstrated that the viral latent genes EBNA3A, 
EBNA3C and LMP1 can regulate expression of members of the cellular Bcl2 family. 
This work identifies an additional pathway used by EBV to promote cell survival, 
namely repression of the cellular pro-apoptotic gene bik by EBNA2. The current work 
describes a novel mechanism by which EBV promotes cell survival, and which extends 
our understanding of how EBV modulates the expression of Bcl2 family proteins. In 
this context, Bik is particularly important given its potential role in B cell survival 
during B cell differentiation within germinal centres. Bik has also been used as a 
therapeutic molecule in gene therapy based approaches to treat difficult cancers 
(Chinnadurai,G. 2008). These results may have important implications for the 
pathogenesis of EBV associated disease such as IM and PTLD and the bik/EBV 
interaction could be a novel target in antiviral strategies.  
In summary, this thesis presents the novel finding that EBV down-regulates the cellular 
pro-apoptotic bik gene by down-regulating the transcriptional co-activator, Smad3, 
which is also a TGFβ signalling mediator. Significantly, Smad3 knockdown in EBV 
negative cell lines coincided with decreased level of Bik. A lower basal Smad3 
expression level was observed in the conditional LCL ER/EB2-5, and also EBV 
negative Ramos and BJAB cells expressing ectopic EBNA-2. The EBV latent 
transcription factor EBNA-2 plays a key role in bik modulation, independently of its 
ability to interact with the cellular transcription factor CBF1. Furthermore for the first 
time bik tran-activation has been observed to coincide with apoptosis induced by the 
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1α,25-(OH)2D3. The PI3K was observed to potentially have a role in trans-activating 
bik in both Ramos and BJAB cells upon 1α,25-(OH)2D3 and BCR cross-linking  induced 
apoptosis. Here it has been shown that the bik gene is a common target for the major 
intrinsic apoptotic signalling pathways in the GC reaction and that EBV negatively 
regulates its expression. As a consequence, EBV-infected naïve B cells undergoing 
clonal expression may be more resistant to such key apoptotic triggers and evade 
physiological elimination in order to transit through the GC reaction. Collectively, these 
findings suggest that bik modulation by EBV through down-regulation of Smad3 may 
be an important EBV-host cell interaction during EBV infection and a contributory 
factor in the development of EBV-associated B lymphomas.  
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Solutions for DNA Manipulation 
 
Storage of DNA 
 
0.5 M EDTA (pH 8.0) 
186.1 g  EDTA 
800 mL  dH2O 
 
The pH was adjusted to 8.0 by addition of NaOH pellets and the volume adjusted to 1 L 
with dH2O.  The solution was sterilised by autoclaving and stored at room temperature. 
 
TE buffer (pH 8.0) 
 
10 mM  Tris-Cl (pH 8.0) 
1 mM   EDTA  (pH 8.0) 
 
Solution for Bacterial Growth Media  
 
Ampicillin stock solution 
A stock solution of ampicillin was made up to a concentration of 100 mg/mL in dH2O. 
The stock solution was filter sterilised and stored at -20˚C. 
 
LB broth 
5 g   Tryptone 
2.5 g   Yeast extract 
5 g   NaCl 
The volume was adjusted to 500 mL, followed by autoclaving for 20 min at 15 lb/sq. and 
storage at 4˚C. 
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LB broth with ampicllin  
Ampicillin was added to autoclaved LB broth to a final concentration of 100 µg/mL and 
stored at 4˚C. 
 
LB agar 
5 g   Tryptone 
2.5 g   Yeast extract 
5 g   NaCl 
7.5 g   Agar 
The volume was adjusted to 500 mL with dH20, followed by autoclaving and agar plates 
were stored at 4˚C. 
 
LB agar with antibiotics 
Antibiotics were added to autoclaved LB broth to a final concentration of 100 µg/mL 
(Ampicillin), after cooling the LB agar to ~50˚C.  Plates were stored at 4˚C. 
 
SOB medium 
10 g   Tryptone 
2.5 g   Yeast extract 
0.025 g  NaCl 
5 mL   KCl (250 mM) 
 
The pH was adjusted to 7.0 with 5 M NaOH.   
The volume was adjusted to 500 mL with dH20 and the medium autoclaved.   
2.5 mL of 2 M MgCl2 was added after cooling the broth to 5˚C and the medium was stored 
at 4˚C.   
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SOC medium 
98 mL  SOB medium 
2 mL  1 M glucose (filter sterilised) 
Stored at 4˚C.  
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Solutions for Preparation of Competent Cells 
 
1 M MgSO4 
24.65 g                            MgSO4.7H20 
100 mL                dH20 
Sterilised by filtering and stored at room temperature. 
 
TFB1 
30 mM  potassium acetate 
10 mM             CaCl2 
50 mM  MnCl2 
100 mM  RbCl 
15%   glycerol 
The pH was adjusted to 5.8 with 1 M acetic acid, and the solution filter sterilised and stored 
at room temperature. 
 
TFB2 
100 mM  MOPS (pH 6.5) 
75 mM  CaCl2 
10 mM  RbCl 
15%    Glycerol 
 
The pH was adjusted to 6.5 with 1 M KOH, and the solution filter sterilised and stored at 
room temperature. 
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Solutions for DNA preparations 
   
Buffer P1 (Re-suspension buffer) 
50 mM    Tris-Cl (pH 8.0) 
10 mM    EDTA (pH8.0) 
100 µg/mL               RNase A 
Stored at 4˚C following addition of RNase A. 
 
DNase-free RNase 
RNase A (1 mg/mL) in upH2O. 
Heated to 100˚C for 30 min.   
Cooled slowly and stored at -20˚C. 
 
Buffer P2 (Lysis buffer) 
200 mM  NaOH 
1% (w/v)  SDS 
Stored at room temperature.  
 
Buffer P3 (Neutralisation buffer) (3 M potassium acetate) 
29.6 g   potassium acetate 
50 mL    dH2O 
11.5 mL  glacial acetic acid 
Adjust volume to 100 mL with dH2O. 
The resulting solution is 3 M with respect to potassium and 5 M with respect to acetate. 
Stored at room temperature. 
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Buffer QBT (Equilibration buffer) 
750 mM  NaCl 
50 mM  MOPS (pH 7.0) 
15% (v/v)  Isopropanol 
0.15% (v/v)  Triton-X 100 
Stored at room temperature. 
 
Buffer QC (Wash buffer) 
1 M   NaCl 
50 mM  MOPS (pH 7.0) 
15% (v/v)  Isopropanol 
Stored at room temperature. 
 
Buffer QF (Elution buffer) 
1.25 M   NaCl 
50 mM  Tris-Cl (pH 8.5) 
15%   Isopropanol 
Stored at room temperature. 
 
50 % (v/v) Glycerol 
25 mL   glycerol 
25 mL   dH2O 
The solution was autoclaved and stored at room temperature. 
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Solutions for Agarose Gel Electrophoresis 
 
50X TAE (Tris-acetate/EDTA electrophoresis buffer) 
242 g                  Tris base 
57.1 mL   Glacial acetic acid 
100 mL   0.5 M EDTA (pH 8.0) 
The volume was adjusted to 1 L with dH2O and the buffer was stored at room temperature. 
 
1X TAE (Working solution) 
20 mL   50X TAE 
980 mL  dH2O 
Stored at room temperature. 
 
Agarose gel loading dye 
40% (w/v)  Sucrose 
0.25% (w/v)  Bromophenol blue 
Stored at room temperature. 
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Solutions for Cell Culture  
 
Media and Supplements 
Supplemented RPMI 1640 (500 mL) 
440 mL  RPMI 1640  
50 mL   Foetal bovine serum (decomplemented at 50˚C for 30 min) 
5 mL   200 mM L-glutamine 
5 mL   penicillin/streptomycin (10 mg/mL) 
 
Estrogen (β-Estradiol) 
A 20 mM solution was prepared in 100% ethanol and stored at -20˚C. 
 
Phosphate buffered saline (PBS) 
5 tablets were dissolved in 500 mL dH2O to give a 1X working concentration of PBS, and 
the solution was sterilised by autoclaving.   
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Solutions for RNA Analysis 
 
DEPC-treated H2O 
1 mL   DEPC 
1000 mL  dH2O 
The mixture was left in a fume cupboard overnight, followed by autoclaving.   
 
RNA loading buffer 
50%    Glycerol 
1 mM   EDTA (pH 8.0) 
0.25%   Bromophenol blue 
0.25%   Xylene cyanol FF 
1 µg/µL  Ethidium bromide 
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Solutions for Protein Analysis 
 
Solutions for Protein Isolation 
Suspension buffer 
0.1 M   NaCl 
0.01 M   Tris-Cl (pH 7.6) 
0.001 M  EDTA (pH 8.0) 
1 µg/mL  leupeptin 
1 µg/mL  Aprotinin 
100 µg/mL  PMSF 
Stored at 4˚C 
 
Leupeptin 
A stock solution of leupeptin was made to a concentration 2 mg/mL in dH2O and stored at 
–20˚C. 
 
Aprotinin 
0.1 M stock solution of aprotinin was made up in dH2O and stored at -20˚C. 
 
PMSF 
A stock solution of PMSF was made up in isopropanol and stored at -20˚C in the dark.  
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2X SDS loading buffer 
100 mM  Tris-Cl (pH 7.6) 
4% (w/v)   SDS 
20% (w/v)  Glycerol 
10% (v/v)  2-mercaptoethanol 
0.2%   Bromophenol blue 
Stored at room temperature. 
 
Solutions for SDS-PAGE/ Western Blotting 
 
Table  A: 10% (v/v) resolving gels and 5 % (v/v) stacking polyacrlyamide gels 
Component 10 % Resolving Gel (mL) 5 % Stacking Gel (mL) 
Acrylagel  3.33 0.42 
Bis-Acrylagel 1.35 0.168 
1.5 M Tris (pH 8.8) 2.5 0 
1 M Tris (pH 6.8) 0 0.312 
dH2O  2.61 1.5475 
10% (v/v) SDS 0.10 0.025 
10% (v/v) APS 0.10 0.025 
TEMED 0.01 0.0025 
Total 10 mL 2.5 mL 
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5X Tris-glycine running buffer 
15.1 g   Tris base 
95.4 g   glycine (pH 8.3) 
50 mL   10 % (w/v) SDS 
Made up to 1L with dH2O and stored at room temperature. 
 
1X Tris-glycine running buffer  
200 mL   5X Tris-glycine running buffer 
800 mL   dH2O 
 
Transfer buffer 
750 mL   dH2O 
2.9 g   Glycine 
5.8 g   Tris base 
3.7 mL   10 % (w/v) SDS 
200 mL   Methanol 
Adjusted volume to 1 L with dH2O and stored at 4˚C. 
 
1X Tris buffered saline (TBS) 
6.1 g   Tris base 
8.8 g    NaCl 
800 mL  dH2O 
The pH was adjusted to 7.5 with HCl and the volume adjusted to 1 L.  Stored at room 
temperature. 
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TBS-T 
1 L   1X TBS 
1 mL   Tween 20 
Stored at room temperature. 
 
Blocking Buffer 
5 g               Non-fat dry milk powder 
100 mL   TBS-T 
Stored at 4 ˚C.
  
 
 
 
